CN117396504A - 抗Sema3A抗体及其用途 - Google Patents
抗Sema3A抗体及其用途 Download PDFInfo
- Publication number
- CN117396504A CN117396504A CN202280038261.5A CN202280038261A CN117396504A CN 117396504 A CN117396504 A CN 117396504A CN 202280038261 A CN202280038261 A CN 202280038261A CN 117396504 A CN117396504 A CN 117396504A
- Authority
- CN
- China
- Prior art keywords
- seq
- antigen binding
- cdr3
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims abstract description 617
- 239000000427 antigen Substances 0.000 claims abstract description 535
- 108091007433 antigens Proteins 0.000 claims abstract description 535
- 102000036639 antigens Human genes 0.000 claims abstract description 535
- 239000012634 fragment Substances 0.000 claims abstract description 306
- 108010090319 Semaphorin-3A Proteins 0.000 claims abstract description 205
- 102000013008 Semaphorin-3A Human genes 0.000 claims abstract description 204
- 241000282414 Homo sapiens Species 0.000 claims abstract description 167
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 43
- 238000003556 assay Methods 0.000 claims abstract description 41
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims abstract description 41
- 230000005764 inhibitory process Effects 0.000 claims abstract description 31
- 238000000338 in vitro Methods 0.000 claims abstract description 27
- 241000282567 Macaca fascicularis Species 0.000 claims abstract description 17
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 12
- 230000005593 dissociations Effects 0.000 claims abstract description 12
- 230000012292 cell migration Effects 0.000 claims abstract description 11
- 238000010232 migration assay Methods 0.000 claims abstract description 7
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 230000001434 glomerular Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 113
- 238000000034 method Methods 0.000 claims description 68
- 150000007523 nucleic acids Chemical group 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 208000017169 kidney disease Diseases 0.000 claims description 18
- 208000020832 chronic kidney disease Diseases 0.000 claims description 14
- 210000000020 growth cone Anatomy 0.000 claims description 14
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 13
- 206010001580 Albuminuria Diseases 0.000 claims description 13
- 208000033626 Renal failure acute Diseases 0.000 claims description 13
- 201000011040 acute kidney failure Diseases 0.000 claims description 13
- 229910052698 phosphorus Inorganic materials 0.000 claims description 13
- 208000024985 Alport syndrome Diseases 0.000 claims description 12
- 208000003215 hereditary nephritis Diseases 0.000 claims description 12
- 229940127121 immunoconjugate Drugs 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 208000001344 Macular Edema Diseases 0.000 claims description 9
- 206010025415 Macular oedema Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000010230 macular retinal edema Diseases 0.000 claims description 9
- 229910052720 vanadium Inorganic materials 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 201000001474 proteinuria Diseases 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000030090 Acute Disease Diseases 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010048962 Brain oedema Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008027 Cerebellar atrophy Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000002682 Hyperkalemia Diseases 0.000 claims description 3
- 206010021036 Hyponatraemia Diseases 0.000 claims description 3
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004155 blood-retinal barrier Anatomy 0.000 claims description 3
- 230000004378 blood-retinal barrier Effects 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 208000025434 cerebellar degeneration Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 201000008284 inappropriate ADH syndrome Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000009852 uremia Diseases 0.000 claims description 3
- 208000018083 Bone metabolism disease Diseases 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 102100032782 Semaphorin-5A Human genes 0.000 claims description 2
- 101710199403 Semaphorin-5A Proteins 0.000 claims description 2
- 208000020450 carbohydrate metabolism disease Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 description 64
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 58
- 102000004169 proteins and genes Human genes 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 49
- 235000001014 amino acid Nutrition 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 34
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 31
- 150000001413 amino acids Chemical class 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 229940109239 creatinine Drugs 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 28
- 239000008363 phosphate buffer Substances 0.000 description 25
- 108010088751 Albumins Proteins 0.000 description 24
- 102000009027 Albumins Human genes 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- -1 e.g. Proteins 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 230000002485 urinary effect Effects 0.000 description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 20
- 210000003734 kidney Anatomy 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- 241000282898 Sus scrofa Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000029142 excretion Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 239000000562 conjugate Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000012216 screening Methods 0.000 description 15
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 210000004962 mammalian cell Anatomy 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000002823 phage display Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 10
- 229940049595 antibody-drug conjugate Drugs 0.000 description 10
- 239000004202 carbamide Substances 0.000 description 10
- 210000004602 germ cell Anatomy 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 238000011199 Dunnett post hoc test Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 8
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000003584 mesangial cell Anatomy 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 6
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 239000002876 beta blocker Substances 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
- 241000880493 Leptailurus serval Species 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 206010063897 Renal ischaemia Diseases 0.000 description 5
- 102100027974 Semaphorin-3A Human genes 0.000 description 5
- 229940083712 aldosterone antagonist Drugs 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010064733 Angiotensins Proteins 0.000 description 4
- 102000015427 Angiotensins Human genes 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000001818 capillary gel electrophoresis Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000005462 in vivo assay Methods 0.000 description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 210000003594 spinal ganglia Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000008646 thermal stress Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 3
- XTMZYFMTYJNABC-ZLUOBGJFSA-N Asn-Ser-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N XTMZYFMTYJNABC-ZLUOBGJFSA-N 0.000 description 3
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- MDOBWSFNSNPENN-PMVVWTBXSA-N His-Thr-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O MDOBWSFNSNPENN-PMVVWTBXSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000632261 Homo sapiens Semaphorin-3A Proteins 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 3
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 108010033266 Lipoprotein(a) Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 206010048988 Renal artery occlusion Diseases 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 3
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000022811 deglycosylation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000010820 immunofluorescence microscopy Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 3
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000002461 renin inhibitor Substances 0.000 description 3
- 229940086526 renin-inhibitors Drugs 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000004217 thyroid hormone receptors Human genes 0.000 description 3
- 108090000721 thyroid hormone receptors Proteins 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 2
- LFFOJBOTZUWINF-ZANVPECISA-N Ala-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O)=CNC2=C1 LFFOJBOTZUWINF-ZANVPECISA-N 0.000 description 2
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 2
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 2
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 2
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- MJJIHRWNWSQTOI-VEVYYDQMSA-N Asp-Thr-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MJJIHRWNWSQTOI-VEVYYDQMSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241001465318 Aspergillus terreus Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- DCJNIJAWIRPPBB-CIUDSAMLSA-N Cys-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N DCJNIJAWIRPPBB-CIUDSAMLSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 2
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 2
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 2
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 2
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 2
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 2
- 244000302512 Momordica charantia Species 0.000 description 2
- 235000009811 Momordica charantia Nutrition 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102100028762 Neuropilin-1 Human genes 0.000 description 2
- 108090000772 Neuropilin-1 Proteins 0.000 description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 2
- WIPAMEKBSHNFQE-IUCAKERBSA-N Pro-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1 WIPAMEKBSHNFQE-IUCAKERBSA-N 0.000 description 2
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 240000003946 Saponaria officinalis Species 0.000 description 2
- 102000014105 Semaphorin Human genes 0.000 description 2
- 108050003978 Semaphorin Proteins 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000037280 Trisomy Diseases 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- OOEUVMFKKZYSRX-LEWSCRJBSA-N Tyr-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OOEUVMFKKZYSRX-LEWSCRJBSA-N 0.000 description 2
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940124691 antibody therapeutics Drugs 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004041 inotropic agent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000013152 interventional procedure Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 210000000557 podocyte Anatomy 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 231100000654 protein toxin Toxicity 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 2
- 229930013292 trichothecene Natural products 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DMYZJLOWGSRVKP-RTBURBONSA-N (2r,4r)-1-n-(4-chlorophenyl)-4-hydroxy-2-n-[4-(3-oxomorpholin-4-yl)phenyl]pyrrolidine-1,2-dicarboxamide Chemical compound N1([C@H](C[C@H](C1)O)C(=O)NC=1C=CC(=CC=1)N1C(COCC1)=O)C(=O)NC1=CC=C(Cl)C=C1 DMYZJLOWGSRVKP-RTBURBONSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- CASCTHHMARGRLB-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide;hydrochloride Chemical compound Cl.CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 CASCTHHMARGRLB-UHFFFAOYSA-N 0.000 description 1
- YABFPHSQTSFWQB-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(1,2,4-triazol-1-yl)-3-(trimethylsilyl)propan-2-ol Chemical compound C=1C=C(F)C=CC=1C(O)(C[Si](C)(C)C)CN1C=NC=N1 YABFPHSQTSFWQB-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- UOJMJBUYXYEPFX-UHFFFAOYSA-N 2-[4-(4-hydroxy-3-propan-2-ylphenoxy)-3,5-dimethylanilino]-2-oxoacetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(NC(=O)C(O)=O)=CC=2C)C)=C1 UOJMJBUYXYEPFX-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- AUYYCJSJGJYCDS-UHFFFAOYSA-N 2/3/6893 Natural products IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-WHPHVCHMSA-N 3,7-dimethyl-1-[(5s)-4,4,6,6,6-pentadeuterio-5-hydroxyhexyl]purine-2,6-dione Chemical compound O=C1N(CCCC([2H])([2H])[C@@H](O)C([2H])([2H])[2H])C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-WHPHVCHMSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- NOBZETMXGVAWIM-UHFFFAOYSA-N 4-[(2-carbamimidoyl-3,4-dihydro-1h-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C2CN(C(=N)N)CCC2=CC=C1OCC(CC1)(C(O)=O)CCN1C1=CC=NC=C1 NOBZETMXGVAWIM-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- LUUMLYXKTPBTQR-UHFFFAOYSA-N 4-chloro-n-[5-methyl-2-(7h-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C(C)=CN=C(C(=O)C=2C=3C=CNC=3N=CN=2)C=1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LUUMLYXKTPBTQR-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 241000237373 Aplysia sp. Species 0.000 description 1
- 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 1
- NECWUSYTYSIFNC-DLOVCJGASA-N Asp-Ala-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NECWUSYTYSIFNC-DLOVCJGASA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- SPKCGKRUYKMDHP-GUDRVLHUSA-N Asp-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N SPKCGKRUYKMDHP-GUDRVLHUSA-N 0.000 description 1
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229940125524 BAY 1101042 Drugs 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 244000293889 Bombax malabaricum Species 0.000 description 1
- 235000004480 Bombax malabaricum Nutrition 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 101000810443 Caenorhabditis elegans Hypoxia-inducible factor prolyl hydroxylase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940122434 Calcium sensitizer Drugs 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102220583904 Cellular tumor antigen p53_S96P_mutation Human genes 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical group OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 208000036828 Device occlusion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102220473545 ELAV-like protein 1_A90R_mutation Human genes 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102220498105 Electron transfer flavoprotein subunit beta_N53A_mutation Human genes 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102220590441 Epoxide hydrolase 3_S30D_mutation Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 229940126043 Galectin-3 inhibitor Drugs 0.000 description 1
- 101100042266 Gallus gallus SEMA3A gene Proteins 0.000 description 1
- 101000632260 Gallus gallus Semaphorin-3A Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 1
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 1
- LTUVYLVIZHJCOQ-KKUMJFAQSA-N Glu-Arg-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LTUVYLVIZHJCOQ-KKUMJFAQSA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 1
- HZWWOGWOBQBETJ-CUJWVEQBSA-N His-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O HZWWOGWOBQBETJ-CUJWVEQBSA-N 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000739767 Homo sapiens Semaphorin-7A Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- RKQAYOWLSFLJEE-SVSWQMSJSA-N Ile-Thr-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N RKQAYOWLSFLJEE-SVSWQMSJSA-N 0.000 description 1
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- FUKDBQGFSJUXGX-RWMBFGLXSA-N Lys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)O FUKDBQGFSJUXGX-RWMBFGLXSA-N 0.000 description 1
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 1
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241001590997 Moolgarda engeli Species 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000004019 NADPH Oxidase 1 Human genes 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000036576 Obstructive uropathy Diseases 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 1
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- JFACETXYABVHFD-WXPPGMDDSA-N Pristimerin Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C[C@H]53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-WXPPGMDDSA-N 0.000 description 1
- FMPJNBPZCVETGY-UHFFFAOYSA-N Pristimerinen Natural products C12=CC=C3C(C)=C(O)C(=O)C=C3C2=C(C)CC2(C)C1(C)CCC1(C)CCC(C(=O)OC)(C)CC12 FMPJNBPZCVETGY-UHFFFAOYSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700141 Rotifera Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108091006614 SLC10A2 Proteins 0.000 description 1
- 108091006649 SLC9A3 Proteins 0.000 description 1
- 102000009203 Sema domains Human genes 0.000 description 1
- 108050000099 Sema domains Proteins 0.000 description 1
- 102100027980 Semaphorin-3C Human genes 0.000 description 1
- 101710199433 Semaphorin-3C Proteins 0.000 description 1
- 102100037545 Semaphorin-7A Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 1
- UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 1
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 1
- KGKWKSSSQGGYAU-SUSMZKCASA-N Thr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KGKWKSSSQGGYAU-SUSMZKCASA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- PZXUIGWOEWWFQM-SRVKXCTJSA-N Tyr-Asn-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O PZXUIGWOEWWFQM-SRVKXCTJSA-N 0.000 description 1
- JJNXZIPLIXIGBX-HJPIBITLSA-N Tyr-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JJNXZIPLIXIGBX-HJPIBITLSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- GNWUWQAVVJQREM-NHCYSSNCSA-N Val-Asn-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GNWUWQAVVJQREM-NHCYSSNCSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 229960000307 avanafil Drugs 0.000 description 1
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 1
- 229950011524 avosentan Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229950002483 bardoxolone Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 101150038738 ble gene Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 101150046240 bsd gene Proteins 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000002092 calcimimetic effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- ZJKZKKPIKDNHDM-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound [Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZJKZKKPIKDNHDM-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960001767 dextrothyroxine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000003182 dose-response assay Methods 0.000 description 1
- 238000011162 downstream development Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 230000002918 effect on proteinuria Effects 0.000 description 1
- XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- FUBBWDWIGBTUPQ-UHFFFAOYSA-N ethyl 2-[4-[3-[(4-fluorophenyl)-hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylanilino]-2-oxoacetate Chemical compound CC1=CC(NC(=O)C(=O)OCC)=CC(C)=C1OC1=CC=C(O)C(C(O)C=2C=CC(F)=CC=2)=C1 FUBBWDWIGBTUPQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 102000057183 human SEMA3A Human genes 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940121575 lademirsen Drugs 0.000 description 1
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 1
- 229960001633 lanthanum carbonate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
- 229960000692 levosimendan Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229960001039 macitentan Drugs 0.000 description 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- MPYACSQFXVMWNO-UHFFFAOYSA-N n-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1C(C)(C)CN1C(=O)C1=CC=C(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)C=C1 MPYACSQFXVMWNO-UHFFFAOYSA-N 0.000 description 1
- YBWLTKFZAOSWSM-UHFFFAOYSA-N n-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=CN=CC=2)OC)=C1NS(=O)(=O)C1=CC=C(C)C=N1 YBWLTKFZAOSWSM-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-OUBTZVSYSA-N nitrogen-15 Chemical compound [15N] QJGQUHMNIGDVPM-OUBTZVSYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960000206 potassium canrenoate Drugs 0.000 description 1
- JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- IXWGHMMOEFOOFA-UHFFFAOYSA-N pristimerin Natural products COC(=O)C1(C)CCC2(C)CCC3(C)C4CC=C5C(=C(O)C(=O)C=C5C4(C)CCC3(C)C2C1)C IXWGHMMOEFOOFA-UHFFFAOYSA-N 0.000 description 1
- JFACETXYABVHFD-UHFFFAOYSA-N pristimerine Natural products CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-UHFFFAOYSA-N 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- AGMMTXLNIQSRCG-UHFFFAOYSA-N quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 description 1
- 229960000577 quinethazone Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 102200110650 rs11466111 Human genes 0.000 description 1
- 102200099928 rs137853185 Human genes 0.000 description 1
- 102220040167 rs141982003 Human genes 0.000 description 1
- 102220267892 rs1555193020 Human genes 0.000 description 1
- 102220289729 rs1555407418 Human genes 0.000 description 1
- 102200068694 rs281865207 Human genes 0.000 description 1
- 102220128896 rs376207606 Human genes 0.000 description 1
- 102220297864 rs761846391 Human genes 0.000 description 1
- 102220085078 rs863225382 Human genes 0.000 description 1
- 102220202090 rs864622596 Human genes 0.000 description 1
- 102220177883 rs886056557 Human genes 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RGYQPQARIQKJKH-UHFFFAOYSA-N setanaxib Chemical compound CN(C)C1=CC=CC(C2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2C)=C1 RGYQPQARIQKJKH-UHFFFAOYSA-N 0.000 description 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 1
- 229960005441 sevelamer carbonate Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- MKNJJMHQBYVHRS-UHFFFAOYSA-M sodium;1-[11-(2,5-dioxopyrrol-1-yl)undecanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O MKNJJMHQBYVHRS-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- DNHPDWGIXIMXSA-CXNSMIOJSA-N tenapanor Chemical compound C12=CC(Cl)=CC(Cl)=C2CN(C)C[C@H]1C1=CC=CC(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C=2C=C(C=CC=2)[C@H]2C3=CC(Cl)=CC(Cl)=C3CN(C)C2)=C1 DNHPDWGIXIMXSA-CXNSMIOJSA-N 0.000 description 1
- FOHWAQGURRYJFK-ONEGZZNKSA-N terevalefim Chemical compound C=1C=NNC=1/C=C/C1=CC=CS1 FOHWAQGURRYJFK-ONEGZZNKSA-N 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 238000002179 total cell area Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 229960000438 udenafil Drugs 0.000 description 1
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
本公开涉及结合人Sema3A的分离的抗体或其抗原结合片段。本公开的分离的抗体或抗原结合片段i)结合序列为SEQ ID NO:600的人Sema3A,解离常数(KD)≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM;ii)与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,特别是其中所述分离的抗体或其抗原结合片段以≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM的解离常数(KD)结合小鼠、食蟹猴、大鼠、猪和/或狗Sema3A;iii)结合序列为SEQ ID NO:600的人Sema3A,其结合活性经表面等离子共振(SPR)测定为≥60%、≥70%、≥80%或≥90%;iv)在体外肾小球膜细胞迁移检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤10nM、≤5nM、≤2.5nM或≤1nM;v)在体外生长锥塌陷检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤50nM、≤25nM、≤10nM或≤5nM;vi)在体外HUVEC排斥检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤1nM或≤0.3nM、≤0.1nM、≤0.07nM、≤0.06nM和/或vii)对序列为SEQ ID NO:600的细胞Sema3A具有增强的效力,诱导HUVEC排斥。
Description
技术领域
本发明提供结合人信号素3A(Sema3A)的分离的抗体或其抗原结合片段。本发明的分离的抗体或抗原结合片段i)结合序列为SEQ ID NO:600的人Sema3A,解离常数(KD)≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM;ii)与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,特别是其中所述分离的抗体或其抗原结合片段以≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM的解离常数(KD)结合小鼠、食蟹猴、大鼠、猪和/或狗Sema3A;iii)结合序列为SEQ IDNO:600的人Sema3A,其结合活性经表面等离子共振(SPR)测定为≥60%,≥70%,≥80%或≥90%;iv)在体外肾小球膜细胞迁移检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤10nM、≤5nM、≤2.5nM或≤1nM;v)在体外生长锥塌陷检测中抑制序列为SEQ IDNO:600的人Sema3A的活性,EC50≤50nM、≤25nM、≤10nM或≤5nM;和/或vi)在体外HUVEC排斥检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤1nM或≤0.3nM、≤0.1nM、≤0.07nM、≤0.06nM和/或vii)对序列为SEQ ID NO:600的细胞Sema3A具有增强的效力,诱导HUVEC排斥。本发明进一步提供编码所述抗体或其抗原结合片段的分离的核酸序列和包含其的载体、表达所述抗体或其抗原结合片段的分离的细胞、生产所述抗体或其抗原结合片段的方法以及包含所述抗体或其抗原结合片段的药物组合物和试剂盒。
本发明的抗体可用于治疗Sema3A水平或活性升高相关的疾病,例如Alport综合征、急性肾损伤(AKI)、原发性局灶节段性肾小球硬化(FSGS)或慢性肾脏病(CKD)。
背景技术
信号素3A(Sema3A)为用作导向蛋白的分泌型二聚体蛋白。它与神经纤毛蛋白-1以及不同的神经丛蛋白构成三元复合物从而激活不同的信号通路。它是细胞迁移、黏附、细胞骨架稳定和凋亡的关键调控分子。Sema3A在成人肾脏的足细胞中表达,受损伤后会被诱导。
过量Sema3A干扰肾小球滤过屏障,诱导滤过屏障的超微结构变化,导致足细胞足突融合以及白蛋白尿。在发生AKI后,Sema3A也会被高度诱导,通过促进肾小管炎症、肾小管上皮细胞凋亡以及滤过屏障超微结构异常加重损伤。啮齿动物的Sema3A的基因缺陷或药物抑制导致不同的肾病动物模型中肾损伤减轻。
此外,Sema3A还在视网膜神经元和内皮中表达。啮齿动物模型中显示其增加血管通透性,促进视网膜炎症和细胞衰老,并抑制视网膜血管再生。Sema3A还在CNS疾病中发挥作用。抑制Sema3A可促进受损轴突的再生和/或保护,降低凋亡细胞数并促进血管生成,从而获得大为改善的功能恢复。
WO 20141/23186公开了一种禽-小鼠嵌合抗体(源于No.4-2克隆株)及两个其人源化IgG1变体,并表明它们适用于治疗阿尔兹海默病。
WO 2017/074013公开了抗Sema3A的IgG抗体A08、C10和F11并表明它们适用于治疗癌症。
目前,尚无抑制Sema3A与其受体相互作用治疗蛋白尿肾病(例如Alport综合征)等疾病的患者的治疗方案,据推测,单克隆的治疗性Sema3A抗体可能最适合用于这种疾病。因此,对用于治疗Sema3A水平或活性升高相关的疾病,例如Alport综合征、急性肾损伤(AKI)、原发性局灶节段性肾小球硬化(FSGS)或慢性肾脏病(CKD)的新型治疗性Sema3A抗体存在巨大的需求,而这种需求迄今尚未得到满足。
发明目的
鉴于现有技术,本发明的目的为提供克服现有技术中Sema3A抗体缺点的新型治疗性Sema3A抗体。具体而言,本发明的目的为提供为有效阻断Sema3A活性的人Sema3A的高亲和力结合剂的新型Sema3A抗体。理想的Sema3A抗体能和多个物种的Sema3A交叉反应以便进行临床前试验。它们在人类治疗中无免疫原性,即其为人的或人源化的抗体。理想的Sema3A抗体对Sema3A有选择性;其不结合非靶分子(off-target)并且尤其不和其他信号素蛋白家族成员交叉反应。
此类新型Sema3A抗体将使与Sema3A水平或活性升高相关的疾病(例如Alport综合征、急性肾损伤(AKI)、原发性局灶节段性肾小球硬化(FSGS)或慢性肾脏病(CKD))的治疗取得重大进展。
发明内容
上述目的和其他目的通过本发明的教导达成。本发明基于新型抗体的发现,其对Sema3A具有特异性亲和力并能为受试者带来治疗益处。
因此,在第一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段i)结合序列为SEQ ID NO:600的人Sema3A,解离常数(KD)≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM;ii)与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,特别是其中所述分离的抗体或其抗原结合片段以≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM的解离常数(KD)结合小鼠、食蟹猴、大鼠、猪和/或狗Sema3A;iii)结合序列为SEQID NO:600的人Sema3A,其结合活性经表面等离子共振(SPR)测定为≥60%,≥70%,≥80%或≥90%;iv)在体外肾小球膜细胞迁移检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤10nM、≤5nM、≤2.5nM或≤1nM;v)在体外生长锥塌陷检测中抑制序列为SEQ IDNO:600的人Sema3A的活性,EC50≤50nM、≤25nM、≤10nM或≤5nM;vi)在体外HUVEC排斥检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤1nM或≤0.3nM、≤0.1nM、≤0.07nM、≤0.06nM和/或vii)对序列为SEQ ID NO:600的细胞Sema3A具有增强的效力,诱导HUVEC排斥。
本发明的分离的抗体或抗原结合片段以高亲和力结合人Sema3A并抑制其功能。因此,本发明的分离的抗体或抗原结合片段可用于治疗与Sema3A水平或活性升高相关的疾病,例如i)肾脏病,尤其是急性和慢性肾脏病、糖尿病肾病、Alport综合征、急性和慢性肾功能衰竭、多囊肾病(PCKD)和抗利尿激素分泌不当综合征(SIADH);ii)肾功能不全的后遗症,尤其是肺水肿、心力衰竭、尿毒症、贫血、电解质紊乱例如高钾血症和低钠血症以及骨骼和碳水化合物代谢紊乱;iii)血管通透性过高、糖尿病视网膜病变、血视网膜屏障受损、黄斑水肿尤其是年龄相关性黄斑水肿、非增殖性年龄相关性黄斑水肿和非增殖性糖尿病性黄斑水肿;iv)中枢或外周神经系统疾病尤其是神经病理性疼痛、脊髓损伤、多发性硬化、创伤性脑损伤、脑水肿和神经退行性疾病(尤其是阿尔兹海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化、进行性核上性麻痹、黑质变性、Shy-Drager综合征、橄榄-脑桥-小脑萎缩和脊髓小脑变性);v)癌症,尤其是肠癌、结直肠癌、肺癌、乳腺癌、脑癌、黑色素瘤、肾细胞癌、白血病、淋巴瘤、T细胞淋巴瘤、胃癌、胰腺癌、宫颈癌、子宫内膜癌、卵巢癌、食管癌、肝癌、头颈部鳞状细胞癌、皮肤癌、泌尿道癌、前列腺癌、绒毛膜癌、咽癌和喉癌。
本发明的分离的抗体或抗原结合片段可进一步用于诊断Sema3A相关的疾病。
另一方面,本发明涉及编码本发明的抗体或抗原结合片段的分离的核酸序列。
另一方面,本发明涉及包含本发明的核酸序列的载体。
另一方面,本发明涉及表达本发明的抗体或抗原结合片段和/或包含本发明的核酸或本发明的载体的分离的细胞。
另一方面,本发明涉及生产本发明的分离的抗体或抗原结合片段的方法,其包括培养本发明的细胞和任选地纯化抗体或其抗原结合片段。
另一方面,本发明涉及包含本发明的分离的抗体或抗原结合片段或本发明的抗体偶联物的药物组合物。
另一方面,本发明涉及包含本发明的分离的抗体或抗原结合片段或本发明的偶联物的试剂盒与使用说明书。
发明详述
参考下列发明的详细描述及其中的实施例可以更容易理解本发明。
定义
除非另有定义,本文使用的所有技术和科学术语具有本发明所属的技术领域的普通技术人员通常理解的含义。然而,以下参考文献可为本发明所属的技术领域的技术人员提供本发明中使用的许多术语的一般性定义,并且只要这类定义合乎本领域中通常理解的含义,以下参考文献就可被引用和使用。这类参考文献包括但不限于:Singleton等人,Dictionary of Microbiology and Molecular Biology(2nd ed.1994);The CambridgeDictionary of Science and Technology(Walker ed.,1988);Hale&Marham,The HarperCollins Dictionary of Biology(1991);Lackie等人,The Dictionary of Cell&Molecular Biology(3d ed.1999);和Cellular and Molecular Immunology,Eds.Abbas,Lichtman和Pober,2nd Edition,W.B.Saunders Company。可查阅任何其他的本领域技术人员可获得的提供本文使用的具有本领域中通常理解的含义的术语定义的技术资源。为了本发明的目的,进一步定义以下术语。其他术语在说明书中的其他地方定义。当用于本文和所附权利要求书中时,单数形式“一(a)”和“所述”包括复数指代对象,除非上下文另有明确指示。因此,例如,提及“一个基因”是提及一个或多个基因并包括本领域技术人员已知的其等同物,等等。
在本发明语境中,术语“包含”或“包括”指“包括,但不限于”。该术语意为开放的,用于限定任何所述的特征、元素、整体、步骤或组分的存在,但不排除一个或多个其他特征、元素、整体、步骤、组分或其组合的存在或添加。因此术语“包含”包括限制性更强的术语“由……组成”和“基本上由……组成”。在一个实施方案中,贯穿本申请且尤其在权利要求书中使用的术语“包含”可替换为术语“由……组成”。
在本文中,术语“约”或“大约”意指在给定值或范围的80%至120%之间,或90%至110%之间,包括95%至105%之间。
术语“多肽”和“蛋白”在本文中可互换使用来指氨基酸残基的聚合物。该术语适用于其中一个或多个氨基酸残基是相应天然存在的氨基酸的人工化学模拟物的氨基酸聚合物,以及适用于天然存在的氨基酸聚合物和非天然存在的氨基酸聚合物。除非另外指出,特定的多肽序列也隐含地涵盖其保守修饰的变体。
本文中使用的“Sema3A”指“信号素3A”,也称为“HH16”、“SemD”、“COLL1”、“SEMA1”、“SEMAD”、“SEMAL”、“coll-1”、“Hsema-I”、“SEMAIII”、“Hsema-III”、“脑衰蛋白1”、“信号素D”、“信号素III”和“信号素L”。
术语“抗Sema3A抗体”和“结合Sema3A的抗体”指能够以足够亲和力结合Sema3A的抗体,从而使该抗体可用作靶向Sema3A的诊断剂和/或治疗剂。在一个实施方案中,抗Sema3A抗体与非相关的非Sema3A蛋白的结合程度低于抗体和Sema3A的结合程度的约10%、约5%或约2%,例如由ELISA标准程序测得的。在某些实施方案中,结合Sema3A的抗体的结合活性(EC50)≤1μM、≤100nM、≤10nM、≤1nM、≤0.1nM、≤0.01nM或≤0.001nM(例如10-8M或更小,例如从10-8M至10-13M,例如从10-9M至10-13M)。在某些实施方案中,抗Sema3A抗体和在不同物种的Sema3A中保守的Sema3A表位结合。
如本文所用,术语“抗体”意指免疫球蛋白分子。抗体可包含四条多肽链,通常通过二硫键相互连接的两条重(H)链(约50-70kDa)和两条轻(L)链(约25kDa)。在特定实施方案中,抗体由两对相同的多肽链组成。每条链的氨基端部分包含约100至110个或更多个氨基酸的主要负责抗原识别的“可变”区。重链可变区在本文中缩写为VH,轻链可变区在本文中缩写为VL。每条链的羧基端部分定义主要负责效应子功能的恒定区。重链恒定区可包含例如三个结构域CH1、CH2和CH3。轻链恒定区由一个结构域(CL)组成。VH区和VL区可进一步细分为高度可变的区域,称作互补决定区(CDR),与更保守的区域交错在一起,称作框架区(FR)。每个VH和VL通常由三个CDR和至多四个FR组成,它们从氨基端到羧基端以例如下列顺序排列:FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4。
如本文所用,术语“互补决定区”(CDR;例如CDR1、CDR2和CDR3)是指抗体可变结构域的氨基酸残基,互补决定区的存在对于抗原结合来说是必需的。每个可变结构域通常具有3个被鉴别为CDR1、CDR2和CDR3的CDR区。每个互补决定区可包含来自如Kabat所定义的“互补决定区”的氨基酸残基(Kabat等人,Sequences of Proteins of ImmunologicalInterest,5th Ed.Public Health Service,National Institutes of Health,Bethesda,MD.(1991))和/或来自“高变环”的那些残基(Chothia和Lesk;J Mol Biol 196:901-917(1987))。在一些情况下,互补决定区可包括来自根据Kabat定义的CDR区和来自高变环的氨基酸。
“框架”或FR残基为除了高变区残基以外的那些可变结构域残基。
短语“恒定区”指抗体分子中赋予效应子功能的部分。
本文中的术语“Fc区”用于定义含有恒定区的至少一部分的免疫球蛋白重链的C端区域。该术语包括天然序列Fc区和变体Fc区。在一个实施方案中,人IgG重链Fc区从Cys226或从Pro230延伸至重链的羧基端。然而,Fc区的C端赖氨酸(Lys447)可以存在或可以不存在。除非在本文中另有规定,否则Fc区或恒定区中的氨基酸残基的编号根据EU编号系统,也称为EU索引,如Kabat等人,Sequences of Proteins of Immunological Interest,5thEd.Public Health Service,National Institutes of Health,Bethesda,MD,1991中所描述的。
根据它们重链恒定区的氨基酸序列,可将免疫球蛋白分为不同类。重链分为μ、Δ、γ、α和ε,分别定义抗体的同种型为IgM、IgD、IgG、IgA和IgE。在特定实施方案中,本发明的抗体为IgG抗体。这些中的若干可进一步分为亚类或同种型,例如IgG1、IgG2、IgG3、IgG4、IgA1和IgA2。在特定实施方案中,本发明的抗体为IgG1、IgG2、IgG3或IgG4抗体,更具体而言为IgG1或IgG4抗体。不同的同种型可能有不同的效应子功能。人轻链分为κ和λ轻链。在轻链和重链中,可变区和恒定区通过约12个或更多氨基酸的“J”区连接,重链还包含多出约10个氨基酸的“D”区。总体参考Fundamental Immunology,Ch.7(Paul,W.,ed.,2nd ed.RavenPress,N.Y.(1989))。
抗体/免疫球蛋白的“功能片段”或“抗原结合抗体片段”据此定义为保留抗原结合区的抗体/免疫球蛋白的片段(例如IgG的可变区)。抗体的“抗原结合区”通常见于抗体的一个或多个高变区中,例如CDR1、CDR2和/或CDR3区;然而,可变“框架”区也可诸如通过提供用于CDR的支架,而在抗原结合中发挥重要作用。优选地,“抗原结合区”包含至少可变轻(VL)链的4-103位氨基酸残基和可变重(VH)链的5-109位氨基酸残基,更优选VL的3-107位氨基酸残基和VH的4-111位氨基酸残基,且特别优选的是完整的VL和VH链(VL的氨基酸位点1-109和VH的氨基酸位点1-113;根据WO 97/08320编号)。
“功能片段”或“抗原结合抗体片段”的非限制性实例包括Fab、Fab’、F(ab’)2、Fv片段、结构域抗体(dAb)、互补决定区(CDR)片段、单链抗体(scFv)、单链抗体片段、双抗体、三抗体、四抗体、微型抗体、线性抗体(Zapata等人,Protein Eng.,8(10):1057-1062(1995));螯合重组抗体、三体(tribodies)或双体(bibodies)、胞内抗体、纳米抗体、小模块免疫药物(SMIP)、抗原结合结构域免疫球蛋白融合蛋白、骆驼源化(camelized)抗体、含VHH的抗体、或突变蛋白或其衍生物、和含有免疫球蛋白的至少一部分(足够赋予多肽特异性抗原结合能力)如CDR序列的多肽(只要抗体保留所需生物活性);和由抗体片段形成的多特异性抗体例如双和三特异性抗体(C.A.K Borrebaeck,editor(1995)Antibody Engineering(Breakthroughs in Molecular Biology),Oxford University Press;R.Kontermann&S.Duebel,editors(2001)Antibody Engineering(Springer Laboratory Manual),Springer Verlag)。除了“双特异性”或“双功能”抗体以外的抗体被理解为其每个结合位点相同。可以将F(ab’)2或Fab改造以最小化或完全除去存在于CH1和CL结构域之间的分子间二硫化物相互作用。抗体经木瓜蛋白酶消化产生两个相同的称作“Fab”片段的抗原结合片段(各自具有单一抗原结合位点)和残留的名称反映可其易结晶能力的“Fc”片段。胃蛋白酶处理产生含有两个“Fv”片段的F(ab’)2片段。“Fv”片段为含有完整的抗原识别和结合位点的最小抗体片段。该区域由一个重链可变结构域和一个轻链可变结构域的紧密非共价缔合的二聚体组成。正是在这种构型下,每个可变结构域的三个CDR相互作用,以在VH-VL二聚体表面确定抗原结合位点。六个CDR共同赋予抗体抗原结合特异性。然而,即使是单个可变结构域(或仅含三个对某抗原有特异性的CDR的半个Fv)也有能力识别和结合抗原。
“单链Fv”或“sFv”或“scFv”抗体片段包含抗体的VH和VL结构域,其中这些结构域存在于单个多肽链中。
优选地,Fv多肽进一步包含VH和VL结构域之间的多肽接头,其使Fv形成抗原结合所需的结构。Fv的综述见Pluckthun的The Pharmacology of Monoclonal Antibodies,vol.113,Rosenburg和Moore eds.,Springer-Verlag,New York,pp.269-315(1994)。
Fab片段还包含轻链的恒定结构域和重链的第一个恒定结构域(CH1)。Fab片段和Fab’片段的区别在于在重链CH1结构域的羧基端添加了几个残基,包括来自抗体铰链区的一个和多个半胱氨酸残基。Fab’-SH是本文中Fab’的名称,其中恒定结构域的半胱氨酸残基具有游离的巯基。F(ab’)2抗体片段最初是以成对的Fab’片段形式形成的,这些片段之间有铰链半胱氨酸残基。
术语“突变蛋白”和“变体”可互换使用,指在可变区或等同于可变区的部分含有至少一个氨基酸取代、缺失或插入的抗体或抗原结合片段,条件是突变蛋白或变体保留所需结合亲和力或生物活性。本发明设想的抗体和抗原结合抗体片段的变体为保留抗体和抗原结合抗体片段的结合活性的分子。
“嵌合抗体”或其抗原结合片段在本文中被定义为其中可变区来源于非人来源并且一些或全部恒定区来源于人来源的抗体或其抗原结合片段。
“人源化抗体”包含例如和任何必要的框架回复突变一起移入源于人序列的V区的CDR区(源自非人物种如小鼠)。因此,人源化抗体通常为人免疫球蛋白(受者抗体),其中受者高变区的残基替换为具有所需特异性、亲和力和结合能力的非人物种(例如小鼠、大鼠、兔或非人灵长类)(供者抗体)高变区的残基。参见例如U.S.Pat.Nos.5,225,539;5,585,089;5,693,761;5,693,762;5,859,205,各自通过引用的方式纳入本文中。在一些情况下,人免疫球蛋白的框架残基替换为相应的非人残基(参见例如U.S.Pat.Nos.5,585,089;5,693,761;5,693,762,各自通过引用的方式纳入本文中)。此外,人源化抗体可能包含受者抗体或供者抗体中不存在的残基。这些改造是为了进一步优化抗体性能(例如获得所需亲和力)。通常,人源化抗体会基本上包含至少一个、通常两个可变结构域的全部,其中全部或基本上全部高变区对应非人免疫球蛋白高变区,全部或基本上全部框架区为人免疫球蛋白序列框架区。人源化抗体可选地同样会包含免疫球蛋白恒定区(Fc)的至少一部分,通常为人免疫球蛋白。更多细节参见Jones等人,Nature 331:522-25(1986);Riechmann等人,Nature332:323-27(1988);和Presta,Curr.Opin.Struct.Biol.2:593-96(1992),各自通过引用的方式纳入本文中。
“人抗体”或“全人抗体”包含人源CDR,即人类来源的CDR。全人抗体和最接近的人种系参照相比可能含有少量种系偏差(根据IMGT数据库(http://www.imgt.org)确定)。例如,本发明的全人抗体和最接近的人种系参照相比可能在CDR含有多至1、2、3、4、5、6、7、8、9或10个种系偏差。全人抗体可由人源B细胞通过克隆技术加细胞富集或永生化步骤开发。然而大部分全人抗体分离自整合人IgG基因座的免疫小鼠或复杂的噬菌体展示组合文库(Brüggemann M.,Osborn M.J.,Ma B.,Hayre J.,Avis S.,Lundstrom B.和Buelow R.,HumanAntibody Production in Transgenic Animals,Arch Immunol Ther Exp(Warsz.)63(2015),101-108;Carter P.J.,Potent antibody therapeutics by design,Nat RevImmunol 6(2006),343-357;Frenzel A.,Schirrmann T.和Hust M.,Phage display-derived human antibodies in clinical development and therapy,MAbs 8(2016),1177-1194;Nelson A.L.,Dhimolea E.和Reichert J.M.,Development trends for humanmonoclonal antibody therapeutics,Nat Rev Drug Discov 9(2010),767-774.)。
若干技术可用于产生全人抗体(参见WO2008/112640A3)。Cambridge AntibodyTechnologies(CAT)和Dyax从分离自免疫人类的外周B细胞获得了抗体cDNA序列,并设计了噬菌体展示文库以尤其特异地识别人可变区序列。简言之,抗体可变区序列和M13噬菌体的Gene III或Gene VIII结构融合。这些抗体可变区序列于携带各自序列的噬菌体尖端表达为Fab或单链Fv(scFv)结构。经过数轮使用不同水平的抗原结合条件(严格性(stringency))的淘选过程,表达对目的抗原有特异性的Fab或scFv结构的噬菌体能被挑选和分离。然后使用标准测序流程可解析所选择的噬菌体的抗体可变区cDNA序列。接下来这些序列可通过现有的抗体工程技术用于重构具有所需同种型的完整的抗体。依照此方法构建的抗体被认为是全人抗体(包括CDR)。为了提高所选择的抗体的免疫反应性(抗原结合亲和力和特异性),可采用体外成熟方法,包括不同重链和轻链的组合缔合、位于重链和轻链CDR3的删除/添加/突变(以模拟V-J和V-D-J重组)和随机突变(以模拟体细胞超突变)。通过此方法产生的“全人”抗体的一个实例为抗肿瘤坏死因子α抗体 (阿达木单抗)。
通过改变亲代序列产生“Human EngineeredTM”抗体的方法阐述于Studnicka等人,U.S.Patent No.5,766,886中。
本发明的抗体可源自重组抗体基因文库。构建重组人抗体基因库的技术的发展以及编码的抗体片段在丝状噬菌体表面的展示提供了直接制备和筛选人抗体的重组方法,其同样能用于人源化抗体、嵌合抗体、鼠抗体或突变蛋白抗体。通过噬菌体技术生产的抗体为细菌产生的抗原结合片段(通常为Fv或Fab片段),因此缺少效应子功能。效应子功能可由两种策略之一引入:片段可改造为哺乳动物细胞中表达的完整的抗体,或改造为具有能够触发效应子功能的第二个结合位点的双特异性抗体片段。通常,抗体的重链VH-CH1和轻链VL-CL经PCR分别克隆后在噬菌体展示组合文库中随机重组,再根据与特定抗原的结合进行筛选。Fab片段在噬菌体表面表达,即与编码它们的基因物理上相连。因此,通过抗原结合的Fab筛选能共筛选Fab编码序列,后者后续可以扩增。经过数轮抗原结合和再扩增(该程序称作淘选),抗原特异性Fab被富集并最终分离。
对于来源于噬菌体展示文库的人抗体,已经有多种方法进行了描述。这些文库可构建于单个主框架上,不同的体内形成的(即人源的)CDR能够结合其中,如描述于Carlsson和Exp.Rev.Mol.Diagn.1(1),102-108(2001),等人,Nat.Biotech.18,852-856(2000)和U.S.Patent No.6,989,250。或者,该抗体文库可基于用计算机设计并由合成的核酸编码的氨基酸序列。实现了计算机设计抗体序列,通过例如分析人序列数据库并利用从中获得的数据设计多肽序列。设计和获得计算机生成的序列的方法描述于例如Knappik等人,J.Mol.Biol.(2000)296:57;Krebs等人,J.Immunol.Methods.(2001)254:67;和U.S.Patent No.6,300,064。综述关于噬菌体展示筛选(例如参见Hoet RM等人,NatBiotechnol2005;23(3):344-8)、众所周知的杂交瘤技术(例如参见和MilsteinNature.1975Aug 7;256(5517):495-7)或小鼠免疫尤其是hMAb小鼠免疫(例如VelocImmune)。
本文使用的术语“单克隆抗体”是指获自基本上同质的抗体群体的抗体,即,所述群体包含的单个抗体除了可能以极少量存在的可能突变(例如天然发生的突变)之外是相同的。因此,所述术语“单克隆”表明所述抗体的性质,即不是不相关的抗体的混合物。与通常包括针对不同决定簇(表位)的不同抗体的多克隆抗体制剂相反,单克隆抗体制剂的每个单克隆抗体均针对抗原上的单一决定簇。除了其特异性之外,单克隆抗体制剂的优势在于它们通常不会被其他免疫球蛋白污染。术语“单克隆”不应被理解为需要通过任何特定的方法产生抗体。例如,使用的单克隆抗体可由杂交瘤法(首次描述于Kohler等人,Nature,256:495(1975))制备,也可由重组DNA法(参见例如U.S.Patent No.4,816,567)制备。“单克隆抗体”还可能是例如重组抗体、嵌合抗体、人源化抗体、人抗体、Human EngineeredTM抗体或抗体片段。
“分离的”抗体是已经被鉴别并且从表达它的细胞的组分中分离的抗体。细胞的污染组分是会干扰抗体的诊断或治疗用途的物质,可包括酶、激素和其他蛋白质的或非蛋白质的溶质。
“分离的”核酸是已经被鉴定且与其天然环境的组分分离的核酸。分离的核酸包括通常含有核酸分子的细胞中含有的核酸分子,但核酸分子存在于染色体外或与其天然染色体位置不同的染色体位置。
如本文所用,抗体“特异性结合至”、“特异性针对”或“特异性识别”目的抗原如Sema3A,即以足够的亲和力结合抗原以使得抗体可用作治疗剂靶向表达抗原的细胞或组织。如本文所用的术语“特异性识别”或“特异性结合至”或“特异性针对”特定多肽或特定多肽靶标上的表位,可以通过例如对抗原的单价KD低于约10-4M,或者低于约10-5M,或者低于约10-6M,或者低于约10-7M,或者低于约10-8M,或者低于约10-9M,或者低于约10-10M,或者低于约10-11M,或者低于约10-12M,或更低的抗体或其抗原结合片段来展现。
如果抗体能够将抗原和一种或多种参照抗原区分开,那么这样的抗体“选择性结合至”、“选择性针对”或“选择性识别”所述抗原。具体而言,“选择性结合至”抗原的抗体与除了前述抗原靶标的直系同源物和变体(例如突变形式、剪接变体,或蛋白水解作用截短的形式)以外的蛋白质无显著交叉反应。在其最一般的形式中,“选择性结合”、“选择性结合至”、“选择性针对”或“选择性识别”是指按照例如以下方法之一测定的抗体区分目的抗原和不相关抗原的能力。这类方法包括但不限于表面等离子共振(SPR)、Western印迹、ELISA测试、RIA测试、ECL测试、IRMA测试和肽扫描。例如,可进行标准ELISA测定。可以通过标准显色进行评分(例如,具有辣根过氧化物酶的二抗和过氧化氢与四甲基联苯胺的混合溶液)。在某些孔中的反应通过例如在450nm下的光密度来进行评分。典型背景(=阴性反应)可以为0.1OD;典型阳性反应可以为1OD。这意味着阳性/阴性的差异可以大于5倍、10倍、50倍,优选大于100倍。通常,通过使用不止单独一个参照抗原而是一组约三至五个不相关的抗原(例如奶粉、BSA、转铁蛋白等)来确定结合选择性。
“结合亲和力”或“亲和力”是指分子的单个结合位点与其结合配偶体之间非共价相互作用总和的强度。除非另有说明,如本文所用,“结合亲和力”是指固有的结合亲和力,其反映结合对(例如抗体和抗原)的成员之间1:1的相互作用。解离常数“KD”通常用于描述分子(例如抗体)与其结合配偶体(例如抗原)之间的亲和力,即,配体结合特定蛋白的紧密程度。配体-蛋白亲和力受到两个分子之间非共价分子间相互作用的影响。亲和力可通过本领域中已知的常规方法测量,包括本文描述的那些。在一个实施方案中,本发明的“KD”或“KD值”是通过使用表面等离子共振测定法使用BiacoreTMT100仪器(GE Healthcare Biacore,Inc.)来测量的。其他合适的设备为Biacore T100、Biacore(R)-2000、Biacore 4000、Biacore(R)-3000(Biacore,Inc.,Piscataway,NJ)或ProteOnTMXPR36仪器(Bio-RadLaboratories,Inc.)。
如本文所用,术语“表位”包括能够特异性结合至免疫球蛋白或T细胞受体的任何蛋白质决定簇。表位决定簇通常由分子的化学活性表面集群(例如氨基酸或糖侧链,或其组合)组成,并且通常具有特定的三维结构特征以及特定的电荷特性。
与参照抗体“结合相同表位的抗体”或与参照抗体“竞争结合的抗体”是指在竞争测定中使参照抗体与其抗原的结合阻断10%、20%、30%、40%、50%或更多的抗体,相对地,参照抗体在竞争测定中使所述抗体与其抗原的结合阻断10%、20%、30%、40%、50%或更多。
术语“成熟的抗体”或“成熟的抗原结合片段”,诸如成熟的Fab变体或“优化的”变体,包括对给定抗原诸如靶蛋白的细胞外结构域表现出更强的结合(即亲和力提高的结合)的抗体或抗体片段的衍生物。成熟是鉴定抗体或抗体片段的六个CDR内导致亲和力增加的少量突变的过程。成熟过程是将突变引入抗体并筛选以鉴定改进的结合物的分子生物学方法的组合。
分别相对于参照多核苷酸或多肽序列的“序列一致性百分比(%)”,被分别定义为(如果需要)比对序列以及引入缺口(gap)以实现最大序列一致性百分比之后,候选序列中分别与参照多核苷酸或多肽序列中核酸或氨基酸残基相同的核酸或氨基酸残基的百分比。保守置换不被认为是序列一致性的一部分。优选无缺口的比对。目的为确定氨基酸序列一致性百分比的比对能够以在本领域技术内的多种方式实现,例如,使用可公开获得的计算机软件例如BLAST、BLAST-2、ALIGN或MegAlign(DNASTAR)软件。本领域技术人员可确定用于比对序列的合适参数,包括在要比较的序列全长上实现最大对齐所需要的任何算法。
“序列同源性”表示相同的或代表保守性氨基酸置换的氨基酸的百分比。
“拮抗性”抗体或“阻断性”抗体是显著抑制(部分或完全)其结合的抗原的生物活性的抗体。在特定实施方案中,本发明的抗体或抗原结合片段为Sema3A阻断性抗体或其抗原结合片段。
术语“抗体偶联物”指与一个或多个包括药物(该情况下抗体偶联物称作“抗体-药物偶联物”(“ADC”))以及高分子量分子如肽或蛋白质的分子偶联的抗体。
术语“抗体药物偶联物”或“ADC”是指与一个或多个细胞毒性剂或细胞抑制剂偶联的抗体,细胞毒性剂或细胞抑制剂例如为化疗剂、药物、生长抑制剂、毒素(例如蛋白毒素(细菌、真菌、植物或动物来源的酶活性毒素)或其片段),或者放射性同位素(即放射性偶联物)。免疫偶联物已经被用于在癌症的治疗过程中局部递送细胞毒性剂,即杀死或抑制细胞的生长或增殖的药物(例如Liu等人,Proc Natl.Acad.Sci.(1996),93,8618-8623)。免疫偶联物可将药物部分靶向递送至肿瘤并在肿瘤细胞内蓄积,而非偶联药物的全身给药可导致对正常细胞和/或组织产生不可接受的毒性水平。抗体毒素偶联物中使用的毒素包括细菌毒素例如白喉毒素、植物毒素例如蓖麻毒素、小分子毒素例如格尔德霉素。所述毒素可通过一些机制——包括微管蛋白结合、DNA结合或拓扑异构酶抑制——发挥它们的细胞毒性效应。
本文中可以通过氨基酸众所周知的三字母符号或通过IUPAC-IUB BiochemicalNomenclature Commission推荐的单字母符号来指代氨基酸。同样地,可以通过其普遍接受的单字母代码指代核苷酸。
如本文所用,术语“载体”是指能够扩增与之连接的另一核酸的核酸分子。该术语包括作为自我复制的核酸结构的载体以及整合到其已被导入的宿主细胞的基因组中的载体。某些载体能够引导与其可操作地连接的核酸的表达。此类载体在本文中称为“表达载体”。
术语“宿主细胞”、“宿主细胞系”和“宿主细胞培养物”可互换使用,是指已经向其中导入至少一个外源核酸的细胞,包括此类细胞的后代。宿主细胞包括“转化子”和“转化的细胞”、“转染子”和“转染的细胞”以及“转导的细胞”,其包括转化/转染/转导的原代细胞和由其衍生的后代,而不考虑传代次数。后代的核酸组成可以与亲本细胞不完全相同,而是可以含有突变。本文包括具有与在初始转化的细胞中筛选或选择的相同的功能或生物活性的突变后代。
如本文所用,短语“治疗有效量”意指按所需治疗方案给药时适合引起所需治疗或预防效果或反应(包括缓解疾病的这些症状的部分或全部或减少疾病的易感性)的治疗或预防性抗体的量。
术语“药物制剂”/“药物组合物”是指这样的制剂,其形式使得允许其中含有的活性成分的生物活性是有效的,且不含对将施用所述制剂的患者而言具有不可接受的毒性的添加成分。
本发明的抗体
一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段结合序列为SEQ ID NO:600的人Sema3A,解离常数(KD)≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM。在特定实施方案中,分离的抗体或其抗原结合片段结合SEQ ID NO:582的His标记的人Sema3A结构域,解离常数(KD)≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,特别是其中所述分离的抗体或其抗原结合片段以≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM的解离常数(KD)结合小鼠、食蟹猴、大鼠、猪和/或狗Sema3A。
在特定此类实施方案中,所述亲和力是与SEQ ID NO:601的小鼠Sema3A、与SEQ IDNO:602的食蟹猴Sema3A、与SEQ ID NO:603的大鼠Sema3A、与SEQ ID NO:604的猪Sema3A、以及与SEQ ID NO:605的狗Sema3A的亲和力。在特定实施方案中,所述亲和力是与SEQ ID NO:583的His标记的小鼠Sema3A结构域、与SEQ ID NO:586的His标记的食蟹猴Sema3A结构域、与SEQ ID NO:584的His标记的大鼠Sema3A结构域、与SEQ ID NO:587的His标记的猪Sema3A结构域以及与SEQ ID NO:585的His标记的狗Sema3A结构域的亲和力。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段结合人Sema3A,其结合活性经表面等离子共振(SPR)测定为≥60%,≥70%,≥80%或≥90%。在特定实施方案中,分离的抗体或其抗原结合片段结合序列为SEQ ID NO:600的人Sema3A,其结合活性经表面等离子共振(SPR)测定为≥60%,≥70%,≥80%或≥90%。在特定实施方案中,分离的抗体或其抗原结合片段结合序列为SEQID NO:582的His标记的人Sema3A结构域,其结合活性经表面等离子共振(SPR)测定为≥60%,≥70%,≥80%或≥90%。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段在体外肾小球膜细胞迁移检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤10nM、≤5nM、≤2.5nM或≤1nM。
具体而言,本发明的分离的抗体或抗原结合片段在使用人原代肾小球系膜细胞的体外划痕实验(在实施例9更详细地描述)中抑制序列为SEQ ID NO:600的人Sema3A的活性。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段在体外生长锥塌陷检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤50nM、≤25nM、≤10nM或≤5nM。
具体而言,如实施例10中所更详细地描述的,本发明的分离的抗体或抗原结合片段在使用小鼠背根神经节(DRG)神经元的体外生长锥塌陷检测中抑制Sema3A诱导的细胞支架塌陷。实施例10中所述的体外生长锥检测为Mikule等人(PMID:12077190)所述生长锥检测的改良版本。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段在体外HUVEC排斥检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤1nM或≤0.3nM、≤0.1nM、≤0.07nM、≤0.06nM。
具体而言,如实施例11中所述的,本发明的分离的抗体或抗原结合片段在体外排斥检测(其中将表达序列为SEQ ID NO:600的Sema3A的HEK293细胞接种于融合的单层人脐静脉内皮细胞(HUVEC)上)中抑制Sema3A诱导的细胞排斥。
另一方面,本发明涉及结合序列为SEQ ID NO:600的Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段在HUVEC排斥检测中具有增强的效力;i)其中所述分离的抗体或其抗原结合片段在HUVEC排斥检测中比SEQ ID 81、85、97、98的TPP-17755或SEQ ID 1、5、17、18的TPP-11489或SEQ ID 800、804、810、811的TPP-30788或SEQ ID 814、818、824、825的TPP-30789或SEQ ID 828、832、838、839的TPP-30790或SEQ ID842、846、852、853的TPP-30791具有增强的效力;ii)其中所述分离的抗体或其抗原结合片段对细胞Sema3A诱导的HUVEC排斥根据EC50值具有比SEQ ID 81、85、97、98的TPP-17755或SEQ ID 1、5、17、18的TPP-11489或SEQ ID 800、804、810、811的TPP-30788或SEQ ID 814、818、824、825的TPP-30789或SEQ ID 828、832、838、839的TPP-30790或SEQ ID 842、846、852、853的TPP-30791强优选>400倍、优选>50倍、优选>5倍、优选>2倍的效力;iii)其中所述分离的抗体或其抗原结合片段比具有前述序列的TPP-17755、TPP-11489、TPP-30788、TPP-30789、TPP-30790或TPP-30791抑制率至少提高30%,优选地Sema3A抑制率至少提高50%;iv)其中所述分离的抗体或其抗原结合片段对人Sema3A体外HUVEC排斥检测具有两位数皮摩尔的活性,而现有技术中具有前述序列的TPP-17755、TPP-11489、TPP-30788、TPP-30789、TPP-30790或TPP-30791的抗体效价在三位数皮摩尔甚至纳摩尔的范围;v)其中所述分离的抗体或其抗原结合片段在体外HUVEC排斥检测中抑制人Sema3A的活性,EC50≤1nM或≤0.3nM、≤0.1nM、≤0.07nM、≤0.06nM,如实施例11中所述。
本发明的分离的抗体或抗原结合片段在HUVEC排斥检测中比TPP-30788-TPP-30791(BI克隆I至IV)具有增强的效力,这可能是由于结合了人Sema3A的不同的表位。
另一方面,本发明涉及结合Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段在体内抑制Sema3A的活性,因为本发明的抗体减少Sema3A诱导的尿白蛋白排泄。因此另一方面,本发明涉及结合Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段在体内具有更高的Sema3A抑制活性,i)其中所述抗体比TPP-30788(BI克隆I)显示出增强的对Sema3A诱导的尿白蛋白排泄的降低作用;ii)其中所述抗体比TPP-17755(Samsung)显示出增强的对Sema3A诱导的尿白蛋白排泄的降低作用;iii)其中所述抗体比TPP-11489(Chiome)显示出增强的对Sema3A诱导的尿白蛋白排泄的降低作用,如实施例12中所述。
本发明的分离的抗体或抗原结合片段在诱导尿白蛋白排泄的体内模型中比TPP-30788-TPP-30791(BI克隆I至IV)表现出改善的的疗效,这可能是由于结合了人Sema3A的不同的表位。
因此另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段i)与TPP-30788(BI克隆I)相比,表现出增强的稳定性(例如用PBS稀释至25mg/mL并以700rpm于40℃下孵育两周时更高的压力稳定性);ii)其中增强的稳定性表明,与TPP-30788(BI克隆I)相比通过SEC测量的单体抗Sema3A抗体的量增加;iii)其中增强的稳定性表明,与TPP-30788(BI克隆I)相比,通过cGE测量的抗Sema3A抗体的LC和HC百分比降低,证明通过残留的LC和HC的存在测量的降解率降低;iv)其中增强的稳定性表明单体抗Sema3A抗体的量维持不变,例如于40℃下以700rpm孵育两周后Δ%单体=1;v)其中增强的稳定性表明抗Sema3A抗体的LC和HC的量维持不变,例如于40℃下以700rpm孵育两周后Δ%LC+HC<1。
因此另一方面,本发明涉及结合人Sema3A的TPP-23298,其中所述分离的抗体或其抗原结合片段i)与TPP-30788(BI克隆I)相比,表现出增强的稳定性(例如用PBS稀释至25mg/mL并以700rpm于40℃下孵育两周时更高的压力稳定性);ii)其中增强的稳定性表明,与TPP-30788(BI克隆I)相比通过SEC测量的单体抗Sema3A抗体的量增加;iii)其中增强的稳定性表明,与TPP-30788(BI克隆I)相比,通过cGE测量的抗Sema3A抗体的LC和HC百分比降低,证明通过残留的LC和HC的存在测量的降解率降低;iv)其中增强的稳定性表明单体抗Sema3A抗体的量维持不变,例如于40℃下以700rpm孵育两周后Δ%单体=1;v)其中增强的稳定性表明抗Sema3A抗体的LC和HC的量维持不变,例如于40℃下以700rpm孵育两周后Δ%LC+HC<1。
因此另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段i)具有增加的溶解度;ii)其中增加的溶解度在回收率为90%的浓缩后以mg/mL测量;iii)其中溶解度与TPP-30788(BI克隆I)相比增加;iv)其中溶解度比TPP-30788(BI克隆I)增加≤1倍、≤1.5倍、≤2倍;v)其中增加的溶解度表明浓缩后单体抗Sema3A抗体百分比未提高,例如由SEC测得Δ%单体<1。
因此另一方面,本发明涉及结合人Sema3A的TPP-23298,其中所述分离的抗体或其抗原结合片段i)具有增加的溶解度;ii)其中增加的溶解度在回收率为90%的浓缩后以mg/mL测量;iii)其中溶解度与TPP-30788(BI克隆I)相比增加;iv)其中溶解度比TPP-30788(BI克隆I)增加≤1倍、≤1.5倍、≤2倍;v)其中增加的溶解度表明浓缩后单体抗Sema3A抗体百分比未提高,例如由SEC测得Δ%单体<1。
因此另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段i)具有比水或PBS更大的黏度;ii)在PBS中黏度比TPP-30788(BI克隆I)更小;iii)其中黏度通过Viscosizer测量,显示cP值为5.1(150mg/mL)。
因此另一方面,本发明涉及结合人Sema3A的TPP-23298,其中所述分离的抗体或其抗原结合片段i)具有比水或PBS更大的黏度;ii)在PBS中黏度比TPP-30788(BI克隆I)更小;iii)其中黏度通过Viscosizer测量,显示cP值为5.1(150mg/mL)。
具体而言如实施例17中所述,本发明的分离的抗体或抗原结合片段比TPP-30788溶解度和稳定性高得多,更耐热压力并且在PBS缓冲液中黏度更小。
具体而言如实施例17中所述,TPP-23298比TPP-30788溶解度和稳定性高得多,更耐热压力并且在PBS缓冲液中黏度更小。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其能由哺乳动物细胞以高滴度生产;i)其中高滴度如实施例16中所述≤200mg/L。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中抗体对活性Sema3A(TPP-13211)比切割的Sema3A TPP-19068有更高的结合选择性;i)其中抗体对活性Sema3A(TPP-13211)的结合选择性比TPP-30788-TPP-30791对活性Sema3A的结合选择性更高,如实施例8中所述。
另一方面,本发明涉及结合人Sema3A的TPP-23298,其中抗体对活性Sema3A(TPP-13211)比切割的Sema3A TPP-19068有更高的结合选择性;i)其中抗体对活性Sema3A(TPP-13211)的结合选择性比TPP-30788-TPP-30791对活性Sema3A的结合选择性更高,如实施例8中所述。
另一方面,本发明涉及结合人Sema3A的分离的抗体或其抗原结合片段,其中抗体和TPP-30788相比结合Sema3A的不同表位;i)其中表位结合由SPR检测测量,如实施例5a中所述。与本发明的分离的抗体或抗原结合片段结合相同表位并竞争结合的所有抗体包含在本发明中。
另一方面,本发明涉及结合人Sema3A的TPP-23298,其中抗体和TPP-30788相比结合Sema3A的不同表位;i)其中表位结合由SPR检测测量,如实施例5a中所述。与本发明的分离的抗体或抗原结合片段结合相同表位并竞争结合的所有抗体包含在本发明中。
另一方面,本发明涉及分离的抗体或其抗原结合片段,其与前述权利要求任一项的分离的抗体或抗原结合片段竞争结合Sema3A,其中分离的抗体或抗原结合片段不与SEQID NO:800、NO:804、NO:810或NO:811的抗体竞争结合Sema3A。
本发明的分离的抗体或抗原结合片段可具有上述特征的任意组合。
本发明的分离的抗体或抗原结合片段为Sema3A阻断性抗体或其抗原结合片段。在特定实施方案中,抗体特异性地并且更特别地选择性地结合信号素3A的Sema3A结构域,并干扰其受体神经纤毛蛋白-1的相互作用。
在特定实施方案中,本发明的分离的抗体或其抗原结合片段与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,尤其是对小鼠、食蟹猴、大鼠、猪和/或狗Sema3A的亲和力比对人Sema3A的亲和力差小于100倍,特别地小于50倍,更特别地小于25倍,甚至更特别地小于10倍并且最特别地小于5倍。
在特定实施方案中,本发明的分离的抗体或其抗原结合片段与人Sema3B、Sema3C、Sema3D、Sema3E、Sema3F和/或Sema3G无显著交叉反应。特别地,分离的抗体或其抗原结合片段与人Sema3G无显著交叉反应。
在特定实施方案中,本发明的分离的抗体或其抗原结合片段抑制Sema3A诱导的白蛋白尿和/或蛋白尿。
在特定实施方案中,本发明的分离的抗体或其抗原结合片段抑制Sema3A诱导的纤维化。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含与SEQ ID NO:141至少90%、至少95%、至少98%、至少99%或100%一致的重链可变结构域以及与SEQ IDNO:145至少90%、至少95%、至少98%、至少99%或100%一致的轻链可变结构域。
在其他特定实施方案中,本发明的分离的抗体或抗原结合片段包含与SEQ ID NO:61至少90%、至少95%、至少98%、至少99%或100%一致的重链可变结构域以及与SEQ IDNO:65至少90%、至少95%、至少98%、至少99%或100%一致的轻链可变结构域。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列RDDYTSRDAFDX(SEQ ID NO:594)的H-CDR3,其中X选自Y和V。特别地,X为Y。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列X1AWDDSLNX2X3X4V(SEQ ID NO:598)的L-CDR3,其中X1选自A和H,其中X2选自V、D和G,特别地其中X2选自V和D,其中X3选自I和Y,并且其中X4选自P和V。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的H-CDR3的重链抗原结合区和含有如上文所定义的L-CDR3的轻链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列SGYSSSWFDPDFDY(SEQ ID NO:64)的H-CDR3。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列X1SYX2GX3NPYVV(SEQ ID NO:599)的L-CDR3,其中X1选自S和Q;其中X2选自E和A;并且其中X3选自P、I和S。特别地,X3选自P和I。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的H-CDR3的重链抗原结合区和含有如上文所定义的L-CDR3的轻链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列SYX1MX2(SEQ ID NO:588)的H-CDR1,其中X1选自G和A并且其中X2选自H、S和L。特别地,重链抗原结合区包含含有序列SYAMX(SEQ ID NO:589)的H-CDR1,其中X选自S和L。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列AIGX1GGDTYYADSVX2G(SEQ ID NO:590)的H-CDR2,其中X1选自T和Y,并且其中X2选自K和M。特别地,重链抗原结合区包含含有序列AIGXGGDTYYADSVKG(SEQ ID NO:591)的H-CDR2,其中X选自T和Y。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列RDDYTSRDAFDX(SEQ ID NO:594)的H-CDR3,其中X选自Y和V。特别地,X为Y。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义H-CDR1、H-CDR2和H-CDR3的重链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列SGSSSNIGSNTVN(SEQ ID NO:46)的L-CDR1。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列YDDLXPS(SEQ ID NO:596)的L-CDR2,其中X选自L和R。特别地,轻链抗原结合区包含含有序列YDDLRPS(SEQ ID NO:127)的L-CDR2。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列X1AWDDSLNX2X3X4V(SEQ ID NO:598)的L-CDR3,其中X1选自A和H,其中X2选自V、D和G,特别地其中X2选自V和D,其中X3选自I和Y,并且其中X4选自P和V。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的L-CDR1、L-CDR2和L-CDR3的轻链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的H-CDR1、H-CDR2和H-CDR3的重链抗原结合区和含有如上文所定义的L-CDR1、L-CDR2和L-CDR3的轻链抗原结合区。
在特定此类实施方案中,与H-CDR1在其5’端直接相邻的氨基酸残基(对应SEQ IDNO:121的参照VH结构域的残基30)为S或Y。
在其他特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列SYEMN(SEQ ID NO:62)的H-CDR1。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列GISWNSGX1IX2YADSVKG(SEQ ID NO:592)的H-CDR2,其中X1选自W和S并且X2选自G和D。特别地,重链抗原结合区包含含有序列GISWNSGWIXYADSVKG(SEQ ID NO:593)的H-CDR2,其中X选自G和D。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有序列SGYSSSWFDPDFDY(SEQ ID NO:64)的H-CDR3。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的H-CDR1、H-CDR2和H-CDR3的重链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列TGSSSXIGAGYDVH(SEQ ID NO:595)的L-CDR1,其中X选自N和D。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列GXSNRPS(SEQ ID NO:597)的L-CDR2,其中X选自N和A。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有序列X1SYX2GX3NPYVV(SEQ ID NO:599)的L-CDR3,其中X1选自S和Q,其中X2选自E和A,并且其中X3选自P、I和S。特别地,X3选自P和I。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的L-CDR1、L-CDR2和L-CDR3的轻链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含含有如上文所定义的H-CDR1、H-CDR2和H-CDR3的重链抗原结合区和含有如上文所定义的L-CDR1、L-CDR2和L-CDR3的轻链抗原结合区。
在特定此类实施方案中,与H-CDR1在其5’端直接相邻的三个氨基酸残基(对应SEQID NO:101的参照VH结构域的残基28至30)为X1FX2,其中X1选自T和D并且X2选自S和D。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含:
i)包含含有SEQ ID NO:44的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:48的L-CDR3的轻链抗原结合区;或
ii)包含含有SEQ ID NO:64的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:68的L-CDR3的轻链抗原结合区;或
iii)包含含有SEQ ID NO:104的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:108的L-CDR3的轻链抗原结合区;或
iv)包含含有SEQ ID NO:124的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:128的L-CDR3的轻链抗原结合区;或
v)包含含有SEQ ID NO:144的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:148的L-CDR3的轻链抗原结合区;或
vi)包含含有SEQ ID NO:164的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:168的L-CDR3的轻链抗原结合区;或
vii)包含含有SEQ ID NO:184的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:188的L-CDR3的轻链抗原结合区;或
viii)包含含有SEQ ID NO:204的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:208的L-CDR3的轻链抗原结合区;或
ix)包含含有SEQ ID NO:224的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:228的L-CDR3的轻链抗原结合区;或
x)包含含有SEQ ID NO:244的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:248的L-CDR3的轻链抗原结合区;或
xi)包含含有SEQ ID NO:264的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:268的L-CDR3的轻链抗原结合区;或
xii)包含含有SEQ ID NO:284的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:288的L-CDR3的轻链抗原结合区;或
xiii)包含含有SEQ ID NO:304的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:308的L-CDR3的轻链抗原结合区;或
xiv)包含含有SEQ ID NO:324的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:328的L-CDR3的轻链抗原结合区;或
xv)包含含有SEQ ID NO:344的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:348的L-CDR3的轻链抗原结合区;或
xvi)包含含有SEQ ID NO:364的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:368的L-CDR3的轻链抗原结合区;或
xvii)包含含有SEQ ID NO:384的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:388的L-CDR3的轻链抗原结合区;或
xviii)包含含有SEQ ID NO:404的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:408的L-CDR3的轻链抗原结合区;或
xix)包含含有SEQ ID NO:424的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:428的L-CDR3的轻链抗原结合区;或
xx)包含含有SEQ ID NO:444的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:448的L-CDR3的轻链抗原结合区;或
xxi)包含含有SEQ ID NO:464的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:468的L-CDR3的轻链抗原结合区;或
xxii)包含含有SEQ ID NO:484的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:488的L-CDR3的轻链抗原结合区;或
xxiii)包含含有SEQ ID NO:504的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:508的L-CDR3的轻链抗原结合区;或
xxiv)包含含有SEQ ID NO:524的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:528的L-CDR3的轻链抗原结合区;或
xxv)包含含有SEQ ID NO:544的H-CDR3的重链抗原结合区和包含含有SEQ ID NO:548的L-CDR3的轻链抗原结合区;或
xxvi)包含含有SEQ ID NO:564的H-CDR3的重链抗原结合区和包含含有SEQ IDNO:568的L-CDR3的轻链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有SEQ ID NO:42、62、102、122、142、162、182、202、222、242、262、282、302、322、342、362、382、402、422、442、462、482、502、522、542和562中任一项的H-CDR1。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含重链抗原结合区,其包含含有SEQ ID NO:43、63、103、123、143、163、183、203、223、243、263、283、303、323、343、363、383、403、423、443、463、483、503、523、543和563中任一项的H-CDR2。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有SEQ ID NO:46、66、106、126、146、166、186、206、226、246、266、286、306、326、346、366、386、406、426、446、466、486、506、526、546和566中任一项的L-CDR1。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含轻链抗原结合区,其包含含有SEQ ID NO:47、67、107、127、147、167、187、207、227、247、267、287、307、327、347、367、387、407、427、447、467、487、507、527、547和567中任一项的L-CDR2。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含:
i)包含含有SEQ ID NO:42的H-CDR1、含有SEQ ID NO:43的H-CDR2和含有SEQ IDNO:44的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:46的L-CDR1、含有SEQ ID NO:47的L-CDR2和含有SEQ ID NO:48的L-CDR3的轻链抗原结合区;或
ii)包含含有SEQ ID NO:62的H-CDR1、含有SEQ ID NO:63的H-CDR2和含有SEQ IDNO:64的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:66的L-CDR1、含有SEQ ID NO:67的L-CDR2和含有SEQ ID NO:68的L-CDR3的轻链抗原结合区;或
iii)包含含有SEQ ID NO:102的H-CDR1、含有SEQ ID NO:103的H-CDR2和含有SEQID NO:104的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:106的L-CDR1、含有SEQ IDNO:107的L-CDR2和含有SEQ ID NO:108的L-CDR3的轻链抗原结合区;或
iv)包含含有SEQ ID NO:122的H-CDR1、含有SEQ ID NO:123的H-CDR2和含有SEQID NO:124的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:126的L-CDR1、含有SEQ IDNO:127的L-CDR2和含有SEQ ID NO:128的L-CDR3的轻链抗原结合区;或
v)包含含有SEQ ID NO:142的H-CDR1、含有SEQ ID NO:143的H-CDR2和含有SEQ IDNO:144的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:146的L-CDR1、含有SEQ IDNO:147的L-CDR2和含有SEQ ID NO:148的L-CDR3的轻链抗原结合区;或
vi)包含含有SEQ ID NO:162的H-CDR1、含有SEQ ID NO:163的H-CDR2和含有SEQID NO:164的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:166的L-CDR1、含有SEQ IDNO:167的L-CDR2和含有SEQ ID NO:168的L-CDR3的轻链抗原结合区;或
vii)包含含有SEQ ID NO:182的H-CDR1、含有SEQ ID NO:183的H-CDR2和含有SEQID NO:184的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:186的L-CDR1、含有SEQ IDNO:187的L-CDR2和含有SEQ ID NO:188的L-CDR3的轻链抗原结合区;或
viii)包含含有SEQ ID NO:202的H-CDR1、含有SEQ ID NO:203的H-CDR2和含有SEQID NO:204的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:206的L-CDR1、含有SEQ IDNO:207的L-CDR2和含有SEQ ID NO:208的L-CDR3的轻链抗原结合区;或
ix)包含含有SEQ ID NO:222的H-CDR1、含有SEQ ID NO:223的H-CDR2和含有SEQID NO:224的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:226的L-CDR1、含有SEQ IDNO:227的L-CDR2和含有SEQ ID NO:228的L-CDR3的轻链抗原结合区;或
x)包含含有SEQ ID NO:242的H-CDR1、含有SEQ ID NO:243的H-CDR2和含有SEQ IDNO:244的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:246的L-CDR1、含有SEQ IDNO:247的L-CDR2和含有SEQ ID NO:248的L-CDR3的轻链抗原结合区;或
xi)包含含有SEQ ID NO:262的H-CDR1、含有SEQ ID NO:263的H-CDR2和含有SEQID NO:264的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:266的L-CDR1、含有SEQ IDNO:267的L-CDR2和含有SEQ ID NO:268的L-CDR3的轻链抗原结合区;或
xii)包含含有SEQ ID NO:282的H-CDR1、含有SEQ ID NO:283的H-CDR2和含有SEQID NO:284的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:286的L-CDR1、含有SEQ IDNO:287的L-CDR2和含有SEQ ID NO:288的L-CDR3的轻链抗原结合区;或
xiii)包含含有SEQ ID NO:302的H-CDR1、含有SEQ ID NO:303的H-CDR2和含有SEQID NO:304的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:306的L-CDR1、含有SEQ IDNO:307的L-CDR2和含有SEQ ID NO:308的L-CDR3的轻链抗原结合区;或
xiv)包含含有SEQ ID NO:322的H-CDR1、含有SEQ ID NO:323的H-CDR2和含有SEQID NO:324的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:326的L-CDR1、含有SEQ IDNO:327的L-CDR2和含有SEQ ID NO:328的L-CDR3的轻链抗原结合区;或
xv)包含含有SEQ ID NO:342的H-CDR1、含有SEQ ID NO:343的H-CDR2和含有SEQID NO:344的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:346的L-CDR1、含有SEQ IDNO:347的L-CDR2和含有SEQ ID NO:348的L-CDR3的轻链抗原结合区;或
xvi)包含含有SEQ ID NO:362的H-CDR1、含有SEQ ID NO:363的H-CDR2和含有SEQID NO:364的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:366的L-CDR1、含有SEQ IDNO:367的L-CDR2和含有SEQ ID NO:368的L-CDR3的轻链抗原结合区;或
xvii)包含含有SEQ ID NO:382的H-CDR1、含有SEQ ID NO:383的H-CDR2和含有SEQID NO:384的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:386的L-CDR1、含有SEQ IDNO:387的L-CDR2和含有SEQ ID NO:388的L-CDR3的轻链抗原结合区;或
xviii)包含含有SEQ ID NO:402的H-CDR1、含有SEQ ID NO:403的H-CDR2和含有SEQ ID NO:404的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:406的L-CDR1、含有SEQ ID NO:407的L-CDR2和含有SEQ ID NO:408的L-CDR3的轻链抗原结合区;或
xix)包含含有SEQ ID NO:422的H-CDR1、含有SEQ ID NO:423的H-CDR2和含有SEQID NO:424的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:426的L-CDR1、含有SEQ IDNO:427的L-CDR2和含有SEQ ID NO:428的L-CDR3的轻链抗原结合区;或
xx)包含含有SEQ ID NO:442的H-CDR1、含有SEQ ID NO:443的H-CDR2和含有SEQID NO:444的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:446的L-CDR1、含有SEQ IDNO:447的L-CDR2和含有SEQ ID NO:448的L-CDR3的轻链抗原结合区;或
xxi)包含含有SEQ ID NO:462的H-CDR1、含有SEQ ID NO:463的H-CDR2和含有SEQID NO:464的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:466的L-CDR1、含有SEQ IDNO:467的L-CDR2和含有SEQ ID NO:468的L-CDR3的轻链抗原结合区;或
xxii)包含含有SEQ ID NO:482的H-CDR1、含有SEQ ID NO:483的H-CDR2和含有SEQID NO:484的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:486的L-CDR1、含有SEQ IDNO:487的L-CDR2和含有SEQ ID NO:488的L-CDR3的轻链抗原结合区;或
xxiii)包含含有SEQ ID NO:502的H-CDR1、含有SEQ ID NO:503的H-CDR2和含有SEQ ID NO:504的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:506的L-CDR1、含有SEQ ID NO:507的L-CDR2和含有SEQ ID NO:508的L-CDR3的轻链抗原结合区;或
xxiv)包含含有SEQ ID NO:522的H-CDR1、含有SEQ ID NO:523的H-CDR2和含有SEQID NO:524的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:526的L-CDR1、含有SEQ IDNO:527的L-CDR2和含有SEQ ID NO:528的L-CDR3的轻链抗原结合区;或
xxv)包含含有SEQ ID NO:542的H-CDR1、含有SEQ ID NO:543的H-CDR2和含有SEQID NO:544的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:546的L-CDR1、含有SEQ IDNO:547的L-CDR2和含有SEQ ID NO:548的L-CDR3的轻链抗原结合区;或
xxvi)包含含有SEQ ID NO:562的H-CDR1、含有SEQ ID NO:563的H-CDR2和含有SEQID NO:564的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:566的L-CDR1、含有SEQ IDNO:567的L-CDR2和含有SEQ ID NO:568的L-CDR3的轻链抗原结合区。
在特定实施方案中,本发明的分离的抗体或抗原结合片段包含:
i)含有SEQ ID NO:41的可变重链结构域和含有SEQ ID NO:45的可变轻链结构域;或
ii)含有SEQ ID NO:61的可变重链结构域和含有SEQ ID NO:65的可变轻链结构域;或
iii)含有SEQ ID NO:101的可变重链结构域和含有SEQ ID NO:105的可变轻链结构域;或
iv)含有SEQ ID NO:121的可变重链结构域和含有SEQ ID NO:125的可变轻链结构域;或
v)含有SEQ ID NO:141的可变重链结构域和含有SEQ ID NO:145的可变轻链结构域;或
vi)含有SEQ ID NO:161的可变重链结构域和含有SEQ ID NO:165的可变轻链结构域;或
vii)含有SEQ ID NO:181的可变重链结构域和含有SEQ ID NO:185的可变轻链结构域;或
viii)含有SEQ ID NO:201的可变重链结构域和含有SEQ ID NO:205的可变轻链结构域;或
ix)含有SEQ ID NO:221的可变重链结构域和含有SEQ ID NO:225的可变轻链结构域;或
x)含有SEQ ID NO:241的可变重链结构域和含有SEQ ID NO:245的可变轻链结构域;或
xi)含有SEQ ID NO:261的可变重链结构域和含有SEQ ID NO:265的可变轻链结构域;或
xii)含有SEQ ID NO:281的可变重链结构域和含有SEQ ID NO:285的可变轻链结构域;或
xiii)含有SEQ ID NO:301的可变重链结构域和含有SEQ ID NO:305的可变轻链结构域;或
xiv)含有SEQ ID NO:321的可变重链结构域和含有SEQ ID NO:325的可变轻链结构域;或
xv)含有SEQ ID NO:341的可变重链结构域和含有SEQ ID NO:345的可变轻链结构域;或
xvi)含有SEQ ID NO:361的可变重链结构域和含有SEQ ID NO:365的可变轻链结构域;或
xvii)含有SEQ ID NO:381的可变重链结构域和含有SEQ ID NO:385的可变轻链结构域;或
xviii)含有SEQ ID NO:401的可变重链结构域和含有SEQ ID NO:405的可变轻链结构域;或
xix)含有SEQ ID NO:421的可变重链结构域和含有SEQ ID NO:425的可变轻链结构域;或
xx)含有SEQ ID NO:441的可变重链结构域和含有SEQ ID NO:445的可变轻链结构域;或
xxi)含有SEQ ID NO:461的可变重链结构域和含有SEQ ID NO:465的可变轻链结构域;或
xxii)含有SEQ ID NO:481的可变重链结构域和含有SEQ ID NO:485的可变轻链结构域;或
xxiii)含有SEQ ID NO:501的可变重链结构域和含有SEQ ID NO:505的可变轻链结构域;或
xxiv)含有SEQ ID NO:521的可变重链结构域和含有SEQ ID NO:525的可变轻链结构域;或
xxv)含有SEQ ID NO:541的可变重链结构域和含有SEQ ID NO:545的可变轻链结构域;或
xxvi)含有SEQ ID NO:561的可变重链结构域和含有SEQ ID NO:565的可变轻链结构域。
在特定实施方案中,本发明的分离的抗体为IgG抗体。在特定此类实施方案中,本发明的分离的抗体为IgG1、IgG2、IgG3或IgG4抗体。最特别地,本发明的分离的抗体为IgG1或IgG4抗体。
在特定实施方案中,本发明的分离的抗体包含:
i)含有SEQ ID NO:57的重链和含有SEQ ID NO:58的轻链;或
ii)含有SEQ ID NO:77的重链和含有SEQ ID NO:78的轻链;或
iii)含有SEQ ID NO:117的重链和含有SEQ ID NO:118的轻链;或
iv)含有SEQ ID NO:137的重链和含有SEQ ID NO:138的轻链;或
v)含有SEQ ID NO:157的重链和含有SEQ ID NO:158的轻链;或
vi)含有SEQ ID NO:177的重链和含有SEQ ID NO:178的轻链;或
vii)含有SEQ ID NO:197的重链和含有SEQ ID NO:198的轻链;或
viii)含有SEQ ID NO:217的重链和含有SEQ ID NO:218的轻链;或
ix)含有SEQ ID NO:237的重链和含有SEQ ID NO:238的轻链;或
x)含有SEQ ID NO:257的重链和含有SEQ ID NO:258的轻链;或
xi)含有SEQ ID NO:277的重链和含有SEQ ID NO:278的轻链;或
xii)含有SEQ ID NO:297的重链和含有SEQ ID NO:298的轻链;或
xiii)含有SEQ ID NO:317的重链和含有SEQ ID NO:318的轻链;或
xiv)含有SEQ ID NO:337的重链和含有SEQ ID NO:338的轻链;或
xv)含有SEQ ID NO:357的重链和含有SEQ ID NO:358的轻链;或
xvi)含有SEQ ID NO:377的重链和含有SEQ ID NO:378的轻链;或
xvii)含有SEQ ID NO:397的重链和含有SEQ ID NO:398的轻链;或
xviii)含有SEQ ID NO:417的重链和含有SEQ ID NO:418的轻链;或
xix)含有SEQ ID NO:437的重链和含有SEQ ID NO:438的轻链;或
xx)含有SEQ ID NO:457的重链和含有SEQ ID NO:458的轻链;或
xxi)含有SEQ ID NO:477的重链和含有SEQ ID NO:478的轻链;或
xxii)含有SEQ ID NO:497的重链和含有SEQ ID NO:498的轻链;或
xxiii)含有SEQ ID NO:517的重链和含有SEQ ID NO:518的轻链;或
xxiv)含有SEQ ID NO:537的重链和含有SEQ ID NO:538的轻链;或
xxv)含有SEQ ID NO:557的重链和含有SEQ ID NO:558的轻链;或
xxvi)含有SEQ ID NO:577的重链和含有SEQ ID NO:578的轻链。
在特定实施方案中,本发明的抗原结合片段为scFv、Fab、Fab’片段或F(ab’)2片段。
在特定实施方案中,本发明的分离的抗体或抗原结合片段为单克隆抗体或其抗原结合片段。
在特定实施方案中,本发明的分离的抗体或抗原结合片段为人的、人源化的或嵌合的抗体或其抗原结合片段,更特别地为全人抗体或其抗原结合片段。
在特定实施方案中,本发明的分离的抗体或抗原结合片段为单克隆抗体。在其他特定实施方案中,本发明的分离的抗体或抗原结合片段为结合Sema3A和至少另一个抗原的多特异性抗体,例如双特异性、三特异性或四特异性抗体。
另一方面,本发明涉及和本发明的分离的抗体或抗原结合片段竞争结合人Sema3A的分离的抗体或其抗原结合片段。
另一方面,本发明涉及包含本发明的分离的抗体或抗原结合片段的抗体偶联物。例如,抗体能够与细胞毒性剂、免疫毒素、发毒团或放射性同位素偶联。本发明还提供了与可检测标记物偶联的抗Sema3A抗体。优选的标记物为放射性标记、酶、发色团或荧光团。抗体同样可能与高分子量分子偶联,例如肽或蛋白质如白细胞介素。
本发明的ADC包含与一个或多个细胞毒性剂偶联的抗Sema3A抗体,所述试剂例如化疗剂或药物、生长抑制剂、毒素(例如蛋白毒素(细菌、真菌、植物、人或动物来源的酶活性毒素)或其片段)或放射性同位素。
在一个实施方案中,本发明的ADC包含与一个或多个药物偶联的如本文所述的抗Sema3A抗体,所述药物包括但不限于美登素类(参见U.S.Patent No.5,208,020、5,416,064和European Patent EP0425235);澳瑞他汀,诸如单甲基澳瑞他汀药物部分DE和DF(MMAE和MMAF)(参见U.S.Patent No.5,635,483和5,780,588和7,498,298);海兔毒素;卡里奇霉素或其衍生物;蒽环类抗生素,诸如柔红霉素或阿霉素;甲氨蝶呤;长春地辛;紫杉烷,诸如多西他赛、紫杉醇、拉洛他赛、替司他赛和奥他赛;单端孢霉烯;和CC1065。
在另一个实施方案中,本发明的ADC包含与酶活性毒素或其片段偶联的如本文所述的抗Sema3A抗体,所述酶活性毒素或其片段包括但不限于白喉毒素A链即白喉毒素的非结合活性片段、外毒素A链(来自铜绿假单胞菌(Pseudomonas aeruginosa))、蓖麻毒素A链、相思子毒素A链、蒴莲根毒素A链、α-帚曲霉素、油桐(Aleurites fordii)蛋白、石竹素(dianthin)蛋白、美洲商陆(Phytolaca americana)蛋白(PAPI、PAPII和PAP-S)、苦瓜(Momordica charantia)抑制剂、麻风树毒蛋白、巴豆毒素、肥皂草(Saponariaofficinalis)抑制剂、白树毒素、丝林霉素、局限曲霉素、酚霉素、伊诺霉素和单端孢霉烯。
在另一个实施方案中,本发明的ADC包含与放射性原子偶联以形成放射性偶联物的如本文所述的抗Sema3A抗体。多种放射性同位素可用于生产放射性偶联物。实例包括227Th、225Ac、211At、131I、125I、90Y、186Re、188Re、153Sm、212Bi、32P、212Pb和Lu的放射性同位素。当放射性偶联物用于检测时,其可以包含用于闪烁显像研究的放射性原子,例如Tc99m,或用于核磁共振(NMR)成像的自旋标记,诸如还是碘-123、碘-131、铟-111、氟-19、碳-13、氮-15、氧-17、钆、锰或铁。
可以使用多种双功能蛋白偶联剂来制备抗体和细胞毒性剂的偶联物,所述双功能蛋白偶联剂诸如N-琥珀酰亚胺基-3-(2-吡啶二巯基)丙酸酯(SPDP)、琥珀酰亚胺基-4-(N-马来酰亚胺基甲基)环己烷-1-羧酸酯(SMCC)、亚氨基四氢噻吩(IT)、亚胺基酯的双功能衍生物(诸如二亚氨代己二酸二甲酯HCl)、活性酯(诸如辛二酸二琥珀酰亚胺酯)、醛(诸如戊二醛)、双叠氮基化合物(诸如双(对叠氮基苯甲酰基)己二胺)、双重氮衍生物(诸如双(对重氮基苯甲酰基)乙二胺)、二异氰酸酯(诸如2,6-二异氰酸甲苯酯)和双活性氟化合物(诸如1,5-二氟-2,4-二硝基苯)。
接头可以是便于在细胞中释放细胞毒性药物的“可切割接头”。例如,酸不稳定接头、肽酶敏感接头、光不稳定接头、二甲基接头或含有二硫化物的接头(Chari等人,CancerRes.52:127-131(1992))。
本发明的ADC包括用交联剂制备的ADC,所述交联剂包括但不限于BMPS、EMCS、GMBS、HBVS、LC-SMCC、MBS、MPBH、SBAP、SIA、SIAB、SMCC、SMPB、SMPH、磺基-EMCS、磺基-GMBS、磺基-KMUS、磺基-MBS、磺基-SIAB、磺基-SMCC和磺基-SMPB和SVSB(琥珀酰亚胺基-(4-乙烯磺酰基)苯甲酸酯),其为市售的(例如来自Pierce Biotechnology,Inc.,Rockford,IL.,U.S.A)。
本发明的优选的抗体和三个现有技术的抗体的氨基酸和核酸序列列于表1和表1A中。
肽变体
本发明的抗体或抗原结合片段不限于本文提供的具体肽序列。相反,本发明还包括这些多肽的变体。根据本公开内容和常规可用技术和参考文献,技术人员能够制备、测试和利用本文公开的抗体的功能性变体,同时理解具有结合Sema3A能力的这些变体落在本发明的范围内。
变体可包括例如,与本文公开的肽序列相比,具有至少一个改变的互补决定区(CDR)(高变的)和/或框架(FR)(可变的)结构域/位置的抗体。
通过改变CDR或FR区中的一个或多个氨基酸残基,技术人员可常规地产生突变的或多样化的抗体序列,所述抗体序列例如可以针对抗原筛选出新的或改进的特性。
本发明的更优选的实施方案为其中如表1和表1A所示选择了VH和VL序列的抗体或其抗原结合片段。技术人员可使用表1和表1A中的数据设计本发明范围内的肽变体。优选通过改变一个或多个CDR区内的氨基酸来构建变体;变体还可以具有一个或多个改变的框架区。例如,与种系序列相比残基有变异可改变肽FR结构域。
或者,技术人员可通过使用例如Knappik A.等人,JMB 2000,296:57-86所述的方法,将本文公开的氨基酸序列与这类抗体的同类的已知序列进行比较,来进行相同的分析。
此外,可如下获得变体:通过使用一种抗体作为进一步优化的起点,通过使所述抗体中的一个或多个氨基酸残基(优选一个或多个CDR中的氨基酸残基)多样化,并且通过筛选所得的抗体变体集合以获得具有改善性能的变体。特别优选的是VL和/或VH的CDR3中的一个或多个氨基酸残基的多样化。多样化可通过例如采用三核苷酸诱变(TRIM)技术(B.等人,Nucl.Acids Res.1994,22:5600)来合成一批DNA分子来进行。抗体或其抗原结合片段包括具有修饰/变化的分子,所述修饰/变化包括但不限于例如导致半衰期改变(例如,修饰Fc部分或连接其他分子例如PEG)、结合亲和力改变或者ADCC或CDC活性改变的修饰。
保守氨基酸变体
可以使得多肽变体保留本文所述的抗体肽序列的整体分子结构。考虑到各氨基酸的特性,技术人员会认识到一些合理的置换。氨基酸置换,即“保守置换”,可以例如在所涉及的残基的极性、电荷、溶解性、疏水性、亲水性和/或两亲性质的相似性的基础上进行。
例如,(a)非极性(疏水)氨基酸包括丙氨酸、亮氨酸、异亮氨酸、缬氨酸、脯氨酸、苯丙氨酸、色氨酸和甲硫氨酸;(b)极性中性氨基酸包括甘氨酸、丝氨酸、苏氨酸、半胱氨酸、酪氨酸、天冬酰胺和谷氨酰胺;(c)荷正电(碱性)氨基酸包括精氨酸、赖氨酸和组氨酸;和(d)荷负电(酸性)氨基酸包括天冬氨酸和谷氨酸。置换通常可以在(a)-(d)组内进行。此外,基于它们破坏α-螺旋的能力,甘氨酸和脯氨酸可以相互置换。相似地,某些氨基酸,例如丙氨酸、半胱氨酸、亮氨酸、甲硫氨酸、谷氨酸、谷氨酰胺、组氨酸和赖氨酸在α-螺旋中更常见,而缬氨酸、异亮氨酸、苯丙氨酸、酪氨酸、色氨酸和苏氨酸在β-折叠中更常见。甘氨酸、丝氨酸、天冬氨酸、天冬酰胺和脯氨酸在转角中常见。一些优选的置换可以在下列组中进行:(i)S和T;(ii)P和G;和(iii)A、V、L和I。鉴于已知的遗传密码以及重组和合成DNA技术,技术人员可以容易地构建编码保守氨基酸变体的DNA。
糖基化变体
当抗体包含Fc区时,可以改变附着于Fc区的糖基。由哺乳动物细胞产生的天然抗体通常包含分支的双分支寡糖,其通常通过N-连接附接至Fc区的CH2结构域的Asn297(使用Kabat EU编号);参见例如Wright等人Trends Biotechnol.15:26-32(1997)。
在某些实施方案中,改变本文提供的抗体以增加或减少抗体被糖基化的程度。可以通过改变表达系统(例如宿主细胞)和/或通过改变氨基酸序列使得生成或去除一个或多个糖基化位点而方便地实现向抗体添加或删除糖基化位点。
在本发明的一个实施方案中,通过在原核宿主中表达来制备具有降低的效应子功能的无糖基抗体或抗体衍生物。合适的原核宿主包括但不限于大肠杆菌(E.coli)、枯草芽孢杆菌(Bacillus subtilis)、鼠伤寒沙门氏菌(Salmonella typhimurium)和假单胞菌属、链霉菌属(Streptomyces)和葡萄球菌属(Staphylococcus)中的各种物种。
在一个实施方案中,提供具有降低的效应子功能的抗体变体,其特征在于所述抗体的Fc部分的CH2结构域中保守的N-连接位点处的修饰。在本发明的一个实施方案中,所述修饰包括重链糖基化位点处的突变以防止该位点处的糖基化。因此,在本发明的一个优选实施方案中,无糖基抗体或抗体衍生物通过重链糖基化位点的突变(即使用Kabat EU编号的N297的突变)来制备,并在适当的宿主细胞中表达。
在本发明的另一个实施方案中,无糖基抗体或抗体衍生物具有降低的效应子功能,其中所述抗体或抗体衍生物的Fc部分的CH2结构域中的保守N-连接位点处的修饰包括去除CH2结构域聚糖,即去糖基化。这些无糖基抗体可以通过常规方法生成,然后酶促去糖基化。用于抗体的酶促去糖基化的方法在本领域中是众所周知的(例如Winkelhake和Nicolson(1976),J Biol Chem.251(4):1074-80)。
在本发明的另一个实施方案中,可以使用糖基化抑制剂衣霉素来实现去糖基化(Nose和Wigzell(1983),Proc Natl Acad Sci USA,80(21):6632-6)。也就是说,修饰是防止所述抗体的Fc部分的CH2结构域中保守的N-连接位点处的糖基化。
在一个实施方案中,提供具有缺乏(直接或间接)附接至Fc区的岩藻糖的糖结构的抗体变体。例如,此类抗体中的岩藻糖的量可以是1%至80%、1%至65%、5%至65%或20%至40%。通过计算相对于由MALDI-TOF质谱法所测量的附接至Asn297的所有糖结构(例如,复合、杂合和高甘露糖结构)的总和,Asn297处的糖链内的岩藻糖的平均量而测定岩藻糖的量,如例如WO 2008/077546中所述。Asn297是指位于Fc区中的约297位(Fc区残基的EU编号)的天冬酰胺残基;然而,由于抗体中微小的序列变化,Asn297也可位于297位的上游或下游约±3个氨基酸处,即,294位和300位之间。此类岩藻糖基化变体可以具有改善的ADCC功能。
关于“去岩藻糖基化的”或“岩藻糖缺乏的”抗体变体的公开的实例包括:Okazaki等人,J Mol.Biol.336:1239-1249(2004);Yamane-Ohnuki等人,Biotech.Bioeng.87:614(2004)。
能够产生去岩藻糖基化的抗体的细胞系的实例包括缺乏蛋白岩藻糖基化的Lec13CHO细胞(Ripka等人,Arch.Biochem.Biophys.249:533-545(1986);和WO 2004/056312)和敲除细胞系,诸如α-1,6-岩藻糖基转移酶基因FUT8敲除的CHO细胞(见例如Yamane-Ohnuki等人,Biotech.Bioeng.87:614(2004);Kanda,Y.等人,Biotechnol.Bioeng.,94(4):680-688(2006))。
还提供具有二等分寡糖的抗体变体,例如其中附接至抗体的Fc区的双分支寡糖被GlcNAc二等分。此类抗体变体可以具有减少的岩藻糖基化和/或改善的ADCC功能。此类抗体变体的实例描述于例如WO 2003/011878;US Patent No.6,602,684;和US2005/0123546。
还提供具有附接至Fc区的寡糖中的至少一个半乳糖残基的抗体变体。此类抗体变体可以具有提高的CDC功能。此类抗体变体描述于例如WO1997/30087;WO1998/58964;和WO1999/22764中。
Fc区变体
在某些实施方案中,可以向本文提供的抗体的Fc区(例如人IgG1、IgG2、IgG3或IgG4 Fc区)中引入一个或多个氨基酸修饰(例如置换),由此生成Fc区变体。
在某些实施方案中,本发明设想一种抗体变体,这种抗体变体具有某些而非全部效应子功能,这使其成为一种理想的候选抗体,适用于体内抗体半衰期很重要但某些效应子功能(诸如补体和ADCC)不必要或有害的应用。可以进行体外和/或体内细胞毒性测定来证实CDC和/或ADCC活性的降低/缺失。例如,可以进行Fc受体(FcR)结合测定来确保抗体缺少FcγR结合(因此可能缺少ADCC活性)但保留FcRn结合能力。在一些实施方案中,在Fc区中进行改变,其导致C1q结合和/或补体依赖的细胞毒作用(CDC)改变(即提高或降低)。
在某些实施方案中,本发明设想具有延长或缩短的半衰期的抗体变体。具有延长的半衰期和提高的与新生儿Fc受体(FcRn)(其负责将母体IgG转移至胎儿(Guyer等人,JImmunol.117:587(1976)和Kim等人,JImmunol.24:249(1994)))的结合的抗体描述于US2005/0014934(Hinton等人)中。那些抗体包含其中具有一个或多个置换的Fc区,所述置换增强Fc区与FcRn的结合。
抗体生成
本发明的抗体可以源自重组抗体文库,其基于已经从大量健康志愿者的抗体中分离的氨基酸序列,例如,使用n-技术将全人CDR重组进新的抗体分子(Carlson和Expert Rev Mol Diagn.2001May;1(1):102-8)。或者例如,Hoet RM等人,NatBiotechnol2005;23(3):344-8中描述的作为全人抗体噬菌体展示文库的抗体文库可用于分离Sema3A特异性抗体。从人抗体文库分离的抗体或抗体片段在本文中被认为是人抗体或人抗体片段。
人抗体可通过给予转基因动物免疫原来进一步制备,所述转基因动物已被改造成能在抗原攻击下产生完整的人抗体或具有人类可变区的完整抗体。此类动物通常含有全部或一部分人免疫球蛋白基因座,其替代内源性免疫球蛋白基因座,或者其在染色体外存在或随机地整合至动物的染色体中。例如,可以进行基因工程小鼠的免疫,尤其是hMAb小鼠(例如VelocImmune或)的免疫。
可以使用杂交瘤技术(例如参见和Milstein,Nature.1975Aug7;256(5517):495-7)生成另外的抗体,产生例如鼠、大鼠或兔抗体,其可以转化为嵌合或人源化抗体。人源化抗体及其制备方法综述于例如Almagro和Fransson,Front.Biosci.13:1619-1633(2008),并且进一步描述于例如Riechmann等人,Nature 332:323-329(1988);Queen等人,Proc.Natl Acad.Sci.USA 86:10029-10033(1989);US Patent No.5,821,337、7,527,791、6,982,321和7,087,409;Kashmiri等人,Methods 36:25-34(2005)(描述特异性决定区(SDR)移植);Padlan,Mol.Immunol.28:489-498(1991)(描述“表面重塑”);Dall'Acqua等人,Methods 36:43-60(2005)(描述“FR改组”);和Osboum等人,Methods 36:61-68(2005)和Klimka等人,Br.J.Cancer,83:252-260(2000)(描述FR改组的“定向选择”方法)。
提供使用重组抗体文库生成抗体的实例。
本发明的DNA分子
本发明还涉及编码本发明的抗体或其抗原结合片段的分离的核酸序列。编码本发明的抗体或其抗原结合片段的分离的核酸序列可例如由Sambrook等人,1989和Ausubel等人,1989所述技术或化学合成(例如Oligonucleotide Synthesis(1984,Gait,ed.,IRLPress,Oxford)所述技术)产生。用于表达的抗体的DNA序列和各自的SEQ ID列于表1和1A中。这些序列在某些情况下针对哺乳动物表达进行优化。本发明的DNA分子不限于本文公开的序列,而是还包括其变体。可通过参考其在杂交中的物理性质来描述本发明内的DNA变体。技术人员应认识到,可以使用核酸杂交技术用DNA鉴定其互补序列及其等同物或同源物(因为DNA是双链的)。还应认识到,可以以小于100%的互补性进行杂交。然而,若选择适当的条件,可以基于DNA序列与特定探针的结构相关性,使用杂交技术以区分DNA序列。对于此类条件的指导,见Sambrook等人,1989见上和Ausubel等人,1995(Ausubel,F.M.,Brent,R.,Kingston,R.E.,Moore,D.D.,Sedman,J.G.,Smith,J.A.,和Struhl,K.eds.(1995).CurrentProtocols in Molecular Biology.New York:John Wiley and Sons)。
两条多核苷酸序列之间的结构相似性可以表示为两个序列彼此杂交的条件的“严格性”的函数。如本文所用,术语“严格性”是指条件不利于杂交的程度。严格条件强烈不利于杂交,并且在此类条件下只有结构上最相关的分子之间能杂交。相反,非严格条件有利于表现出较低程度的结构相关性的分子的杂交。因此,杂交严格性与两个核酸序列的结构关系直接相关。
杂交严格性随着许多因素而变化,所述因素包括总DNA浓度、离子强度、温度、探针大小和破坏氢键键合的试剂的存在。促进杂交的因素包括高DNA浓度、高离子强度、低温、较长的探针大小和不存在破坏氢键键合的试剂。杂交通常在以下两个阶段中进行:“结合”阶段和“洗涤”阶段。
功能等同的DNA变体
可以根据其编码的产物来描述本发明范围内的另一类DNA变体。这些功能等同的多核苷酸的特征在于:由于遗传密码的简并性,它们编码相同的肽序列。
应认识到,可以以几种不同方式构建本文提供的DNA分子的变体。例如,它们可以作为完全合成的DNA来构建。有效合成寡核苷酸的方法是广泛可得的。参见Ausubel等人,Section 2.11,Supplement 21(1993)。可以由Khorana等人,J.Mol.Biol.72:209 217(1971)首次报道的方式合成和组装重叠的寡核苷酸;也参见Ausubel等人,见上,Section8.2。优选用基因5’和3’端处工程改造的方便的限制性位点设计合成的DNA以促进克隆至适当载体中。
如所示,生成变体的方法始于本文公开的DNA之一,然后构建定点诱变。参见Ausubel等人,见上,Chapter 8,Supplement 37(1997)。在典型方法中,将目标DNA克隆至单链DNA噬菌体载体中。分离单链DNA,且与含有所需的一个或多个核苷酸变异的寡核苷酸杂交。合成互补链,且将双链噬菌体导入宿主中。所得子代中的一些将含有所需的突变体,其可使用DNA测序来证实。此外,增加子代噬菌体成为所需突变体的概率的各种方法是可得的。这些方法是本领域技术人员众所周知的,且用于生成此类突变体的试剂盒是商业可得的。
重组DNA构建体和表达
本发明进一步提供包含本发明的核苷酸序列中的一种或多种的重组DNA构建体。本发明的重组构建体可以与载体(诸如质粒、噬菌粒、噬菌体或病毒载体)结合使用,向所述载体中插入编码本发明的抗体或其抗原结合片段或其变体的DNA分子。
因此,一方面,本发明涉及包含本发明的核酸序列的载体。
可通过在宿主细胞中重组表达编码轻链和重链或其部分的核酸序列来制备本文提供的抗体、抗原结合部分或其变体。为了重组表达抗体、抗原结合部分或其变体,宿主细胞可以用一种或多种重组表达载体(其携带编码轻链和/或重链或其部分的DNA片段)转染,使得轻链和重链在宿主细胞中表达。使用标准重组DNA方法制备和/或获得编码重链和轻链的核酸,将这些核酸插入重组表达载体中,且将所述载体导入宿主细胞中,诸如描述于以下的那些:Sambrook,Fritsch和Maniatis(编),Molecular Cloning:A Laboratory Manual,Second Edition,Cold Spring Harbor,N.Y.,(1989);Ausubel,F.M.et al.(eds.)CurrentProtocols in Molecular Biology,Greene Publishing Associates,(1989)和Boss等人的U.S.Pat.No.4,816,397。
此外,可将编码重链和/或轻链的可变区的核酸序列转化为例如编码全长抗体链、Fab片段或scFv的核酸序列。可将编码VL或VH的DNA片段与编码例如抗体恒定区或柔性接头的另一DNA片段可操作地连接(使得由两个DNA片段编码的氨基酸序列符合读框)。人重链和轻链恒定区的序列是本领域已知的(参见例如Kabat,E.A.等人(1991)Sequences ofProteins of Immunological Interest,Fifth Edition,U.S.Department of Health andHuman Services,NIH Publication No.91-3242),且涵盖这些区域的DNA片段可通过标准PCR扩增获得。
为了生成编码scFv的多核苷酸序列,可将编码VH和VL的核酸与编码柔性接头的另一片段可操作地连接,使得VH和VL序列可表达为连续的单链蛋白,其中VL和VH区由柔性接头连接(参见例如Bird等人(1988)Science 242:423-426;Huston等人(1988)Proc.Natl.Acad.Sci.USA 85:5879-5883;McCafferty等人,Nature(1990)348:552-554)。
为了表达抗体、其抗原结合片段或其变体,可以使用标准重组DNA表达方法(参见例如Goeddel,Gene Expression Technology.Methods in Enzymology 185,AcademicPress,San Diego,Calif.(1990))。例如,可将编码所需多肽的DNA插入表达载体中,然后将其转染至合适的宿主细胞中。合适的宿主细胞是原核细胞和真核细胞。原核宿主细胞的实例是例如细菌,真核宿主细胞的实例是酵母、昆虫和昆虫细胞、植物和植物细胞、转基因动物或哺乳动物细胞。可使用标准技术(例如磷酸钙转染、DEAE葡聚糖介导的转染、电穿孔、转导或噬菌体感染)将重组构建体导入宿主细胞中。
在一些实施方案中,将编码重链和轻链的DNA插入不同载体中。在其他实施方案中,将编码重链和轻链的DNA插入相同的载体中。应理解,表达载体的设计(包括调控序列的选择)受宿主细胞的选择、所需蛋白的表达水平以及表达是组成型还是诱导型等因素的影响。
因此,另一方面,本发明涉及表达本发明的抗体或抗原结合片段和/或包含本发明的核酸或本发明的载体的分离的细胞。
分离的细胞可以是表达载体适用的几乎任何细胞。分离的细胞可以是例如高等真核宿主细胞诸如哺乳动物细胞、低等真核宿主细胞诸如酵母细胞,并且可以是原核细胞诸如细菌细胞。
另一方面,本发明涉及生产本发明的分离的抗体或抗原结合片段的方法,其包括本发明的细胞的培养。在特定实施方案中,本发明的细胞于适合抗体表达的条件下培养,回收抗体或其抗原结合片段。在特定实施方案中,纯化抗体或其抗原结合片段,尤其是纯化至以重量计至少95%的均一性。
细菌表达
通过将编码所需蛋白的DNA序列连同合适的翻译起始和终止信号以及功能启动子插入可操作阅读相(operable reading phase)中,来构建可用于细菌的有效表达载体。所述载体会包含一个或多个表型选择标记以及一个复制起点以确保维持所述载体,以及根据需要在宿主内提供扩增。用于转化的合适的原核宿主包括但不限于大肠杆菌、枯草芽孢杆菌、鼠伤寒沙门氏菌和假单胞菌属、链霉菌属和葡萄球菌属中的各种物种。
细菌载体可以是例如基于噬菌体、质粒或噬菌粒的。这些载体可含有选择标记和细菌复制起点,其来源于通常含有众所周知的克隆载体pBR322(ATCC 37017)的元件的可商购的质粒。转化合适的宿主菌株并使所述宿主菌株生长至适当细胞密度之后,通过适当的方法(例如温度变化或化学诱导)去阻遏/诱导所选择的启动子,并且将细胞培养额外的时间。通常通过离心收获细胞,通过物理或化学方法使细胞破裂,并且保留所得的粗提取物用于进一步纯化。
在细菌系统中,根据所表达的蛋白的预期用途,可有利地选择多种表达载体。例如,当要生产大量这样的蛋白例如用于生产抗体或用于筛选肽文库时,可能需要引导表达高水平的易于纯化的融合蛋白产物的载体。
因此,本发明的一个实施方案为包含编码本发明的新型抗体的核酸序列的表达载体。
本发明的抗体或其抗原结合片段或其变体包括天然纯化的产物、化学合成方法的产物和通过重组技术从原核宿主产生的产物,所述原核宿主包括例如大肠杆菌、枯草芽孢杆菌、鼠伤寒沙门氏菌和假单胞菌属、链霉菌属和葡萄球菌属中的各种物种,优选大肠杆菌细胞。
哺乳动物表达
用于哺乳动物宿主细胞表达的优选调控序列包括指导蛋白在哺乳动物细胞中的高水平表达的病毒元件,诸如源自以下的启动子和/或增强子:巨细胞病毒(CMV)(诸如CMV启动子/增强子)、猿猴病毒40(SV40)(诸如SV40启动子/增强子)、腺病毒(例如腺病毒主要晚期启动子(AdMLP))和多瘤病毒。抗体的表达可以是组成型的或受调控的(例如可通过添加或除去小分子诱导剂(诸如和Tet系统结合的四环素)来诱导)。对于病毒调控元件及其序列的更多描述参见例如Stinski的U.S.5,168,062、Bell等人的U.S.4,510,245和Schaffner等人的U.S.4,968,615。重组表达载体还可以包括复制起点和选择标记(参见例如U.S.4,399,216、4,634,665和U.S.5,179,017)。合适的选择标记包括在已经引入载体的宿主细胞上赋予对药物(诸如G418、嘌呤霉素、潮霉素、杀稻瘟菌素、/博来霉素或甲氨蝶呤)的抗性的基因,或利用营养缺陷型的选择标记诸如谷氨酰胺合成酶(Bebbington等人,Biotechnology(N Y).1992Feb;10(2):169-75)。例如,二氢叶酸还原酶(DHFR)基因赋予甲氨蝶呤抗性,neo基因赋予G418抗性,来自土曲霉(Aspergillus terreus)的bsd基因赋予杀稻瘟菌素抗性,嘌呤霉素N-乙酰转移酶赋予嘌呤霉素抗性,Sh ble基因产物赋予Zeocin抗性,且潮霉素抗性由大肠杆菌潮霉素抗性基因(hyg或hph)赋予。选择标记如DHFR或谷氨酰胺合成酶也可用于与MTX和MSX结合的扩增技术。
表达载体至宿主细胞中的转染可以使用标准技术(诸如电穿孔、核转染、磷酸钙沉淀、脂质体转染、基于聚阳离子的转染诸如基于聚乙烯亚胺(PEI)的转染和DEAE葡聚糖转染)实施。
用于表达本文提供的抗体、其抗原结合片段或其变体的合适的哺乳动物宿主细胞包括中国仓鼠卵巢(CHO细胞)诸如CHO-K1、CHO-S、CHO-K1SV[包括Urlaub和Chasin,(1980)Proc.Natl.Acad.Sci.USA 77:4216-4220和Urlaub等人,Cell.1983Jun;33(2):405-12中描述的dhfr-CHO细胞,与例如R.J.Kaufman和P.A.Sharp(1982)Mol.Biol.159:601-621中描述的DHFR选择标记一起使用;和Fan等人,Biotechnol Bioeng.2012Apr;109(4):1007-15中例举的其他敲除细胞]、NS0骨髓瘤细胞、COS细胞、HEK293细胞、HKB11细胞、BHK21细胞、CAP细胞、EB66细胞和SP2细胞。
表达也可能在表达系统(诸如HEK293、HEK293T、HEK293-EBNA、HEK293E、HEK293-6E、HEK293-Freestyle、HKB11、Expi293F、293EBNALT75、CHO Freestyle、CHO-S、CHO-K1、CHO-K1SV、CHOEBNALT85、CHOS-XE、CHO-3E7或CAP-T细胞)中是瞬时或半稳定的(例如Durocher等人,Nucleic Acids Res.2002Jan 15;30(2):E9)。
在一些实施方案中,设计表达载体使得表达的蛋白分泌到宿主细胞生长的培养基中。抗体、其抗原结合片段或其变体可以使用标准蛋白纯化方法从培养基中回收。
纯化
本发明的抗体或其抗原结合片段或其变体可以通过众所周知的方法从重组细胞培养物回收并纯化,所述方法包括但不限于硫酸铵或乙醇沉淀、酸提取、蛋白A色谱法、蛋白G色谱法、阴离子或阳离子交换色谱法、磷酸纤维素色谱法、疏水相互作用色谱法、亲和色谱法、羟磷灰石色谱法和凝集素色谱法。高效液相色谱法(“HPLC”)也可用于纯化。参见例如Colligan,Current Protocols in Immunology或Current Protocols in ProteinScience,John Wiley&Sons,NY,N.Y.,(1997-2001),例如Chapter1、4、6、8、9、10,各自通过引用的方式整体纳入本文中。
本发明的抗体或其抗原结合片段或其变体包括天然纯化的产物、化学合成方法的产物和通过重组技术从真核宿主(包括例如酵母、高等植物、昆虫和哺乳动物细胞)产生的产物。根据重组生产方法中使用的宿主,本发明的抗体可以是糖基化的或可以是非糖基化的。此类方法描述于许多标准实验室手册中,诸如Sambrook,见上,Section 17.37-17.42;Ausubel,见上,Chapter 10、12、13、16、18和20。
在优选实施方案中,抗体被纯化(1)至抗体按重量计大于95%,且在一个进一步优选的实施方案中,按重量计大于99%,如例如通过Lowry法、UV-Vis光谱法或通过SDS毛细管凝胶电泳(例如在CaliperGXII、GX 90或Bio-Rad生物分析仪设备上)所测定的,(2)至足以获得N端或内部氨基酸序列的至少15个残基的程度,或(3)至通过在还原或非还原条件下的SDS-PAGE使用考马斯蓝或优选银染色达到均质。分离的天然产生的抗体包括重组细胞内的原位抗体,因为抗体的天然环境的至少一种组分将不存在。然而,通常,分离的抗体可通过至少一个纯化步骤来制备。
治疗方法
治疗方法涉及向需要治疗的受试者施用治疗有效量的本发明设想的抗体或其抗原结合片段或其变体。“治疗有效”量在本文定义为抗体或其抗原结合片段(作为单剂量或根据多剂量方案单独或与其他药剂联合)足以降低患者Sema3A活性的量,其使得不利病况得以缓解,但该量是毒理学上可耐受的。所述受试者可以是人或非人动物(例如兔、大鼠、小鼠、狗、猴或其他低等灵长类动物)。
因此,一方面,本发明涉及本发明的分离的抗体或抗原结合片段或包含本发明的分离的抗体或抗原结合片段的偶联物或包含本发明的分离的抗体或抗原结合片段的药物组合物,其用作药物。
本发明的分离的抗体或抗原结合片段可用作多种Sema3A相关疾病的治疗或诊断工具。
因此,另一方面,本发明涉及本发明的分离的抗体或抗原结合片段或包含本发明的分离的抗体或抗原结合片段的偶联物或包含本发明的分离的抗体或抗原结合片段的药物组合物,其用于治疗和/或预防肾脏病,尤其是急性和慢性肾脏病、糖尿病肾病、Alport综合征以及急性和慢性肾功能衰竭。术语“肾脏病”或“肾病”描述肾不能从血液中过滤去除废物的一类疾病。肾脏病有两种主要类型:急性肾脏病(急性肾损伤,AKI)和慢性肾脏病(CKD)。本发明的分离的抗体或抗原结合片段或包含其的偶联物或药物组合物可进一步用于治疗和/或预防多重损伤(例如缺血再灌注损伤、施用造影剂、体外循环手术、休克和脓毒症)导致的急性肾损伤的后遗症。在本发明的语境中,术语肾功能衰竭和肾功能不全包括肾功能不全的急性和慢性表现以及潜在的或相关的肾脏病例如肾灌注不足、透析中低血压、梗阻性尿路病、肾小球病、IgA肾病、肾小球肾炎、急性肾小球肾炎、肾小球硬化、肾小管间质病,肾脏病例如原发性和先天性肾脏病、肾炎、Alport综合征、肾脏炎症、免疫性肾脏病例如肾移植排斥反应和免疫复合物诱导的肾脏病、有毒物质诱导的肾病、造影剂诱导的肾病;轻微病变性肾小球肾炎(脂性肾病);膜性肾小球肾炎;局灶节段性肾小球硬化(FSGS);溶血尿毒综合征(HUS)、淀粉样变性病、Goodpasture综合征、韦格纳肉芽肿、-Henoch紫癜、糖尿病和非糖尿病肾病、肾盂肾炎、肾囊肿、肾硬化、高血压肾硬化和肾病综合征,其诊断特征在于例如肌酸酐和/或水排泄异常减少,尿素、氮、钾和/或肌酸酐的血浓度异常升高,肾脏酶例如谷氨酰合成酶活性改变,尿渗量或尿量改变,微量白蛋白尿增加,大量白蛋白尿,肾小球和小动脉损伤,肾小管扩张,高磷血症和/或需要透析。本发明还涉及本发明的分离的抗体或抗原结合片段或包含其的偶联物或药物组合物,其用于治疗和/或预防肾功能不全的后遗症,例如肺水肿、心力衰竭、尿毒症、贫血、电解质紊乱(例如高钾血症、低钠血症)以及骨骼和糖代谢紊乱。本发明的化合物同样适合治疗和/或预防多囊肾病(PCKD)和抗利尿激素分泌不当综合征(SIADH)。
此外,本发明的分离的抗体或抗原结合片段或包含其的偶联物或药物组合物可用于治疗和/或预防血管通透性过高、糖尿病视网膜病变、血视网膜屏障受损和后续的黄斑水肿,优选年龄相关性黄斑水肿、非增殖性年龄相关性黄斑水肿和非增殖性糖尿病性黄斑水肿。
而且,本发明的分离的抗体或抗原结合片段或包含其的偶联物或药物组合物适合预防或治疗中枢或外周神经系统疾病,例如神经病理性疼痛、脊髓损伤、多发性硬化、创伤性脑损伤、脑水肿或神经退行性疾病,其中神经退行性疾病为阿尔兹海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化、进行性核上性麻痹、黑质变性、Shy-Drager综合征、橄榄-脑桥-小脑萎缩或脊髓小脑变性。
此外,本发明的分离的抗体或抗原结合片段或包含其的偶联物或药物组合物可用于治疗和/或预防癌症,其中癌症为肠癌、结直肠癌、肺癌、乳腺癌、脑癌、黑色素瘤、肾细胞癌、白血病、淋巴瘤、T细胞淋巴瘤、胃癌、胰腺癌、宫颈癌、子宫内膜癌、卵巢癌、食管癌、肝癌、头颈部鳞状细胞癌、皮肤癌、泌尿道癌、前列腺癌、绒毛膜癌、咽癌或喉癌。
上述疾病已在人类中深入研究,但也以类似病因存在于其他动物(包括哺乳动物)中,并且可通过施用本发明的药物组合物来治疗。
本发明的抗体或抗原结合片段或其变体可以与已知的药物共同施用,在一些情况下,该抗体或其抗原结合片段自身可被修饰。例如,抗体或其抗原结合片段或其变体可以与药物或其他肽或蛋白质偶联,可进一步提高疗效。
本发明的抗体或其抗原结合片段或其变体可以作为单独的药剂施用或与一种或多种额外的治疗剂联合施用,其中所述联合不引起不可接受的不良反应。
因此,另一方面,本发明涉及本发明的分离的抗体或抗原结合片段或本发明的偶联物或本发明的药物组合物,其用于与一种或多种另外的治疗活性化合物同时、分别或依次联合使用。
与本发明的抗体或抗原结合片段联合使用的治疗活性化合物的非限制性实例为:
-降血压药,例如优选自钙拮抗剂、血管紧张素II拮抗剂、ACE抑制剂、NEP抑制剂、血管肽酶抑制剂、内皮素拮抗剂、肾素抑制剂、α受体阻断剂、β受体阻断剂、盐皮质激素受体拮抗剂和利尿剂;
-抗糖尿病药(降血糖或抗高血糖药),例如优选胰岛素及衍生物、磺酰脲类、双胍类、噻唑烷二酮类、阿卡波糖、DPP4抑制剂、GLP-1类似物或SGLT抑制剂(列净类);
-抑制信号转导级联反应的化合物,尤其是酪氨酸和/或丝氨酸/苏氨酸激酶抑制剂,例如尼达尼布、达沙替尼、尼洛替尼、伯舒替尼、瑞戈非尼、索拉非尼、舒尼替尼、西地尼布、阿西替尼、特拉替尼、伊马替尼、布立尼布、帕唑帕尼、瓦他拉尼、吉非替尼、厄洛替尼、拉帕替尼、卡奈替尼、来他替尼、培利替尼、司马沙尼或坦度替尼;
-抗炎药,例如包括乙酰水杨酸(阿司匹林)、布洛芬和萘普生的非甾体抗炎药(NSAID),糖皮质激素例如优选泼尼松、泼尼松龙、甲泼尼龙、曲安西龙、地塞米松、倍氯米松、倍他米松、氟尼缩松、布地奈德或氟替卡松,或5-氨基水杨酸衍生物,白三烯拮抗剂,TNF-α抑制剂和趋化因子受体拮抗剂例如CCR1、2和/或5抑制剂,NF-κB抑制剂和Nerf2激活剂;
-抗纤维化药,例如TGF-β拮抗剂或microRNA-21抑制剂;
-有机硝酸盐和NO供体,例如硝普钠、硝酸甘油、单硝酸异山梨酯、硝酸异山梨酯、吗多明或SIN-1和吸入性NO;
-抑制环磷酸鸟苷(cGMP)降解的化合物,例如磷酸二酯酶(PDE)
1、2、5和/或9抑制剂,尤其是PDE-5抑制剂例如西地那非、伐地那非、他达拉非、乌地那非、达生他非、阿伐那非、米罗那非、罗地
那非、CTP-499或PF-00489791;
-钙增敏剂,例如优选左西孟旦;
-抗血栓药,特别选自血小板聚集抑制剂、抗凝剂和分解血纤蛋白原的物质;
-激活NO和血红素依赖性以及非NO和血红素依赖性cGMP合成的药剂,例如优选可溶性鸟苷酸环化酶(sGC)调节剂,例如优选利奥
西呱、西那西呱、维利西呱或BAY 1101042;
-脂肪代谢调节剂,例如优选自甲状腺受体激动剂,胆固醇合成抑制剂(例如优选HMG-CoA还原酶或鲨烯合成抑制剂),ACAT抑制剂,CETP抑制剂,MTP抑制剂,PPAR-α、PPAR-γ和/或PPAR-δ激动剂,胆固醇吸收抑制剂,脂肪酶抑制剂,胆汁酸高分子吸附剂,胆汁酸重吸收抑制剂和脂蛋白(a)拮抗剂。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与血小板聚集抑制剂(尤其是阿司匹林、氯吡格雷、噻氯匹定或双嘧达莫)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与凝血酶抑制剂(尤其是希美加群、达比加群、美拉加群、比伐卢定或依诺肝素)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与GPIIb/IIIa拮抗剂(尤其是替罗非班或阿昔单抗)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与Xa因子抑制剂联合施用,Xa因子抑制剂特别选自利伐沙班、阿哌沙班、奥米沙班、非地沙班、雷扎沙班、磺达肝素、艾卓肝素、DU-176b、PMD-3112、YM-150、KFA-1982、EMD-503982、MCM-17、MLN-1021、DX9065a、DPC 906、JTV 803、SSR-126512和SSR-128428。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与肝素或低分子量(LMW)肝素衍生物联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与维生素K拮抗剂(特别选自香豆素)联合施用。
降血压药特别选自钙拮抗剂、血管紧张素AII拮抗剂、ACE抑制剂、NEP抑制剂、血管肽酶抑制剂、内皮素拮抗剂、肾素抑制剂、α受体阻断剂、β受体阻断剂、盐皮质激素受体拮抗剂和利尿剂。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与钙拮抗剂(特别选自硝苯地平、氨氯地平、维拉帕米和地尔硫)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与血管紧张素AII受体拮抗剂联合施用,血管紧张素AII受体拮抗剂特别选自氯沙坦、坎地沙坦、缬沙坦、替米沙坦、厄贝沙坦、奥美沙坦、依普沙坦、恩布沙坦和阿齐沙坦。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与ACE抑制剂联合施用,ACE抑制剂特别选自依那普利、卡托普利、赖诺普利、雷米普利、地拉普利、福辛普利、喹那普利、培哚普利、贝那普利和群多普利。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与内皮素拮抗剂联合施用,内皮素拮抗剂特别选自波生坦、达卢生坦、安立生坦、替唑生坦、西他生坦、阿伏生坦、马西替坦和阿曲生坦。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与肾素抑制剂(特别选自阿利吉仑、SPP-600和SPP-800)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与盐皮质激素受体拮抗剂联合施用,盐皮质激素受体拮抗剂特别选自非奈利酮、螺内酯、坎利酮、坎利酸钾、依普利酮、艾沙利酮(CS-3150)或阿帕利酮(MT-3995)、CS-3150和MT-3995。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与利尿剂联合施用,利尿剂特别选自呋塞米、布美他尼、吡咯他尼、托拉塞米、苄氟噻嗪、氯噻嗪、氢氯噻嗪、希帕胺、吲达帕胺、氢氟噻嗪、甲氯噻嗪、多噻嗪、三氯噻嗪、氯噻酮、美托拉宗、喹乙宗、乙酰唑胺、双氯非那胺、醋甲唑胺、甘油、异山梨醇、甘露醇、阿米洛利和氨苯蝶啶。
脂肪代谢调节剂特别选自CETP抑制剂,甲状腺受体激动剂,胆固醇合成抑制剂(例如HMG-CoA还原酶或鲨烯合成抑制剂),ACAT抑制剂,MTP抑制剂,PPAR-α、PPAR-γ和/或PPAR-δ激动剂,胆固醇吸收抑制剂,胆汁酸高分子吸附剂,胆汁酸重吸收抑制剂,脂肪酶抑制剂和脂蛋白(a)拮抗剂。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与Nerf2激活剂(特别选自甲基巴多索隆)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与甲状腺受体激动剂(特别选自D-甲状腺素、3,5,3’-三碘甲状腺原氨酸(T3)、CGS 23425和阿昔替罗(CGS26214))联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与他汀类HMG-CoA还原酶抑制剂联合施用,他汀类HMG-CoA还原酶抑制剂特别选自洛伐他汀、辛伐他汀、普伐他汀、氟伐他汀、阿托伐他汀、瑞舒伐他汀和匹伐他汀。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与PPAR-γ调节剂(特别选自吡格列酮和罗格列酮)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与PPAR-δ调节剂(特别选自ASP1128、GW 501516和BAY 68-5042)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与胆固醇吸收抑制剂(特别选自依折麦布、替奎安和帕马苷)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与脂肪酶抑制剂(特别选自奥利司他)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与胆汁酸高分子吸附剂联合施用,胆汁酸高分子吸附剂特别选自考来烯胺、考来替泊、考来维仑、考来胶和考来替兰。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与胆汁酸重吸收抑制剂联合施用,胆汁酸重吸收抑制剂特别选自ASBT(IBAT)抑制剂例如AZD-7806、S-8921、AK-105、BARI-1741、SC-435和SC-635。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与脂蛋白(a)拮抗剂(特别选自吉卡宾钙(CI-1027)和烟酸)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与TGF-β拮抗剂(特别选自吡非尼酮和非苏木单抗)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与抗microRNA-21寡核苷酸(特别选自Lademirsen)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与HIF-PH抑制剂(特别选自莫立司他和罗沙司他)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与CCR2拮抗剂(特别选自CCX-140)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与TNF-α拮抗剂(特别选自阿达木单抗)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与半乳糖凝集素3抑制剂(特别选自GCS-100)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与肝细胞生长因子模拟物(特别选自Refanalin)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与p53调节剂(特别选自QPI-1002)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与NOX1/4抑制剂(特别选自GKT-137831)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与影响维生素D代谢的药物(特别选自胆钙化醇和帕立骨化醇)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与细胞生长抑制剂(特别选自环磷酰胺)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与抗VEGF治疗(特别选自雷珠单抗、贝伐单抗和阿柏西普)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与免疫抑制剂(特别选自环孢素)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与磷结合剂(特别选自司维拉姆和碳酸镧)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与治疗甲状旁腺功能亢进的拟钙剂联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与治疗铁缺乏的药剂(特别选自铁剂)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与治疗高尿酸血症的药剂(特别选自别嘌醇和拉布立酶)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与治疗贫血的糖蛋白激素(特别选自促红细胞生成素)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与用于免疫治疗的生物制品(特别选自阿巴西普、利妥昔单抗、依库珠单抗和贝利尤单抗)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与JAK抑制剂联合施用,JAK抑制剂特别选自芦可替尼、托法替尼、巴瑞替尼、CYT387、GSK2586184、来他替尼、帕克替尼(SB1518)和TG101348。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与治疗微血栓的前列环素类似物联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与碱化治疗(特别选自碳酸氢钠)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与mTOR抑制剂(特别选自依维莫司和雷帕霉素)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与NHE3抑制剂(特别选自AZD1722)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与eNOS调节剂(特别选自沙丙蝶呤)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与CTGF抑制剂(特别选自FG-3019)联合施用。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与一种或多种额外的治疗剂联合施用,额外的治疗剂选自利尿剂、血管紧张素AII拮抗剂、ACE抑制剂、β受体阻断剂、盐皮质激素受体拮抗剂、抗糖尿病药、有机硝酸盐和NO供体、可溶性鸟苷酸环化酶(sGC)激动剂和激活剂和正性肌力药。
在特定实施方案中,本发明的分离的抗体或抗原结合片段与一种或多种额外的治疗剂联合施用,额外的治疗剂选自利尿剂、血管紧张素AII拮抗剂、ACE抑制剂、β受体阻断剂、盐皮质激素受体拮抗剂、抗糖尿病药、有机硝酸盐和NO供体、可溶性鸟苷酸环化酶(sGC)激动剂和激活剂、正性肌力药、抗炎药、免疫抑制剂、磷结合剂和调节维生素D代谢的抗体。
联合治疗包括施用含有本发明的抗体或抗原结合片段或其变体和一种或多种额外的治疗剂的单一药物剂型,以及以其自己分别的药物剂型施用本发明抗体或抗原结合片段以及各个额外的治疗剂。例如,本发明的抗体或其抗原结合片段或其变体和治疗剂可以以单一液体组合物的形式共同给予患者,或者各药剂可以以分别的剂型施用。
当使用分别的剂型时,本发明的抗体或抗原结合片段或其变体和一种或多种额外的治疗剂可以在基本上相同的时间(例如同时)或者在分别错开的时间(例如依次地)施用。
本发明的抗体或抗原结合片段或其变体可以与手术干预联合使用,手术干预包括但不限于:
-大型心血管手术,例如冠状动脉旁路移植术(CABG)、心脏瓣膜修复或心脏瓣膜置换术、起搏器或植入式心律转复除颤器(ICD)置入术、迷宫手术、动脉瘤修复术、颈动脉手术/动脉内膜剥脱术和取栓术;
-大型非心脏手术,例如胸、骨科、泌尿外科手术。
诊断方法
此外,本发明的抗体或抗原结合片段能够以原形或组合物形式用于研究和诊断,或作为分析参比标准品等。
抗Sema3A抗体或其抗原结合片段可用于检测Sema3A的存在。因此,另一方面,本发明涉及用作诊断试剂的本发明的分离的抗体或抗原结合片段或本发明的抗体偶联物。
药物组合物和给药
另一方面,本发明涉及包含本发明的分离的抗体或抗原结合片段或本发明的抗体偶联物的药物组合物。为了治疗任何前述疾病,可使用一种或多种生理上可接受的载体、赋形剂或助剂,以任何常规方式配制按本发明使用的药物组合物。关于制剂和给药技术的更多细节可参见最新版Remington's Pharmaceutical Sciences(Ed.Maack Publishing Co,Easton,Pa.)。
根据所治疗的疾病类型,本发明的抗体或抗原结合片段可通过任何合适的方式(其可以改变)施用。可能的给药途径包括口服、胃肠外或局部给药。胃肠外递送方式包括动脉内、肌内、皮下、髓内、鞘内、心室内、静脉内、腹膜内或鼻内给药。此外,本发明的抗体或抗原结合片段可用例如逐渐减量的抗体通过脉冲输注施用。优选通过注射给药,最优选静脉内或皮下注射,其在某种程度上取决于是短期还是长期用药。给药量将取决于多种因素,诸如临床症状、个体体重、是否施用其他药物等。技术人员应认识到,给药途径可根据待治疗的疾病或病症而改变。
本发明的药物组合物单独包含本发明的抗体或抗原结合片段,或包含本发明的抗体或抗原结合片段与至少一种其他药剂(诸如稳定剂)的组合。本发明的抗体或抗原结合片段可以在任何无菌的生物相容性药物载体(包括但不限于盐水、缓冲盐水、右旋糖和水)中施用。在特定实施方案中,本发明的药物组合物可包含一种或多种其他药物活性化合物,尤其是适合治疗Sema3A相关疾病的一种或多种其他药物活性化合物。任何这些药剂可单独施用于患者,或以药物组合物形式(与一种或多种赋形剂或药学上可接受的载体混合)与其他药剂或药物联合施用于患者。在特定实施方案中,药学上可接受的载体是药学上惰性的。
口服给药的药物组合物可使用在本领域中众所周知的药学上可接受的载体以适于口服给药的剂量配制。这类载体使得所述药物组合物可被配制为患者口服的片剂、丸剂、糖衣丸剂、胶囊剂、液体剂、凝胶剂、糖浆剂、膏剂、混悬剂等。
口服使用的药物制剂可通过以下方式获得:将活性化合物与固体赋形剂组合,可选地研磨所得的混合物,根据需要加入合适的助剂之后,加工颗粒混合物以获得片剂或糖衣丸芯。合适的赋形剂是糖类或蛋白质填充剂例如糖类,包括乳糖、蔗糖、甘露醇或山梨醇;来自玉米、小麦、大米、土豆或其他植物的淀粉;纤维素例如甲基纤维素、羟丙基甲基纤维素或羧甲基纤维素钠;胶,包括阿拉伯胶和西黄蓍胶;以及蛋白质例如明胶和胶原。根据需要,可加入崩解剂或增溶剂,例如交联的聚乙烯吡咯烷酮、琼脂、海藻酸或它们的盐,例如海藻酸钠。
糖衣丸芯可具有合适的包衣例如浓缩糖溶液,其还可能含有阿拉伯胶、滑石粉、聚乙烯吡咯烷酮、凝胶、聚乙二醇和/或二氧化钛、漆溶液以及合适的有机溶剂或溶剂混合物。可向所述片剂或糖衣丸包衣中加入染料或色素,用于产品识别或表征活性化合物的量,即剂量。
可口服使用的药物制剂包括由明胶制成的推入式(push-fit)胶囊,以及由明胶和包衣(例如甘油或山梨醇)制成的软的密封胶囊。推入式胶囊可含有与填充剂或粘合剂(例如乳糖或淀粉)、润滑剂(例如滑石粉或硬脂酸镁)和可选的稳定剂混合的活性成分。在软胶囊中,可在有或没有稳定剂的情况下将活性化合物溶解或悬浮在合适的液体,例如脂肪油、液体石蜡或液体聚乙二醇中。
胃肠外给药的药物制剂包括活性化合物的水溶液。为了注射,可以将本发明的药物组合物配制于水溶液中,优选生理相容性缓冲液例如Hank’s溶液、林格液或生理缓冲盐水。水性注射混悬液可含有增加该混悬液的黏度的物质,例如羧甲基纤维素钠、山梨醇或葡聚糖。此外,所述活性化合物的混悬液可以制备为适当的油性注射混悬液。合适的亲脂性溶剂或赋形剂包括脂肪油例如芝麻油,或者合成的脂肪酸酯例如油酸乙酯或甘油三酯,或者脂质体。可选地,所述混悬液还可含有合适的稳定剂或增加所述化合物的溶解度以允许制备高度浓缩溶液的试剂。
为了局部或经鼻给药,可将适合待渗透的特定屏障的渗透剂用于制剂中。这类渗透剂在本领域中众所周知。
本发明的药物组合物可以以本领域中已知的方式制备,例如通过常规的混合、溶解、制粒、糖衣丸制备、研磨、乳化、胶囊化、包埋或冻干方法。
所述药物组合物可以以盐的形式提供,可以与酸来形成,所述酸包括但不限于盐酸、硫酸、乙酸、乳酸、酒石酸、苹果酸、琥珀酸等。盐更易溶于相应的游离碱形式的水性或其他质子性溶剂。在其他情况中,优选的制剂可以为1mM-50mM组氨酸或磷酸盐或Tris、0.1%-2%蔗糖和/或2%-7%甘露醇中的冻干粉,pH值范围为4.5-7.5,其可选地包含在使用之前与缓冲液组合的额外的物质如聚山梨酯。
在制备配制于可接受的载体中的包含本发明化合物的药物组合物之后,可将其置于适当的容器中并加标签说明用于治疗所标明的疾病。对于抗Sema3A的抗体或其抗原结合片段的给药,这类标签会包括给药的量、频率和方法。
治疗有效量
适用于本发明的药物组合物包括其中含有有效量的活性成分以实现预期目的(例如治疗以Sema3A水平或活性升高为特征的特定疾病状态)的组合物。有效剂量的确定在本领域技术人员的能力之内。
确定本发明的新型抗体或其抗原结合片段或其变体的治疗有效量,主要取决于具体患者特征、给药途径以及治疗的疾病的性质。一般性指导记载于例如InternationalConference on Harmonization的出版物以及REMINGTON'S PHARMACEUTICAL SCIENCES,Chapter 27和28,pp.484-528(18th ed.,Alfonso R.Gennaro,Ed.,Easton,Pa.:MackPub.Co.,1990)中。更具体地,确定治疗有效量,将取决于药物的毒性和疗效这些因素。毒性可使用本领域中众所周知的和上述参考文献中记载的方法测定。疗效可利用相同的指导结合下文实施例中所述的方法测定。
对于任何化合物,治疗有效量可在细胞培养测定,或在动物模型(通常为小鼠、兔、狗、猪或猴)中初步评估。动物模型也可用于获得理想的浓度范围和给药途径。然后这类信息可用于确定在人中给药的有效剂量和途径。
治疗有效量是指改善症状或疾病的抗体或其抗原结合片段的量。这类化合物的疗效和毒性可通过在细胞培养物或实验动物中进行的标准药学程序来确定,例如ED50(在群体的50%中治疗有效的剂量)和LD50(对群体的50%致死的剂量)。治疗作用和毒性作用之间的剂量比为治疗指数,其可表示为比率ED50/LD50。表现出大的治疗指数的药物组合物是优选的。获自细胞培养测定和动物研究的数据被用于配制一系列人用剂量。这类化合物的剂量优选地在循环浓度的范围内,所述范围包括具有很少毒性或无毒性的ED50。根据所用的剂型、患者的敏感性和给药途径,剂量在该范围内有所变化。
确切剂量由医生个人根据待治疗的患者来选择。调整剂量和给药以提供足够水平的活性部分或维持所需的作用。可以考虑的其他因素包括疾病状态的严重程度,患者的年龄、体重和性别;饮食、给药的时间和频率、联合用药、反应敏感性和对治疗的耐受性/反应。根据具体制剂的半衰期和清除率,长效药物组合物可例如每3至4天、每周、每两周一次或每三周一次给药。
根据给药途径,正常剂量可以在0.1至100,000微克,最高达约10g的总剂量的范围内变化。文献中提供具体剂量和递送方式的指导。参见U.S.Pat.No.4,657,760、5,206,344或5,225,212。
试剂盒
另一方面,本发明涉及包含本发明的分离的抗体或抗原结合片段或本发明的偶联物的试剂盒与使用说明书。在特定实施方案中,试剂盒包含一个或多个装有前述本发明组合物的一种或多种成分的容器。这类容器可附有管理药物或生物制品的生产、使用或销售的政府机构所规定的格式的声明,其反映机构批准人用产品的生产、使用或销售。
附图说明
图1A:TPP-15370(灰条)、TPP-11489(条纹条)和TPP-17755(方格条)对小鼠中Sema3A诱导的白蛋白排泄的Sema3A抑制作用。所示为均值±标准差(S.D.)(n=10)。***、****:P<0.001、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图1B:TPP-23298(灰条)、TPP-11489(点纹条)和TPP-17755(条纹条)对小鼠中Sema3A诱导的白蛋白排泄的Sema3A抑制作用。所示为均值±标准差(n=10)。***、****:P<0.001、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图2A:用TPP-15370(白圆形)和TPP-232989(黑圆形)相较于用TPP-11489(黑三角形)治疗后小鼠中Sema3A诱导的白蛋白尿。在两个单独的实验中进行比较。所示为均值(n=10)。n.s.=统计学上不显著(与TPP-15370比较);*=P<0.05(与TPP-23298比较)。非配对t检验。
图2B:用TPP-15370(白圆形)和TPP-232989(黑圆形)相较于用TPP-17755(黑正方形)治疗后小鼠中Sema3A诱导的白蛋白尿。在两个单独的实验中进行比较。所示为均值(n=10)。n.s.=统计学上不显著(与TPP-15370比较);*=P<0.05(与TPP-23298比较)。非配对t检验。
图2C:用TPP-15370(白圆形)和TPP-232989(黑圆形)相较于用TPP-30788(黑菱形)治疗后小鼠中Sema3A诱导的白蛋白尿。在两个单独的实验中进行比较。所示为均值(n=10)。n.s.=统计学上不显著(与TPP-15370比较);*=P<0.05(与TPP-23298比较)。非配对t检验。
图3:TPP-23374(点纹条)、TPP-23298(灰条)和TPP-15370(条纹条)对小鼠I/R损伤后A:血清肌酸酐水平、B:血清尿素水平和C:尿白蛋白排泄的Sema3A抑制作用。所示为均值±标准差(n=8-10)。*、**、****:P<0.05、P<0.01、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图4:TPP-15370(灰条)、TPP-11489(条纹条)和TPP-17755(方格条)对小鼠I/R损伤后A:血清肌酸酐水平、B:血清尿素水平和C:尿白蛋白排泄的Sema3A抑制作用。所示为均值±标准差(n=8-10)。*、**、****:P<0.05、P<0.01、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图5:TPP-23298(灰条)、TPP-11489(条纹条)和TPP-17755(方格条)对小鼠I/R损伤后A:血清肌酸酐水平、B:血清尿素水平和C:尿白蛋白排泄的Sema3A抑制作用。所示为均值±标准差(n=10-12)。*、**、****:P<0.05、P<0.01、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图6:TPP-15374(灰条)、TPP-11489(条纹条)对小鼠I/R损伤后A:血清肌酸酐水平、B:血清尿素水平和C:尿白蛋白排泄的Sema3A抑制作用。所示为均值±标准差(n=10-12)。*、**、***、****:P<0.05、P<0.01、P<0.001、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图7:TPP-15370(灰条)、TPP-11489(条纹条)对Alport综合征小鼠蛋白尿的Sema3A抑制作用。所示为均值±标准差(n=8-10)。****:P<0.0001(与同种型对照比较)。Dunnett事后检验。
图8:TPP-15370(灰条)、TPP-11489(条纹条)对Alport综合征小鼠的A:血清肌酸酐水平、B:血清尿素水平和纤维化、C:肌成纤维细胞和D:胶原沉积的Sema3A抑制作用。所示为均值±标准差(n=8-10)。*、***、****:P<0.05、P<0.001、P<0.0001(与同种型对照比较)。Dunnett事后检验。
图9:TPP-23298在猪单侧肾IRI模型(缺血105min)中的单剂量预防设置中的Sema3A抑制作用。在左肾动脉中的球囊充气的30min前给予TPP-23298(A;黑点)或IgG对照(空心圆)(10mg/kg)。假手术动物的数值用菱形表示。个体动物的血浆肌酸酐浓度时间进程(A)和相较于实验开始时(0h)基线值的肌酸酐血浆浓度平均变化时间进程(B)。间隔24-27h的肌酸酐清除率平均值。左(损伤的)和右(未损伤的)肾以及假手术动物的肾的两边分开的肌酸酐清除率(C)。全身肌酸酐清除率(D);均值±SEM,(B)中的P值来自t检验,(C)和(D)中的*/***:P<0.05/0.001,与相应对照比较的单向方差分析(ANOVA),然后进行Dunnett多重比较。
图10:使用SPR的基于三明治的表位分选(binning)实验的图示(也参见实施例5a)。
图11:HRA图像分析步骤:11A)DAPI/CM细胞的荧光显微图像;11B)所选区域中细胞的识别;11C)无细胞区域尺寸的计算(灰色区域)。图12:显示HUVEC排斥检测中抗体浓度为80pM时的Sema3A抑制率(参见实施例11)。每个柱以下列从左到右的顺序代表一个抗体:TPP-23298(黑柱)、TPP-30788、TPP-30789、TPP-30790和TPP-30791。
具体实施方式
实施例1:Sema3A序列和工具生成
表2:本发明使用的工具
使用瞬时转染的HEK293-6E细胞(National Research Council Canada)通过哺乳动物细胞培养生产Sema3A结构域。所有构建体受CMV启动子调控,并且序列包含C端FXa切割位点,然后是6×His标签。使用添加0.1%泊洛沙姆F68(Life Technologies)和4mMGlutaMAXTM(Life Technologies)的F17培养基(Life Technologies)进行细胞培养。转染后24h,加入1%超低IgG胎牛血清(Life Technologies)和0.5mM丙戊酸(Sigma-)。将细胞上清液进行无菌过滤,随后进行纯化或在纯化前通过错流过滤进行浓缩。
使用由亲和色谱和体积排阻色谱组成的两步纯化操作纯化Sema3A结构域。简言之,将细胞培养上清液加入连接至Avant系统的Ni2+-NTA柱(GE Healthcare)。用4CV 50mM NaH2PO4、300mM NaCl(pH 8)平衡柱,再用10CV运行缓冲液冲洗,直至到达基线。用6CV含250mM咪唑,pH 8.0的运行缓冲液进行洗脱。合并洗脱峰的馏分,用200膜(截留分子量10kDa,Sartorius)浓缩并使用连接至pureTM25系统的SuperdexTM200柱(GE Healthcare)进行体积排阻色谱。在pH 7.4的DPBS中平衡和运行色谱柱。合并结构域洗脱峰的馏分并用Vivaflow 200Hydrosart膜(截留分子量10kDa,Sartorius)浓缩。在用于纯度和单分散性的分析体积排阻色谱(Superdex200)和SDS-PAGE上评估最终蛋白质量。将Sema结构域等分,在液氮中速冻,保存于-80℃至后续使用。
实施例2:从BioInvent抗体文库生成抗体
使用全人抗体噬菌体展示文库(BioInvent n-CoDeR Fabλ文库)分离本发明的人单克隆抗体,其通过使用以下方案的针对重组人Sema3A(TPP-13211,R&D Systems)的筛选实现。简言之,将Immunotubes(Nunc)用100μg溶于1mL PBS(磷酸盐缓冲液)的靶分子(huSema3A)或包含不相关Fc的非靶分子通过端对端旋转(end-over-end rotation)于室温(RT)下涂覆一小时。将靶抗原和缺失抗原涂覆的免疫管和空的免疫管用PBS+0.05%Tween20(PBST)洗涤4次,然后用3mL 3%奶粉的PBST溶液利用端对端旋转在室温下封闭1h。将噬菌体文库的试样解冻,使其在3%奶粉的PBST溶液中利用端对端旋转在室温下封闭1h。将未涂覆的缺失免疫管用4mL PBS洗涤3次,然后加入封闭的噬菌体文库并利用端对端旋转在室温下孵育30min。对于未涂覆靶抗原的缺失免疫管重复该步骤。将huSema3A涂覆的免疫管用4mL PBS洗涤3次,然后加入耗竭的文库,利用端对端旋转于室温下孵育90min。经过严格洗涤(4mL PBST 4次和4mL PBS1次)后,用500μL 100nM TEA洗脱特异性结合涂覆的靶标的表达Fab的噬菌体,于室温下孵育10min,然后加入500μL pH 7.5的Tris-HCl中和。使用500μL洗脱的噬菌体感染大肠杆菌菌株HB101。之后用M13KO7辅助噬菌体(InvitrogenTM)在大肠杆菌菌株HB101中扩增噬菌体。在后续的两轮筛选中,靶标浓度降至25μg/mL。对于首次定性评估,来自每轮筛选的88个随机挑选的表达Fab的噬菌体克隆在单孔中表达并测定相较于不相关的非靶分子对huSema3A的结合。发现来自本实施例中第3轮的克隆池含有60%的阳性命中率并被选择用于进一步筛选。
在下一步中,通过大批去除该池中的基因III融合使可溶性Fab表达并挑选2208个单克隆用于在大肠杆菌菌株TOP10中表达并在huSema3A结合ELISA中评估含Fab的上清液。还使用NGS方法确定所有2208个克隆的VH和VL序列。确定了154个阳性结合huSema3A的不同克隆。这些结合阳性的Fab片段在验证性结合ELISA中进行了检测,还评估了与小鼠Sema3A-Fc(TPP-13357,R&D Systems)的结合以及特异性检测(使用额外的非靶分子,鼠Sema3F(R&DSystems))。基于此分析,优先处理48个人/小鼠交叉反应性Sema3A结合Fab。接下来用CaptureSelectTMCH1填料(matrix)(Life Technologies)从25mL表达培养物中纯化这些Fab片段,用12.5mM pH 2.5的柠檬酸洗脱,最后用ZebaTM脱盐离心板(Thermo Fisher)将缓冲液置换为PBS。通过表面等离子共振(SPR)对所有48个纯化的Fab片段进行动力学排序,检测与人和小鼠Sema3A的结合情况,并将其重排(reformat)为全长人IgG1并再次在SPR中进行结合检测(参见实施例4)。
实施例3:先导抗体TPP-15370和TPP-15374的序列优化、种系化和亲和力成熟
对IgG1抗体TPP-15370和TPP-15374进行先导物优化程序,目标为(i)优化其亲和力、(ii)提高功能效率、(iii)降低基于序列的免疫原性风险以及(iv)提高与下游开发过程的相容性。
通过第一轮单一突变聚集,然后在种系化和序列优化的抗体骨架中进行最能提高亲和力和效力的氨基酸置换的重组来完成亲和力成熟。
对于突变聚集,为了密码子多样化,使用包括NNK在内的合成寡核苷酸通过定点诱变在下列单个氨基酸位点生成NNK(N=A或G或C或T,K=G或T)随机化。对于TPP-15370,分析了下列区域对亲和力的作用:GFTFSSYGMH(VH SEQ ID NO:41的26-35位残基)、WVSAIGTGGDTYYADSVMG(VH SEQ ID NO:41的47-65位残基)、ARRDDYTSRDAFDV(VH SEQ IDNO:41的96-109位残基)、SGSSSNIGSNTVNWY(VL SEQ ID NO:45的23-37位残基)、LLIYYDDLLPS(VL SEQ ID NO:45的47-57位残基)和AAWDDSLNGYVV(VL SEQ ID NO:45的90-101位残基)。
对于TPP-15374,分析了下列区域对亲和力的作用:GFTFSSYEMN(VH SEQ ID NO:61的26-35位残基)、WVSGISWNSGSIGYADSVKG(VH SEQ ID NO:61的47-66位残基)、ARSGYSSSWFDPDFDY(VH SEQ ID NO:61的97-112位残基)、TGSSSNIGAGYDVHWY(VL SEQ IDNO:65的23-38位残基)、LLIYGNSNRPS(VL SEQ ID NO:65的48-58位残基)和SSYAGSNPYV(VLSEQ ID NO:65的91-101位残基)。
对所得的单NNK文库进行测序并分别鉴定了TPP15370和TPP-15374的约1000个单氨基酸置换变体。它们通过哺乳动物细胞瞬时转染表达,所得表达上清液的抗体浓度归一化后用表面等离子共振和竞争ELISA进行筛选。
对于TPP-15370和TPP-15374的种系化和序列优化过程,挑选轻链和重链的最近的种系家族并仔细检查潜在的CMC相关残基。CDR区和FW区中的最接近的人种系的变异以及CDR区中潜在的CMC相关残基通过定点诱变进行调整并通过功能和生物物理试验(非特异性结合、DSC中的温度稳定性)进行检测。所得的单回复突变和后续的组合IgG变体通过哺乳动物细胞瞬时转染表达,所得表达上清液的抗体浓度归一化后在结合测定(SPR、竞争ELISA)和功能试验中进行筛选。这产生了TPP-15370的种系化和序列优化的分子TPP-21565和TPP-15374的种系化和序列优化的分子TPP-18533。TPP-21565相较于TPP-15370携带轻链中的回复突变L55R和R80Q以及重链中的回复突变G33A、H35S、M64K和V109Y。TPP-18533相较于TPP-15374携带轻链中的回复突变A10V、T13A、S78T、R81Q、S82A。
对于最终的TPP-21565重组文库,挑选八个在NNK文库筛选步骤中表现出更高的亲和力和功能效率的单置换变体。轻链突变A90H、G98D、G98V、Y99I和V100P与重链突变S30Y、S35L和T53Y重组到一个重组文库(连续氨基酸命名,参考由SEQ ID NO:121-VH和125-VL定义的TPP-21565)中。
对于最终的TPP-18533重组文库,挑选十一个在NNK文库筛选步骤中表现出更高的亲和力和功能效率的单置换变体。轻链突变N28D、N53A、S91K、S91Q、A94E、S96I和S96P与重链突变T28D、S30D、S57W和G59Y重组到一个重组文库(连续氨基酸命名,参考由SEQ ID NO:101-VH和105-VL定义的TPP-18533)中。
对于TPP-18533,生成寡核苷酸以在每个选定的位点引入选定的突变或相应的野生型氨基酸。使用连续几轮重叠延伸PCR进行文库构建。最终的PCR产物连接至哺乳动物IgG4(S228P)表达载体中,变体利用大规模平行测序技术进行测序。对于TPP-21565,将重组变体设计为不同的克隆并克隆至含IgG4(S228P)的表达质粒中。
超过1000个的TPP-18533的独特的组合氨基酸置换变体和超过100个的TPP-21565的独特的组合变体通过此方法生成,通过哺乳动物细胞瞬时转染表达,所得表达上清液的抗体浓度归一化后以不同数量在SPR、竞争ELISA和功能试验中进行筛选。根据这些试验的结果将突变体分为“改进的”或“未改进的”。
表1和1A列出了本发明的优选候选抗体,其在组合文库筛选步骤中选出,在结合Sema3A和拮抗Sema3A依赖性生物活性以及本发明的抗体各自的氨基酸和核酸序列方面为最有效的。
实施例4:使用表面等离子共振测定亲和力和物种交叉反应性
为了评估抗Sema3A抗体的结合动力学和亲和力及其物种交叉反应性特征,利用表面等离子共振(SPR)进行结合测定。在Biacore T200仪器或Biacore 8K+仪器(Cytiva)上于25℃下使用测定缓冲液HBS P+,300mM NaCl、0.75mM CaCl2、2.5mM MgCl2、1mg/mL BSA、0.05%NaN3进行结合测定。通过抗人Fc IgG(“人抗体捕获试剂盒”,Order No.BR100839,Cytiva)捕获抗体,或在为Fc标记的分析物的情况下,通过抗人Fab IgG(“人Fab捕获试剂盒”,Order No.28958325,Cytiva)捕获抗体,所述IgG共价氨基偶联至系列S CM5传感器芯片(Cytiva)。按照制造商的说明书使用1-乙基-3-(3-二甲氨基丙基)碳二亚胺盐酸盐(EDC)、N-羟基琥珀酰亚胺(NHS)和乙醇胺HCl,pH 8.5(“氨基偶联试剂盒”BR-1000-50,Cytiva)进行氨基偶联。对于噬菌体展示苗头物(hit),使用Fc标记的人和小鼠Sema3A作为分析物,浓度范围为1.56-200nM。使用人、小鼠、食蟹猴、大鼠、狗和猪的单价Sema3A结构域作为分析物,在多循环动力学模式中系列浓度为0.024-3.125nM或仅在结合分析中为100nM。传感器表面在每次抗原注射后用pH 2.0的甘氨酸再生。将获得的传感图进行双参照处理(减去流动池信号和缓冲液注入)并使用Biacore T200 Evaluation Software拟合至1:1Langmuir结合模型,从而得到动力学数据。结果列于表3、4和4a中。
表3:通过SPR使用TPP-13211和TPP-13357测定的源自噬菌体展示苗头物的抗Sema3A IgG1抗体的亲和力。n.b.=无结合,n.d.=无法确定
大部分噬菌体展示苗头物在较低的纳摩尔范围内结合人和小鼠二聚体Sema3A。
表4:通过SPR使用TPP-19068、TPP-19069、TPP-19122、TPP-19120、TPP-19121、TPP-20176作为分析物测定的源自TPP-15370和TPP-15374的抗Sema3A抗体以及现有技术的抗体(TPP-30792纯化自HEK细胞表达)的亲和力。
TPP-15370和TPP-15374的所有衍生抗体相较于其亲本抗体以及大部分现有技术抗体在较低的皮摩尔范围内对Sema3A结构域的亲和力显著提高。
表4a:在结合试验中通过SPR使用100nM TPP-19068(人)测定的抗Sema3A IgG1抗体的亲和力。n.d.=由于多相行为无法确定
与在SPR中不结合Sema3A分子的全长3H4 IgG1(TPP-30792)相反,TPP-30792的Fab变体TPP-31357结合人Sema3A,但亲和力低于TPP-23298。
实施例5:使用表面等离子共振测定结合活性
为了评估抗Sema3A抗体的结合活性,利用表面等离子共振(SPR)进行结合测定。在Biacore T200仪器(Cytiva)上于25℃下使用测定缓冲液HBS P+,300mM NaCl、0.75mMCaCl2、2.5mM MgCl2、1mg/mL BSA、0.05% NaN3进行结合测定。通过共价氨基偶联至系列SCM5传感器芯片(Cytiva)的抗人Fc IgG(“人抗体捕获试剂盒”,Order No.BR100839,Cytiva)捕获抗体。按照制造商的说明书使用1-乙基-3-(3-二甲氨基丙基)碳二亚胺盐酸盐(EDC)、N-羟基琥珀酰亚胺(NHS)和乙醇胺HCl,pH 8.5(“氨基偶联试剂盒”BR-1000-50,Cytiva)进行氨基偶联。使用人、小鼠、食蟹猴、大鼠、狗和猪的单价Sema3A结构域作为分析物,在多循环动力学模式中系列浓度为0.024-3.125nM。传感器表面在每次抗原注射后用pH2.0的甘氨酸再生。将获得的传感图进行双参照处理(减去流动池信号和缓冲液注入)并使用Biacore T200 Evaluation软件拟合至1:1Langmuir结合模型,从而得到实验拟合的RMax值。计算结合活性首先需要根据方程1计算理论RMax:
方程1:RMax的理论计算。R配体=以RU为单位的配体水平,Mr=分子量,效价配体=每个抗体分子的结合位点量,此处为2
根据方程2用实验确定的RMax除以理论计算的RMax确定结合活性:
方程2:结合活性[%]的计算
表5:捕获后的配体水平汇总,被测抗体的实验、理论和结合活性
SPR实验中计算的结合活性为表面连接的配体的活性量度。如表5所示,TPP-15370、TPP-15374、TPP-23298以及TPP 30788-30791能以大约100%的活性结合所有被测Sema3A结构域,说明所有结合区域完全能够结合。现有技术抗体TPP-17755根据物种仅能达到50-60%的活性水平。现有技术抗体TPP-11489显示出低于50%的甚至更低的水平,但小鼠和猪的更高。惊人的是,为了达到这种活性水平,TPP-11489的配体水平需要比其他抗体高出10倍以上,这总体表明与TPP-15370、TPP-15374和TPP-23298相比,TPP-11489的结合活性要低的多。
实施例6:竞争ELISA
为了在竞争ELISA装置中进行筛选,将涂覆缓冲液(碳酸盐基pH 9.6,CANDOR121125)中浓度为0.5μg/mL的人Sema3A(TPP-13211)于10℃下过夜涂覆到384孔板(GreinerBio-One,781077)上。将平板用50μL PBS 0.05% Tween洗涤3次后,将平板用50μLSmartBlockTM(CANDOR 113500)于20℃下封闭1h,再如所述洗涤3次。
然后,将20μL预混的抗体溶液加入平板中并在10℃下孵育18h。对于预混的抗体溶液,对于每个孔,将一种生物素化的亲本抗体(为TPP-15370或TPP-15374)与一种在其CDR区含一个或多个氨基酸变化(重组变体)且不含任何生物素标记的抗体以1:1、1:5或5:1的比率混合。作为额外的对照,还使用了与人Sema3A没有任何结合的同种型对照抗体作为竞争抗体。加入的抗体溶液的总浓度为0.25μg/mL。在孵育时间内,由于抗体竞争人Sema3A蛋白上的相同表位,它们以竞争方式结合到平板上。
接着用50μL PBS 0.05% Tween洗涤3次后,加入20μL链霉亲和素-HRP溶液(R&DSystems,DY998,以1:200溶于PBS 0.05% Tween 10%Smart Block中)并于20℃下孵育1h,再用50μL PBS 0.05% Tween洗涤3次,加入20μL AmplexTMRed溶液(Invitrogen A12222,以1:1000溶于50mM含1:10000的30% H2O2的pH7.6的NaP缓冲液)。最终于20℃下孵育20min后,使用595nm的发射波长和530nm的激发波长测定信号。由于亲本抗体TPP-15370和TPP-15374的生物素化,只有这些变体的结合能被检测。因此,例如与亲本抗体与其非生物乙酰化版本的竞争相比,与具有优异结合力的抗体变体的竞争显示出较低的结合信号。
总共测量了103个TPP-15370的重组变体和1136个TPP-15374的重组变体。为了分析并且为了校正板间差异,将ELISA原始值归一化至与同种型对照抗体TPP-9809竞争的值。
表6列出了选定的TPP-15370和TPP-15374的重组变体的竞争ELISA的值。所示的为分别以1比5或1比1的比率测量的与同种型对照抗体TPP-9809的比率。
表6:TPP-15374和TPP-15370的重组变体的竞争ELISA的值。所示的分别为当归一化为同种型对照抗体TPP-9809时(分别以1比5或1比1的比率测量),与选定的重组变体的同种型对照抗体的比率
实施例5a:使用表面等离子共振(SPR)的表位分选
使用SPR通过利用经典的三明治法进行表位分选实验以确定抗Sema3A抗体的表位分选。在此实验中,将一种抗体固定至SPR芯片,注入Sema3A,监测结合(图10A)。在Sema3A成功结合至一抗后,将二抗注入至结合Sema3A的固定化单抗(mAb)的复合物上,监测额外的结合(图10B和图10C)。若二抗和一抗竞争结合Sema3A,则注射二抗后检测不到额外的结合信号,表明两种抗体结合相同或非常邻近的Sema3A表位(图10C)。若二抗不和一抗竞争结合Sema3A,则注射二抗后检测到额外的结合信号,表明两种抗体结合不同的Sema3A表位(图10B)。
在Biacore T200仪器(Cytiva)上于25℃下使用测定缓冲液HBS P+,300mM NaCl、0.75mM CaCl2、2.5mM MgCl2、1mg/mL BSA、0.05%NaN3进行实验。抗体共价氨基偶联至系列SCM5传感器芯片(Cytiva)。按照制造商的说明书使用1-乙基-3-(3-二甲氨基丙基)碳二亚胺盐酸盐(EDC)、N-羟基琥珀酰亚胺(NHS)和乙醇胺HCl,pH 8.5(“氨基偶联试剂盒”BR-1000-50,Cytiva)进行氨基偶联。使用浓度为200nM的人单价Sema3A结构域作为第一分析物,接着第二次注入竞争抗体。以所有可能的组合操作此装置。传感器表面在每次抗原注射后用pH2.0的甘氨酸再生。表6a显示分选结果。
表6a:表位分选结果的矩阵视图(+=额外结合,-=无额外结合)
“+”表示注入二抗产生额外结合信号,表明两种被测抗体结合两个不同的Sema3A表位
“-”表示注入二抗未产生额外结合信号,表明两种被测抗体竞争结合重叠或邻近的Sema3A表位
与TPP-30788(BI克隆I)相比,分选实验有力地表明TPP-23298的另一个表位,说明两种抗体靶向Sema3A上的独立/不同的表位,而TPP-23298可能与TPP-17755(Samsung)有重叠或邻近的表位。
实施例7:评估与非靶分子的结合
为了评估抗Sema3A单抗(TPP-15370,亲本单抗)的特异性,使用Retrogenix技术进行非靶分子筛选。对于初筛,将5484个表达载体(同时编码ZsGreen1和全长人类质膜蛋白或细胞表面拴系的人类分泌蛋白)一式两份地排列于16个微阵列玻片。人HEK293细胞用于反向转染/表达。
细胞固定后向每个玻片加入测试抗体使终浓度为20μg/mL。通过使用与预筛选中所用相同的AF647抗hIgG Fc检测抗体进行结合检测。筛选16个玻片组中每组的两个平行测定的玻片。根据重复点的强度将苗头物分为“强、中等、弱或非常弱”。
筛选对表达5484种人质膜蛋白和人分泌蛋白的固定化HEK293细胞的结合后,Retrogenix的技术未识别测试抗体TPP-15370有特异性脱靶相互作用。观察到与Sema3A(其原始靶标)的结合。这些数据表明TPP-15370对其原始靶标的高特异性。
实施例8:抗Sema3A单抗的选择性
信号素蛋白能细分为存在于脊椎动物中的五类(3-7类)。为了评估亲本抗Sema3A单抗TPP-15370和TPP-15374在3类信号素(Sema3A-G)中的选择性特征,使用来自R&DSystems的Sema3A、Sema3B、Sema3C、Sema3D、Sema3E和Sema3F分子进行ELISA测定。两种抗体均不结合Sema3B、Sema3C、Sema3D、Sema3E和Sema3F。
由于最近发现Sema3G具有肾保护作用(PMID:27180624),检测抗体是否不结合Sema3G很重要。为了评估与Sema3A相对于Sema3G的结合选择性,将1nM重组人Sema3A-Fc嵌合体(R&D Systems)或重组人GST-Sema3G(Abnova)涂布到MaxiSorp平板上,以0.00015-10μg/mL的剂量反应曲线用抗体进行孵育,并使用HRP偶联的抗人抗血清和化学发光底物对抗体结合进行定量。
表7:Sema3G作为非靶分子检测的非靶分子ELISA的值
如表7所示,本发明的所有被测抗体以及现有技术的抗体不结合肾保护性Sema3G。
Sema3A是一种含有两个弗林蛋白酶切割位点的分泌蛋白,以活性和非活性切割形式存在。在体内环境中,Sema3A的两种形式并存。为了检测抗Sema3A抗体是否能区分非活性和活性形式,并且为了检测与仅含Sema3A结构域(类似切割的Sema3A TPP-19068)的非活性版本相比,抗体如何与活性Sema3A(类似全长Sema3A TPP-13211)结合,进行了ELISA测定。被测抗体对活性Sema3A的ELISA信号除以被测抗体对非活性Sema3A的ELISA信号作为读数。
表7a:通过ELISA测定的抗Sema3A抗体结合活性相对于非活性Sema3A的比率
*结合TPP-13211/TPP-19068的ELISA比率低于1表明对活性Sema3A的结合活性更高。
结合TPP-13211/TPP-19068的ELISA比率高于1表明对非活性Sema3A的结合活性更高。
如表7a所示的结合分析清楚地表明本发明的抗体(TPP-23298)比TPP-30788-TPP-30791(BI克隆)对活性Sema3A有更强的结合,很可能因为它们靶向对活性Sema3A表现更高选择性的不同表位。
实施例9:肾小球膜细胞迁移检测中的体外疗效
通过将含血清的培养基中的细胞接种到Imagelock板中24小时产生融合的单层原代人肾小球膜细胞。替换为无血清培养基后,使用Woundmaker工具造成划伤,然后用1nM重组人Sema3A-Fc嵌合体(R&D Systems)不加或加抑制性抗体处理细胞。在Incucyte中进行细胞成像,24小时后使用Incucyte集成细胞迁移分析软件模块评估伤口闭合程度。
表8:MCM测定中噬菌体展示苗头物和重组变体的EC50值
如表8所示,我们发现了人肾小球膜细胞迁移检测中效力在三位数皮摩尔范围内的抗体,其远比现有技术的抗体有效。
实施例10:生长锥塌陷检测中的体外疗效
为了测定抗体对Sema3A诱导的细胞骨架塌陷的效力,使用与所述(PMID:12077190)相似而稍作修改的生长锥塌陷检测。简言之,从E13C57BL/6J小鼠胚胎分离小鼠背根神经节(DRG)神经元,用NeurobasalTM培养基+100ng/mL NGF+B-27+10%FCS在聚L-赖氨酸和层粘连蛋白涂覆的96孔板上培养。20小时后,用10nM重组人Sema3A-Fc嵌合体(R&DSystems)不加或加抑制性抗体处理细胞1小时,接着固定PFA,再用Alexa 488-鬼笔环肽染色。使用免疫荧光显微术通过每孔超过100个生长锥的肌动蛋白生长锥面积/形状/纹理评估生长锥塌陷的程度。
表9:生长锥塌陷检测中噬菌体展示苗头物和重组变体的EC50值
如表9所示,鉴定出的抗体在鼠生长锥塌陷检测中也显示出在个位数纳摩尔范围内的效力,同样远比被测的现有技术的抗体(二至三位数纳摩尔的效力)有效。
实施例11:HUVEC排斥检测中的体外疗效
重组人Sema3A-Fc嵌合体(R&D Systems)和人生物流体中的Sema3A不同,因为其包含若干突变的氨基酸以及在其羧基端的额外的蛋白质片段。此外,前述检测(人肾小球膜细胞迁移检测和鼠生长锥塌陷检测)使用均匀分布的Sema3A,其与描述的组织中Sema3A的梯度分布相反。我们假设这些区别会导致抗体对重组体相比于内源性蛋白具有不同的效力。因此,我们采用了一种以梯度人野生型Sema3A为拮抗剂的检测(PMID:17569671)。简言之,在此HUVEC排斥检测中,将表达序列为SEQ ID NO:600的人Sema3A的人胚胎肾293细胞(HEK293)接种于不含或含抑制性抗体的EGM-2培养基中的融合的单层人脐静脉内皮细胞(HUVEC)上,培养72小时,固定,用DAPI染色并使用免疫荧光显微术(测量无细胞面积)评估细胞排斥的程度。结果,底物人Sema3A过量存在。
根据DAPI/CM染色细胞的免疫荧光显微图像(CM=HCS CellMaskTM染色剂,将整个细胞染色以界定总细胞区域)进行如下数据分析:根据DAPI/CM信号识别细胞(图11B)。界定并选中用于分析的细胞区域。计算此区域中的无细胞区域(图11C)。根据抗体处理的孔相较于同种型处理的孔中由Sema3A诱导的“无细胞区域”计算抑制率。用抑制率对抗体浓度作图,计算各个抗体的EC50值。
数据分析的具体步骤如下进行:
1.对每孔对应80%孔面积的四个视野成像。将所有这些视野拼接到一起用于通过DAPI/CM荧光检测细胞。
2.根据DAPI/CM面积计算“细胞面积”。
3.根据“总面积”减“细胞面积”计算“无细胞区域”。
4.根据抗体处理的孔相对于同种型处理的孔中Sema3A诱导的“无细胞区域”计算抑制率。
5.使用GraphPad Prism软件用非线性回归(可变斜率模型=四参数剂量反应曲线)测定EC50值。
表10:排斥检测中选定的抗体的EC50值,第一次实验
抗体 | EC50(pM) |
TPP-15370 | 800 |
TPP-23298 | 80 |
TPP-23334 | 120 |
TPP-23337 | 170 |
TPP-23340 | 180 |
TPP-23341 | 113 |
TPP-23373 | 180 |
TPP-23374 | 77 |
TPP-23375 | 123 |
表10a:排斥检测中与现有技术的抗体比较的第二次实验中的TPP-23298的EC50值
如表10和10a所示,前述人肾小球膜细胞迁移检测和鼠生长锥塌陷检测中与现有技术的抗体的效力区别,在使用梯度天然野生型(wt)Sema3A(处理过的非活性Sema3A和未消化的活性Sema3A的混合物)的HUVEC排斥检测中甚至更为显著。通过测量由相应EC50值表示的皮摩尔活性,对HUVEC排斥检测中比TPP-17755、TPP-11489、TPP-30788、TPP-30789、TPP-30790或TPP-30791增强的效力进行定量。TPP-23298显示两位数皮摩尔的活性,而现有技术的抗体TPP-17755、TPP-11489、TPP-30788、TPP-30789、TPP-30790或TPP-30791的效力在三位数皮摩尔或甚至纳摩尔范围内。
作为对结果的另一种说明,通过测量各个抗体在80pM的特定浓度下的无细胞区域对HUVEC排斥检测中的增强的效力进行定量。TPP-23298比TPP-30788、TPP-30789、TPP-30790或TPP-30791显示更高的Sema3A抑制率(图12)。
分析表10和10a中显示的两次检测的数据,TPP-23298对细胞Sema3A诱导的HUVEC排斥显示最高的效力。BI抗体TPP-30788、TPP-30798、TPP-30790和TPP-30791显示稍高的EC50值(2-5倍)。Samsung抗体TPP-17755的效力远低于TPP-23298(50倍)。Chiome抗体TPP-11489仅在最高测试浓度下示出抑制活性,产生大于本发明的上述抗体400倍的预测的EC50值。这说明在类似未添加任何外源性重组信号素3A的天然环境的条件下,本发明的抗体以最强的活性抑制Sema3A诱导的细胞排斥,如表10和10a所示。
实施例12:检测肾保护作用的体内试验:抑制小鼠中Sema3A诱导的白蛋白尿
Sema3A抑制剂降低通过全身注射重组Sema3A诱导的尿白蛋白排泄。在Sema3A诱导的白蛋白尿模型中如下研究化合物对减少白蛋白尿的有益作用:
给购自Taconic的雄性C57BL/6小鼠(8至10周龄)静脉注射抗Sema3A抗体。施用抗体三十分钟后,通过静脉注射人重组Sema3A(1.0mg/kg,R&D Systems)诱导白蛋白尿。将动物置于代谢笼中并采集4h尿液。通过临床生化分析仪(Pentra 400)测量尿肌酸酐。按照制造商的方案使用小鼠特异性白蛋白ELISA(Abcam)评估尿白蛋白。使用尿肌酸酐和白蛋白计算尿白蛋白肌酸酐比(ACR)。通过单向方差分析和Dunnett多重比较校正分析组间区别。统计显著性定义为P<0.05。使用GraphPad Prism 8进行所有统计分析。
表11-15a显示Sema3A诱导的小鼠白蛋白尿模型中TPP-15370、TPP-15374、TPP-11489、TPP-17755、TPP-30788和TPP-23298的剂量反应试验。TPP-15370、TPP-23298相较于TPP-11489和/或TPP-17755和/或TPP-30788对减少白蛋白尿的作用如图1-2所示。
本发明的抗体减少Sema3A诱导的尿白蛋白排泄。
实施例13:检测肾保护作用的体内试验:小鼠急性缺血/再灌注损伤(I/RI)模型
单侧肾切除的小鼠在缺血再灌注损伤后可从Sema3A抑制剂的治疗中获益。在小鼠肾缺血再灌注损伤模型中如下研究Sema3A抗体对肾功能的有益作用:
实验室繁育的6-8周龄雄性C57BL/6J小鼠获自Charles River。在标准实验室条件(12小时光暗周期,可自由获取正常食物和饮用水)下饲养小鼠。对于缺血再灌注损伤模型,在每个对照和实验组中各使用共8-10只。
通过连续吸入异氟烷麻醉动物。在对侧肾缺血操作的7天前通过右侧胁腹切口进行右肾切除。在肾缺血开始的一小时前给小鼠通过静脉注射施用抗体和相应的同种型对照。麻醉小鼠并做左侧胁腹切口。通过剥离左肾蒂暴露肾血管。在25min(小鼠)的缺血过程中使用无创血管夹阻断血流(动脉和静脉)。通过去除血管夹完成再灌注。用5.0聚丙烯缝线闭合腹壁(肌层和皮肤)。(丁丙诺啡,0.025mg/kg s.c.)用作镇痛药。
在缺血的24h后于处死前用代谢笼过夜采集每只动物的尿液。通过临床生化分析仪(Pentra 400)测量尿肌酸酐。在Pentra分析仪中使用小鼠特异性白蛋白试剂盒(Hitachi)评估尿白蛋白。使用尿肌酸酐和白蛋白确定白蛋白尿(白蛋白/肌酸酐比)。处死后,在终末麻醉下获取血液样本。血样离心后分离血清。通过临床生化分析仪(Pentra 400)测定血清肌酸酐和血清尿素。通过单向方差分析和Dunnett多重比较校正分析组间区别。统计显著性定义为P<0.05。使用GraphPad Prism 8进行所有统计分析。
表16-20显示小鼠急性肾缺血/再灌注损伤模型中TPP-15370、TPP-15374、TPP-11489、TPP-17755、TPP-30788和TPP-23298的剂量反应试验。图3显示I/RI模型中以15mg/kg治疗后TPP-23374、TPP-23298和TPP-15370的疗效。TPP-15370、TPP-23298和TPP-15374相较于TPP-11489和/或TPP-17755的治疗效果如图4-6所示。
抗体通过减少血清肌酸酐和血清尿素(替代肾小球滤过率)以及尿白蛋白排泄减轻缺血/再灌注诱导的肾损害。
实施例14:检测肾保护作用的体内试验:Alport综合征模型(Col4α3缺陷小鼠)
Alport小鼠的表型与Alport患者的表型类似,包括肾小球基底膜特征性增厚和断裂以及大量蛋白尿。Alport小鼠可能因其肾中Sema3A表达增加而从Sema3A抑制剂的治疗中获益。在Alport小鼠模型中如下研究Sema3A阻断性抗体对肾功能的有益作用:Col4α3(129-Col4a3tm1Dec/J)敲除小鼠(Jackson Laboratory,USA)种群通过杂合动物交配建立于BayerAG,伍珀塔尔,德国的繁育设施中。4-5周龄的雄性和雌性纯合和野生型Col4α3小鼠获自Bayer AG的动物繁育设施并用于此研究。
将纯合小鼠(HOM)按照其年龄和性别随机分组(每组n=10)。小鼠每周施用一次同种型对照和TPP-15370和TPP-23298。TPP-11489两周使用一次。始于治疗开始前,每周用代谢笼采集每只动物的尿液一次。通过临床生化分析仪(Pentra 400)测量尿肌酸酐和总蛋白。使用尿肌酸酐和白蛋白确定蛋白尿(蛋白/肌酸酐比)。治疗开始后第21天或第28天处死后,在终末麻醉下获取血液样本。血样离心后分离血清。通过临床生化分析仪(Pentra 400)测量血清肌酸酐和血清尿素。
采集肾脏并分成两部分。一部分液氮速冻用于mRNA分析。另一部分储存于Davidson固定液用于制备组织切片。从采集的肾脏部分中分离总RNA。将肾组织均质化,获取RNA并转录成cDNA。使用TaqManTM实时PCR分析肾组织中促纤维化标志物的肾mRNA表达。为了在蛋白质水平上评估纤维化,使用标准程序用α-平滑肌肌动蛋白(αSMA)和天狼星红/固绿胶原染色给石蜡组织切片染色。
使用Axio Scan.Z1(Zeiss)显微镜和Zen软件通过计算机图像分析获得肾脏中α-平滑肌肌动蛋白(αSMA)阳性和天狼星红(胶原)阳性面积的定量测量值。
所有数据表示为均值±标准差。通过单向方差分析和Dunnett多重比较校正分析组间区别。统计显著性定义为P<0.05。使用GraphPad Prism8进行所有统计分析。
表21A-21C和22A-22C显示Alport模型中用TPP-15370和TPP-23298治疗后获得的对蛋白尿、肾功能和肾纤维化的效果。用TPP-15370相较于TPP-11489治疗后对蛋白尿、肾功能和肾纤维化的效果示于图7和8中。
本发明的抗体在Alport综合征的小鼠模型中阻止肾脏病的进展。本发明的抗体减少尿白蛋白排泄,降低肌酸酐和血清尿素(替代肾小球滤过率)以及纤维化(通过肌成纤维细胞染色和胶原沉积定量)。
实施例15:检测肾保护作用的体内试验:猪单侧肾IRI模型
在成年小型猪的微创单侧肾动脉球囊导管闭塞模型测试了TPP-23298,再灌注后随访约24小时。实验使用体重范围14至17kg的雌性哥廷根小型猪(Ellegaard,丹麦)。将动物随机分配至实验组。
在盲法对照研究中给6只动物施用TPP-23298,与6只匹配的IgG治疗的对照比较。经过肾动脉闭塞以外的所有治疗程序且接受磷酸盐缓冲液载体的动物仅用作假处理参照组。
在肾动脉闭塞开始前,将TPP-23298以体重调整的剂量溶于1mL/kg终体积的磷酸盐缓冲液中作为单剂量通过缓慢静脉注射施用(预防设置)。
为了实验第1天的介入手术,将猪通过丙泊酚和芬太尼联用麻醉并在泮库溴铵的肌肉松弛下通过经口气管导管人工通气。通过连续输注乳酸林格液连续进行容量(volume)替代。手术开始前,分别通过肌肉注射恩诺沙星和静脉注射肝素提供抗生素和预防血栓形成。使用配有前肢套的非侵入性兽医设备监测血压和心率。
以下所有介入操作在严格无菌条件下进行。导管经颈背部皮肤皮下穿行至颈静脉用于给药。将鞘管置于股动脉(优选左侧)中并固定,通过其将内置球囊导管的曲棍球棒导管向上游推送进腹主动脉,并将其头端插入左或右肾动脉口。然后伸出球囊导管并给球囊充气阻断到肾脏的血流。使用商用超声诊断仪通过多普勒超声控制球囊的正确定位。在基线处和缺血开始后2h采集血浆样本。
闭塞开始后于预定时间点(从90到120min)通过给球囊放气并撤出导管和鞘管使肾缺血得以确切缓解。血管缝合和伤口闭合后,动物从麻醉中苏醒并在出现自主呼吸后拔管。
肾动脉闭塞后约22至23小时,通过和泮库溴铵联用重新麻醉动物并如所述人工通气。通过颈动脉导管侵入性地监测血压和心率。通过静脉以流速为10mL/kg/h的乳酸林格液进行容量替代。通过下腹部的小切口剥离膀胱壁上的两条输尿管并插入导管采集各侧的尿液用于体积测定和尿分析。所有参数稳定时开始记录和采集样本,其通常在闭塞后24小时。在基线处和三小时中的每小时(24-27h间隔)采集血液样本。同时以三次1h的间隔采集尿液。
测定尿体积流量(VU)和尿肌酸酐浓度([Crea]U)后根据标准公式CLCrea=VU*[Crea]U/[Crea]Pl(其中[Crea]Pl代表血浆肌酸酐浓度)计算各侧的肌酸酐清除率(CLCrea)。通过将每只动物的左和右肾CLCrea相加计算全身CLCrea。
结果描述于图9。在单侧肾动脉闭塞105min后的实验设置中,在闭塞前30min以预防方式施用TPP-23298明显防止缺血/再灌注诱导的肌酸酐清除率下降。
实施例16:哺乳动物细胞培养中的抗Sema3A抗体表达滴度
用编码抗Sema3A抗体重链和轻链的pTT5质粒或TPP-30792的Fab片段(TPP-31357)转染HEK293-6E细胞。转染前两天,将HEK293-6E细胞以5×10^5个细胞/mL的密度分至装有含0.1%泊洛沙姆F68(GibcoTM,24040032)和4mM GlutaMAX(Gibco,35050061)的FreeStyleTMF17表达培养基(Gibco,A1383501)的摇瓶中,构成所需表达体积的90%。HEK293-6E细胞于37℃、5% CO2在75rpm下振荡培养。
为了转染,将DNA和聚乙烯亚胺(Polysciences,23966)混进含4mM GlutaMAX(Gibco,35050061)的FreeStyleTMF17表达培养基(Gibco,A1383501)中,构成最终表达体积的10%。溶液孵育10分钟后加入摇瓶。
转染后24小时,将1%(v/v)超低IgG胎牛血清(Gibco,16250078)和0.05%(v/v)1N丙戊酸(Sigma,P4543)加入摇瓶。
转染后4天开始每天监测细胞活力和密度,活力测定为70%时通过离心和无菌过滤收获上清液。为了测定生产滴度,通过HPLC系统(Agilent,1100HPLC系统)将100μL收集的上清液上样至0.1mL POROSTMA亲和柱(Thermo ScientificTM,2100100),使用50mM磷酸钠(Sigma,S0751、S9763)、150mM NaCl(Sigma,S6546)、5%异丙醇(Sigma,34863),pH 7.2作为运行缓冲液。然后,使用12mM HCl(Sigma,H9892)、150mM NaCl、5%异丙醇pH 2洗脱蛋白质。使用已知大小的蛋白质建立5μg/mL至150μg/mL的校准曲线并同样通过HPLC系统上样至POROS A柱。考虑到上清液中蛋白质的大小和消光系数,可使用标准曲线计算准确的滴度。TPP-30792在CHO中的表达类似HEK细胞,除了使用质粒pTT22AKT。
表23:哺乳动物细胞中的抗Sema3A抗体表达滴度[mg/L]
滴度[mg/L] | |
TPP-23298 | 203.6 |
TPP-17755(Samsung) | 277.0 |
TPP-11489(Chiome) | 132.0 |
TPP-30791(BI克隆IV) | 333.0 |
TPP-30790(BI克隆III) | 160.9 |
TPP-30789(BI克隆II) | 187.6 |
TPP-30788(BI克隆I) | 240.2 |
TPP-30792(3H4 Univ Ramot) | 3.0(HEK)、3.2(CHO) |
TPP-31357(TPP-30792的Fab) | 未确定 |
本发明的抗体和除了TPP-30792以外的所有现有技术抗体可在哺乳动物细胞中以高滴度生产,如表23所示。TPP-30792在HEK或CHO细胞中均无法大量表达。从4.5升HEK293细胞培养物中总共能纯化出125μg TPP-30792。类似地,TPP-30792的Fab片段(TPP-31357)从5升HEK293细胞培养物中仅产生200μg纯化的Fab。
实施例17:抗Sema3A抗体CMC参数稳定性和溶解度的分析
已知大于50mg/mL的高浓度蛋白质溶液通常也表现出比较低浓度蛋白质溶液更高的黏度。升高的黏度不利于蛋白质溶液(尤其是以小应用体积)的可递送性(deliverability),且会增加注射时间和注射部位的疼痛。除此之外,高黏度影响工业中的大规模蛋白质生产。因此,降低高浓度蛋白质溶液的黏度的同时在较长的保质期内维持稳定性对体内治疗设置尤其重要。
高浓度溶液中的蛋白质通常不如在稀释的溶液中稳定,因为蛋白质倾向于聚集并且可在更高浓度下可逆地自我聚集。聚集会不利地影响结构完整性,因此也不利地影响体内治疗设置中的功能性、生物利用性蛋白质的量。这使注射给药进一步复杂化。
蛋白质的溶解度是另一个重要的质量标准。分离的蛋白质的溶解度增加使得能够制备体内治疗设置所需的高度浓缩溶液。
因此,提供黏度降低且稳定性和溶解度提高的高浓度蛋白质溶液对治疗性分子的治疗适用性是有益的。
为了评估用于潜在治疗用途的抗Sema3A抗体的CMC(化学、制造、控制)参数稳定性、溶解度和黏度,将抗体TPP-23289和TPP-30788(BI克隆I)用PBS稀释至25mg/mL并以700rpm于40℃下孵育两周。尽管抗体通常短期储存于4-10℃或长期冷冻于≤-18℃或≥-81℃,将哺乳动物抗体暴露于≥40℃的温度(哺乳动物平均体温为36℃-39℃)类似于热应力条件。在此热应力条件下检测加速蛋白质稳定性/应力稳定性。通过在PBS缓冲液中使用连接至系统(Cytiva)的Superdex 200柱(Cytiva)的体积排阻色谱和使用Caliper系统(PerkinElmer)的毛细管凝胶电泳分析稳定性。特征变化计算为相对于未受压的起始物质的百分比。通过在PBS缓冲液中使用截留分子量30kDa的离心过滤器(Millipore)浓缩抗Sema3A抗体来测定溶解度。以从浓缩器中90%的回收率测定溶解度并使用在UV280nm处的吸收测量蛋白浓度。
表24:TPP-23298和TPP-30788的CMC参数概况;SEC=体积排阻色谱,cGE=毛细管凝胶电泳
*SEC=体积排阻色谱;**cGE=毛细管凝胶电泳
如上所述,稳定性、溶解度和黏度是治疗性分子的关键CMC参数。通过SEC和/或cGE分析热应力条件如暴露于40℃或浓缩步骤后的结构完整性,以了解施加的应力对结构完整性的影响。施加应力后和起点相比小于1%的变化说明分子稳定,而>1%的变化说明分子不稳定。与TPP-30788相比,TPP-23289在PBS中的溶解度更高,要高出两倍以上,这非常有利于例如实现低施用量。此外,TPP-23289比TPP-30788更稳定且更耐热应力,而且在PBS缓冲液中黏度更小。
序列
表1:本发明的优选的抗体和三个现有技术抗体的氨基酸序列和核酸序列。TPP-11489对应源于4-2号克隆株的人源化2型Chiome抗体(WO 2014/123186);TPP-15051代表其鼠IgG1变体。TPP-30788-TPP-30791对应Ingelheim抗体(BI)克隆I-IV(WO2020/225400)。TPP-30792对应University Ramot抗体克隆I(WO 2020/261281)。
表1A:表1中各个SEQ ID下提及的本发明的抗体的对应氨基酸序列和核酸序列。SEQ ID 581至587为智人(Homo sapiens)(SEQ ID 581、582)、小家鼠(Mus Musculus)(SEQID 583)、褐家鼠(Rattus norvegicus)(SEQ ID 584)、家犬(Canis lupus familiaris)(SEQ ID 585)、成束猴(Macaca fascicularis)(SEQ ID 586)、野猪(Sus scrofa)(SEQ ID587)对应的Sema3A蛋白序列。
序列表
<110> 拜耳公司(Bayer AG)
<120> 新型抗Sema3A抗体及其用途
<130> BHC201071
<160> 691
<170> PatentIn version 3.5
<210> 1
<211> 124
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Gly Ile Asp Asp Asp Gly Asp Ser Asp Thr Arg Tyr Ala Pro Ala
50 55 60
Val Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Lys His Thr Gly Ile Gly Ala Asn Ser Ala Gly Ser Ile Asp
100 105 110
Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 2
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 2
Ser Tyr Pro Met Gly
1 5
<210> 3
<211> 18
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 3
Gly Ile Asp Asp Asp Gly Asp Ser Asp Thr Arg Tyr Ala Pro Ala Val
1 5 10 15
Lys Gly
<210> 4
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 4
His Thr Gly Ile Gly Ala Asn Ser Ala Gly Ser Ile Asp Ala
1 5 10
<210> 5
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 5
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Gly Gly Ser Tyr Thr Gly Ser Tyr
20 25 30
Tyr Tyr Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Thr Val
35 40 45
Ile Tyr Tyr Asn Asn Lys Arg Pro Ser Asp Ile Pro Glu Arg Phe Ser
50 55 60
Gly Ser Leu Ser Gly Thr Thr Asn Thr Leu Thr Ile Ser Gly Val Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Ala Asp Asn Ser Gly
85 90 95
Asp Ala Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105
<210> 6
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 6
Ser Gly Gly Gly Ser Tyr Thr Gly Ser Tyr Tyr Tyr Gly
1 5 10
<210> 7
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 7
Tyr Asn Asn Lys Arg Pro Ser
1 5
<210> 8
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 8
Gly Ser Ala Asp Asn Ser Gly Asp Ala
1 5
<210> 9
<211> 372
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 9
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctatccta tgggctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtggccggc atcgacgacg atggcgatag cgatacaaga 180
tacgcccctg ccgtgaaggg cagagccacc atctccagag acaacagcaa gaacaccgtg 240
tacctgcaga tgaacagcct gagagccgag gacaccgccg tgtactattg tgccaagcac 300
acaggcatcg gcgccaattc tgccggctct attgatgcct ggggccaggg aacactggtc 360
acagtttctt ca 372
<210> 10
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 10
agctatccta tgggc 15
<210> 11
<211> 54
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 11
ggcatcgacg acgatggcga tagcgataca agatacgccc ctgccgtgaa gggc 54
<210> 12
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 12
cacacaggca tcggcgccaa ttctgccggc tctattgatg cc 42
<210> 13
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 13
agctatgagc tgacacagcc tccaagcgtg tccgtgtctc ctggacagac cgccagaatc 60
acatgtagcg gcggaggcag ctacaccggc agctactact atggctggta tcagcagaag 120
cccggacagg cccctgtgac cgtgatctac tacaacaaca agcggcccag cgacatcccc 180
gagagatttt ctggctctct gagcggcacc accaacacac tgacaatctc tggcgtgcag 240
gccgaggacg aggccgatta ctattgtggc agcgccgata atagcggcga cgcctttggc 300
accggcacca aagttacagt gcta 324
<210> 14
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 14
agcggcggag gcagctacac cggcagctac tactatggc 39
<210> 15
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 15
tacaacaaca agcggcccag c 21
<210> 16
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 16
ggcagcgccg ataatagcgg cgacgcc 27
<210> 17
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 17
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Gly Ile Asp Asp Asp Gly Asp Ser Asp Thr Arg Tyr Ala Pro Ala
50 55 60
Val Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Lys His Thr Gly Ile Gly Ala Asn Ser Ala Gly Ser Ile Asp
100 105 110
Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly
450
<210> 18
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 18
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Gly Gly Ser Tyr Thr Gly Ser Tyr
20 25 30
Tyr Tyr Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Thr Val
35 40 45
Ile Tyr Tyr Asn Asn Lys Arg Pro Ser Asp Ile Pro Glu Arg Phe Ser
50 55 60
Gly Ser Leu Ser Gly Thr Thr Asn Thr Leu Thr Ile Ser Gly Val Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Ala Asp Asn Ser Gly
85 90 95
Asp Ala Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys
100 105 110
Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln
115 120 125
Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly
130 135 140
Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly
145 150 155 160
Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala
165 170 175
Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser
180 185 190
Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val
195 200 205
Ala Pro Thr Glu Cys Ser
210
<210> 19
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 19
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctatccta tgggctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtggccggc atcgacgacg atggcgatag cgatacaaga 180
tacgcccctg ccgtgaaggg cagagccacc atctccagag acaacagcaa gaacaccgtg 240
tacctgcaga tgaacagcct gagagccgag gacaccgccg tgtactattg tgccaagcac 300
acaggcatcg gcgccaattc tgccggctct attgatgcct ggggccaggg aacactggtc 360
acagtttctt cagccagcac caagggcccc agcgtgttcc ctctggcccc tagcagcaag 420
agcacatctg gcggaacagc cgccctgggc tgcctcgtga aggactactt tcccgagccc 480
gtgaccgtgt cctggaactc tggcgctctg acaagcggcg tgcacacctt tccagccgtg 540
ctgcagagca gcggcctgta ctctctgagc agcgtcgtga cagtgcccag cagctctctg 600
ggcacccaga cctacatctg caacgtgaac cacaagccca gcaacaccaa ggtggacaag 660
aaggtggaac ccaagagctg cgacaagacc cacacctgtc ccccttgtcc tgcccccgaa 720
ctgctgggag gcccttccgt gttcctgttc cccccaaagc ccaaggacac cctgatgatc 780
agccggaccc ccgaagtgac ctgcgtggtg gtggatgtgt cccacgagga ccctgaagtg 840
aagttcaatt ggtacgtgga cggcgtggaa gtgcacaacg ccaagaccaa gcctagagag 900
gaacagtaca acagcaccta ccgggtggtg tccgtgctga cagtgctgca ccaggactgg 960
ctgaacggca aagagtacaa gtgcaaggtg tccaacaagg ccctgcctgc ccccatcgag 1020
aaaaccatca gcaaggccaa gggccagccc cgcgaacccc aggtgtacac actgccccca 1080
agcagggacg agctgaccaa gaaccaggtg tccctgacct gtctcgtgaa aggcttctac 1140
ccctccgata tcgccgtgga atgggagagc aacggccagc ccgagaacaa ctacaagacc 1200
accccccctg tgctggacag cgacggctca ttcttcctgt acagcaagct gaccgtggac 1260
aagtcccggt ggcagcaggg caacgtgttc agctgcagcg tgatgcacga ggccctgcac 1320
aaccactaca cccagaagtc cctgagcctg agccctggc 1359
<210> 20
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 20
agctatgagc tgacacagcc tccaagcgtg tccgtgtctc ctggacagac cgccagaatc 60
acatgtagcg gcggaggcag ctacaccggc agctactact atggctggta tcagcagaag 120
cccggacagg cccctgtgac cgtgatctac tacaacaaca agcggcccag cgacatcccc 180
gagagatttt ctggctctct gagcggcacc accaacacac tgacaatctc tggcgtgcag 240
gccgaggacg aggccgatta ctattgtggc agcgccgata atagcggcga cgcctttggc 300
accggcacca aagttacagt gctaggccag cctaaagccg cccctagcgt gaccctgttc 360
cctccaagca gcgaggaact gcaggccaac aaggccaccc tcgtgtgcct gatcagcgac 420
ttctatcctg gcgccgtgac cgtggcctgg aaggccgata gctctcctgt gaaggccggc 480
gtggaaacca ccacccctag caagcagagc aacaacaaat acgccgccag cagctacctg 540
agcctgaccc ccgagcagtg gaagtcccac agatcctaca gctgccaagt gacccacgag 600
ggcagcaccg tggaaaagac agtggcccct accgagtgca gc 642
<210> 21
<211> 124
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 21
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Gly Ile Asp Asp Asp Gly Asp Ser Asp Thr Arg Tyr Ala Pro Ala
50 55 60
Val Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Lys His Thr Gly Ile Gly Ala Asn Ser Ala Gly Ser Ile Asp
100 105 110
Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 22
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 22
Ser Tyr Pro Met Gly
1 5
<210> 23
<211> 18
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 23
Gly Ile Asp Asp Asp Gly Asp Ser Asp Thr Arg Tyr Ala Pro Ala Val
1 5 10 15
Lys Gly
<210> 24
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 24
His Thr Gly Ile Gly Ala Asn Ser Ala Gly Ser Ile Asp Ala
1 5 10
<210> 25
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 25
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Gly Gly Ser Tyr Thr Gly Ser Tyr
20 25 30
Tyr Tyr Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Thr Val
35 40 45
Ile Tyr Tyr Asn Asn Lys Arg Pro Ser Asp Ile Pro Glu Arg Phe Ser
50 55 60
Gly Ser Leu Ser Gly Thr Thr Asn Thr Leu Thr Ile Ser Gly Val Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Ala Asp Asn Ser Gly
85 90 95
Asp Ala Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105
<210> 26
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 26
Ser Gly Gly Gly Ser Tyr Thr Gly Ser Tyr Tyr Tyr Gly
1 5 10
<210> 27
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 27
Tyr Asn Asn Lys Arg Pro Ser
1 5
<210> 28
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 28
Gly Ser Ala Asp Asn Ser Gly Asp Ala
1 5
<210> 29
<211> 372
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 29
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctatccta tgggctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtggccggc atcgacgacg atggcgatag cgatacaaga 180
tacgcccctg ccgtgaaggg cagagccacc atctccagag acaacagcaa gaacaccgtg 240
tacctgcaga tgaacagcct gagagccgag gacaccgccg tgtactattg tgccaagcac 300
acaggcatcg gcgccaattc tgccggctct attgatgcct ggggccaggg aacactggtc 360
acagtttctt ca 372
<210> 30
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 30
agctatccta tgggc 15
<210> 31
<211> 54
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 31
ggcatcgacg acgatggcga tagcgataca agatacgccc ctgccgtgaa gggc 54
<210> 32
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 32
cacacaggca tcggcgccaa ttctgccggc tctattgatg cc 42
<210> 33
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 33
agctatgagc tgacacagcc tccaagcgtg tccgtgtctc ctggacagac cgccagaatc 60
acatgtagcg gcggaggcag ctacaccggc agctactact atggctggta tcagcagaag 120
cccggacagg cccctgtgac cgtgatctac tacaacaaca agcggcccag cgacatcccc 180
gagagatttt ctggctctct gagcggcacc accaacacac tgacaatctc tggcgtgcag 240
gccgaggacg aggccgatta ctattgtggc agcgccgata atagcggcga cgcctttggc 300
accggcacca aagttacagt gcta 324
<210> 34
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 34
agcggcggag gcagctacac cggcagctac tactatggc 39
<210> 35
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 35
tacaacaaca agcggcccag c 21
<210> 36
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 36
ggcagcgccg ataatagcgg cgacgcc 27
<210> 37
<211> 448
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 37
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Pro Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Gly Ile Asp Asp Asp Gly Asp Ser Asp Thr Arg Tyr Ala Pro Ala
50 55 60
Val Lys Gly Arg Ala Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Lys His Thr Gly Ile Gly Ala Asn Ser Ala Gly Ser Ile Asp
100 105 110
Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr
115 120 125
Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn
130 135 140
Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val
180 185 190
Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val
195 200 205
Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg
210 215 220
Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser
225 230 235 240
Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu
245 250 255
Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro
260 265 270
Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala
275 280 285
Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val
290 295 300
Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe
305 310 315 320
Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr
325 330 335
Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile
340 345 350
Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys
355 360 365
Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp
370 375 380
Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp
385 390 395 400
Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser
405 410 415
Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly
420 425 430
Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys
435 440 445
<210> 38
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 38
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Gly Gly Ser Tyr Thr Gly Ser Tyr
20 25 30
Tyr Tyr Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Thr Val
35 40 45
Ile Tyr Tyr Asn Asn Lys Arg Pro Ser Asp Ile Pro Glu Arg Phe Ser
50 55 60
Gly Ser Leu Ser Gly Thr Thr Asn Thr Leu Thr Ile Ser Gly Val Gln
65 70 75 80
Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ser Ala Asp Asn Ser Gly
85 90 95
Asp Ala Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys
100 105 110
Ser Ser Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Glu
115 120 125
Thr Asn Lys Ala Thr Leu Val Cys Thr Ile Thr Asp Phe Tyr Pro Gly
130 135 140
Val Val Thr Val Asp Trp Lys Val Asp Gly Thr Pro Val Thr Gln Gly
145 150 155 160
Met Glu Thr Thr Gln Pro Ser Lys Gln Ser Asn Asn Lys Tyr Met Ala
165 170 175
Ser Ser Tyr Leu Thr Leu Thr Ala Arg Ala Trp Glu Arg His Ser Ser
180 185 190
Tyr Ser Cys Gln Val Thr His Glu Gly His Thr Val Glu Lys Ser Leu
195 200 205
Ser Arg Ala Asp Cys Ser
210
<210> 39
<211> 1344
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 39
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctatccta tgggctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtggccggc atcgacgacg atggcgatag cgatacaaga 180
tacgcccctg ccgtgaaggg cagagccacc atctccagag acaacagcaa gaacaccgtg 240
tacctgcaga tgaacagcct gagagccgag gacaccgccg tgtactattg tgccaagcac 300
acaggcatcg gcgccaattc tgccggctct attgatgcct ggggccaggg aacactggtc 360
acagtttctt cagccaagac cacccccccc agcgtgtacc ctctggctcc tggatctgcc 420
gcccagacca acagcatggt caccctgggc tgcctcgtga agggctactt ccctgagcct 480
gtgaccgtga cctggaacag cggctctctg tctagcggcg tgcacacctt tccagccgtg 540
ctgcagagcg acctgtacac cctgagcagc agcgtgaccg tgcctagcag cacctggcct 600
agcgagacag tgacctgcaa cgtggcccac cctgccagca gcacaaaggt ggacaagaaa 660
atcgtgcccc gggactgcgg ctgcaagccc tgtatctgta ccgtgcccga ggtgtccagc 720
gtgttcatct tcccacccaa gcccaaggac gtgctgacca tcaccctgac ccccaaagtg 780
acctgtgtgg tggtggacat cagcaaggac gaccccgagg tgcagttcag ttggttcgtg 840
gacgacgtgg aagtgcacac agcccagacc cagcccagag aggaacagtt caacagcacc 900
ttcagaagcg tgtccgagct gcccatcatg caccaggact ggctgaacgg caaagagttc 960
aagtgcagag tgaacagcgc cgccttccct gcccccatcg agaaaaccat ctccaagacc 1020
aagggcagac ccaaggcccc tcaggtgtac acaatccccc cacccaaaga acagatggcc 1080
aaggacaagg tgtccctgac ctgcatgatc accgatttct tcccagagga catcaccgtg 1140
gaatggcagt ggaacggcca gcccgccgag aactacaaga acacccagcc tatcatggac 1200
accgacggca gctacttcgt gtacagcaag ctgaacgtgc agaagtccaa ctgggaggcc 1260
ggcaacacct tcacctgtag cgtgctgcac gagggcctgc acaatcacca caccgagaag 1320
tccctgtccc acagccctgg caag 1344
<210> 40
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 40
agctatgagc tgacacagcc tccaagcgtg tccgtgtctc ctggacagac cgccagaatc 60
acatgtagcg gcggaggcag ctacaccggc agctactact atggctggta tcagcagaag 120
cccggacagg cccctgtgac cgtgatctac tacaacaaca agcggcccag cgacatcccc 180
gagagatttt ctggctctct gagcggcacc accaacacac tgacaatctc tggcgtgcag 240
gccgaggacg aggccgatta ctattgtggc agcgccgata atagcggcga cgcctttggc 300
accggcacca aagttacagt gctaggccag cccaagagca gccctagcgt gaccctgttc 360
cctccaagca gcgaggaact ggaaacaaac aaggccaccc tcgtgtgcac catcaccgac 420
ttctaccccg gcgtcgtgac cgtggactgg aaggtggacg gcaccccagt gacccagggc 480
atggaaacca cccagcccag caagcagagc aacaacaagt acatggccag cagctacctg 540
accctgaccg ccagagcctg ggagagacac agctcctaca gctgccaagt gacccacgag 600
ggccacaccg tggaaaagag cctgagcaga gccgactgca gc 642
<210> 41
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 41
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Met
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Val Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 42
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 42
Ser Tyr Gly Met His
1 5
<210> 43
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 43
Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Met Gly
1 5 10 15
<210> 44
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 44
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Val
1 5 10
<210> 45
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 45
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 46
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 46
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 47
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 47
Tyr Asp Asp Leu Leu Pro Ser
1 5
<210> 48
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 48
Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Val
1 5 10
<210> 49
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 49
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctatggca tgcactgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gatagcgtga tgggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggatgcctt cgatgtgtgg ggccagggaa cactggttac cgtttcttca 360
<210> 50
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 50
agctatggca tgcac 15
<210> 51
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 51
gccatcggca caggcggcga tacctactat gccgatagcg tgatgggc 48
<210> 52
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 52
agggacgact acaccagcag ggatgccttc gatgtg 36
<210> 53
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 53
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgctgcctag cggcgtgccc 180
gatagatttt ctggcagcaa gagcggcaca agcgccagcc tggctatctc tggactgaga 240
tctgaggacg aggccgacta ctattgcgcc gcctgggacg atagcctgaa cggctatgtg 300
gttttcggcg gaggcaccaa gctgaccgtg cta 333
<210> 54
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 54
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 55
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 55
tacgacgacc tgctgcctag c 21
<210> 56
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 56
gccgcctggg acgatagcct gaacggctat gtggtt 36
<210> 57
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 57
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Met
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Val Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445
Gly
<210> 58
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 58
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 59
<211> 1347
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 59
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctatggca tgcactgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gatagcgtga tgggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggatgcctt cgatgtgtgg ggccagggaa cactggttac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggccccta gcagcaagag cacatctggc 420
ggaacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gctctctggg cacccagacc 600
tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggaaccc 660
aagagctgcg acaagaccca cacctgtccc ccttgtcctg cccccgaact gctgggaggc 720
ccttccgtgt tcctgttccc cccaaagccc aaggacaccc tgatgatcag ccggaccccc 780
gaagtgacct gcgtggtggt ggatgtgtcc cacgaggacc ctgaagtgaa gttcaattgg 840
tacgtggacg gcgtggaagt gcacaacgcc aagaccaagc ctagagagga acagtacaac 900
agcacctacc gggtggtgtc cgtgctgaca gtgctgcacc aggactggct gaacggcaaa 960
gagtacaagt gcaaggtgtc caacaaggcc ctgcctgccc ccatcgagaa aaccatcagc 1020
aaggccaagg gccagccccg cgaaccccag gtgtacacac tgcccccaag cagggacgag 1080
ctgaccaaga accaggtgtc cctgacctgt ctcgtgaaag gcttctaccc ctccgatatc 1140
gccgtggaat gggagagcaa cggccagccc gagaacaact acaagaccac cccccctgtg 1200
ctggacagcg acggctcatt cttcctgtac agcaagctga ccgtggacaa gtcccggtgg 1260
cagcagggca acgtgttcag ctgcagcgtg atgcacgagg ccctgcacaa ccactacacc 1320
cagaagtccc tgagcctgag ccctggc 1347
<210> 60
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 60
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgctgcctag cggcgtgccc 180
gatagatttt ctggcagcaa gagcggcaca agcgccagcc tggctatctc tggactgaga 240
tctgaggacg aggccgacta ctattgcgcc gcctgggacg atagcctgaa cggctatgtg 300
gttttcggcg gaggcaccaa gctgaccgtg ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 61
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 61
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 62
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 62
Ser Tyr Glu Met Asn
1 5
<210> 63
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 63
Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 64
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 64
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 65
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 65
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 66
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 66
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 67
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 67
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 68
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 68
Ser Ser Tyr Ala Gly Ser Asn Pro Tyr Val Val
1 5 10
<210> 69
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 69
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctc tatcggctac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 70
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 70
agctacgaga tgaac 15
<210> 71
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 71
ggcatcagct ggaatagcgg ctctatcggc tacgccgaca gcgtgaaggg c 51
<210> 72
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 72
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 73
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 73
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtaccg gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat ctctggactg 240
agatctgagg acgaggccga ctactactgc agcagctatg ccggcagcaa cccctacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt cta 333
<210> 74
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 74
accggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 75
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 75
ggcaacagca acagacccag c 21
<210> 76
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 76
agcagctatg ccggcagcaa cccctacgtt gtg 33
<210> 77
<211> 452
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 77
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 78
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 78
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 79
<211> 1356
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 79
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctc tatcggctac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggc 1356
<210> 80
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 80
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtaccg gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat ctctggactg 240
agatctgagg acgaggccga ctactactgc agcagctatg ccggcagcaa cccctacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 81
<211> 116
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 81
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Trp Ile Tyr Tyr Asp Ser Gly Ser Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Leu Asn Gly Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 82
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 82
Asp Tyr Ala Met Ser
1 5
<210> 83
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 83
Trp Ile Tyr Tyr Asp Ser Gly Ser Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 84
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 84
Leu Asn Gly Asp Phe Asp Tyr
1 5
<210> 85
<211> 110
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 85
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ala Asp Ser His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu
85 90 95
Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 86
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 86
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Asp Val Ser
1 5 10
<210> 87
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 87
Ala Asp Ser His Arg Pro Ser
1 5
<210> 88
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 88
Gly Ala Trp Asp Ser Ser Leu Ser Gly Tyr Val
1 5 10
<210> 89
<211> 348
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 89
gaagttcagc tgctggaatc tggcggcgga ctggttcaaa caggcggctc tctgagactg 60
agctgtgccg cctctggctt caccttcagc gattacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtcctgg atctactacg acagcggcag caagtactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actattgcgc caagctgaac 300
ggcgacttcg actattgggg ccagggcaca ctggtcacag tctcttca 348
<210> 90
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 90
gattacgcca tgagc 15
<210> 91
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 91
tggatctact acgacagcgg cagcaagtac tacgccgaca gcgtgaaggg c 51
<210> 92
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 92
ctgaacggcg acttcgacta t 21
<210> 93
<211> 330
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 93
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc aacaacgacg tgtcctggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac gccgacagcc acagacctag cggcgtgcca 180
gatagattca gcggctctaa gagcggcaca tctgccagcc tggccatctc tggactgaga 240
tctgaggacg aggccgacta ctattgcggc gcctgggatt ctagcctgag cggctatgtt 300
tttggcggag gcaccaagct gaccgtgcta 330
<210> 94
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 94
agcggcagca gctccaacat cggcaacaac gacgtgtcc 39
<210> 95
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 95
gccgacagcc acagacctag c 21
<210> 96
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 96
ggcgcctggg attctagcct gagcggctat gtt 33
<210> 97
<211> 445
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 97
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Trp Ile Tyr Tyr Asp Ser Gly Ser Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Leu Asn Gly Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
115 120 125
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
130 135 140
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145 150 155 160
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
165 170 175
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
180 185 190
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
195 200 205
Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
210 215 220
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225 230 235 240
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
245 250 255
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
260 265 270
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
275 280 285
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
290 295 300
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305 310 315 320
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
325 330 335
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
340 345 350
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
355 360 365
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
370 375 380
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385 390 395 400
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
405 410 415
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
420 425 430
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 98
<211> 216
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 98
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Asp Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ala Asp Ser His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu
85 90 95
Ser Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
115 120 125
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
130 135 140
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145 150 155 160
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
165 170 175
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
180 185 190
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
195 200 205
Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 99
<211> 1335
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 99
gaagttcagc tgctggaatc tggcggcgga ctggttcaaa caggcggctc tctgagactg 60
agctgtgccg cctctggctt caccttcagc gattacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtcctgg atctactacg acagcggcag caagtactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actattgcgc caagctgaac 300
ggcgacttcg actattgggg ccagggcaca ctggtcacag tctcttcagc cagcaccaag 360
ggccccagcg tgttccctct ggcccctagc agcaagagca catctggcgg aacagccgcc 420
ctgggctgcc tcgtgaagga ctactttccc gagcccgtga ccgtgtcctg gaactctggc 480
gctctgacaa gcggcgtgca cacctttcca gccgtgctgc agagcagcgg cctgtactct 540
ctgagcagcg tcgtgacagt gcccagcagc tctctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagaagg tggaacccaa gagctgcgac 660
aagacccaca cctgtccccc ttgtcctgcc cccgaactgc tgggaggccc ttccgtgttc 720
ctgttccccc caaagcccaa ggacaccctg atgatcagcc ggacccccga agtgacctgc 780
gtggtggtgg atgtgtccca cgaggaccct gaagtgaagt tcaattggta cgtggacggc 840
gtggaagtgc acaacgccaa gaccaagcct agagaggaac agtacaacag cacctaccgg 900
gtggtgtccg tgctgacagt gctgcaccag gactggctga acggcaaaga gtacaagtgc 960
aaggtgtcca acaaggccct gcctgccccc atcgagaaaa ccatcagcaa ggccaagggc 1020
cagccccgcg aaccccaggt gtacacactg cccccaagca gggacgagct gaccaagaac 1080
caggtgtccc tgacctgtct cgtgaaaggc ttctacccct ccgatatcgc cgtggaatgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc cccctgtgct ggacagcgac 1200
ggctcattct tcctgtacag caagctgacc gtggacaagt cccggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagtccctg 1320
agcctgagcc ctggc 1335
<210> 100
<211> 648
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 100
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc aacaacgacg tgtcctggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac gccgacagcc acagacctag cggcgtgcca 180
gatagattca gcggctctaa gagcggcaca tctgccagcc tggccatctc tggactgaga 240
tctgaggacg aggccgacta ctattgcggc gcctgggatt ctagcctgag cggctatgtt 300
tttggcggag gcaccaagct gaccgtgcta ggccagccta aagccgcccc tagcgtgacc 360
ctgttccctc caagcagcga ggaactgcag gccaacaagg ccaccctcgt gtgcctgatc 420
agcgacttct atcctggcgc cgtgaccgtg gcctggaagg ccgatagctc tcctgtgaag 480
gccggcgtgg aaaccaccac ccctagcaag cagagcaaca acaaatacgc cgccagcagc 540
tacctgagcc tgacccccga gcagtggaag tcccacagat cctacagctg ccaagtgacc 600
cacgagggca gcaccgtgga aaagacagtg gcccctaccg agtgcagc 648
<210> 101
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 101
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 102
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 102
Ser Tyr Glu Met Asn
1 5
<210> 103
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 103
Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 104
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 104
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 105
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 105
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 106
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 106
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 107
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 107
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 108
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 108
Ser Ser Tyr Ala Gly Ser Asn Pro Tyr Val Val
1 5 10
<210> 109
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 109
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctc tatcggctac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 110
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 110
agctacgaga tgaac 15
<210> 111
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 111
ggcatcagct ggaatagcgg ctctatcggc tacgccgaca gcgtgaaggg c 51
<210> 112
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 112
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 113
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 113
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt tctagctacg ccggcagcaa cccctacgtg 300
gtgtttggcg gaggcaccaa gctgacagtt cta 333
<210> 114
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 114
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 115
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 115
ggcaacagca acagacccag c 21
<210> 116
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 116
tctagctacg ccggcagcaa cccctacgtg gtg 33
<210> 117
<211> 452
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 117
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 118
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 118
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 119
<211> 1356
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 119
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctc tatcggctac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggc 1356
<210> 120
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 120
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt tctagctacg ccggcagcaa cccctacgtg 300
gtgtttggcg gaggcaccaa gctgacagtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 121
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 121
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 122
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 122
Ser Tyr Ala Met Ser
1 5
<210> 123
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 123
Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 124
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 124
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 125
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 125
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 126
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 126
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 127
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 127
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 128
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 128
Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Val
1 5 10
<210> 129
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 129
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc attggcacag gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 130
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 130
agctacgcca tgagc 15
<210> 131
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 131
gccattggca caggcggcga tacctactac gccgactctg tgaagggc 48
<210> 132
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 132
agggacgact acaccagcag ggacgccttc gattat 36
<210> 133
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 133
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cggctatgtt 300
gttttcggcg gaggcaccaa gctgaccgtt cta 333
<210> 134
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 134
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 135
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 135
tacgacgacc tgcggcctag c 21
<210> 136
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 136
gccgcctggg acgacagcct gaacggctat gttgtt 36
<210> 137
<211> 449
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 137
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445
Gly
<210> 138
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 138
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Gly Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 139
<211> 1347
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 139
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc attggcacag gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggccccta gcagcaagag cacatctggc 420
ggaacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gctctctggg cacccagacc 600
tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggaaccc 660
aagagctgcg acaagaccca cacctgtccc ccttgtcctg cccccgaact gctgggaggc 720
ccttccgtgt tcctgttccc cccaaagccc aaggacaccc tgatgatcag ccggaccccc 780
gaagtgacct gcgtggtggt ggatgtgtcc cacgaggacc ctgaagtgaa gttcaattgg 840
tacgtggacg gcgtggaagt gcacaacgcc aagaccaagc ctagagagga acagtacaac 900
agcacctacc gggtggtgtc cgtgctgaca gtgctgcacc aggactggct gaacggcaaa 960
gagtacaagt gcaaggtgtc caacaaggcc ctgcctgccc ccatcgagaa aaccatcagc 1020
aaggccaagg gccagccccg cgaaccccag gtgtacacac tgcccccaag cagggacgag 1080
ctgaccaaga accaggtgtc cctgacctgt ctcgtgaaag gcttctaccc ctccgatatc 1140
gccgtggaat gggagagcaa cggccagccc gagaacaact acaagaccac cccccctgtg 1200
ctggacagcg acggctcatt cttcctgtac agcaagctga ccgtggacaa gtcccggtgg 1260
cagcagggca acgtgttcag ctgcagcgtg atgcacgagg ccctgcacaa ccactacacc 1320
cagaagtccc tgagcctgag ccctggc 1347
<210> 140
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 140
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cggctatgtt 300
gttttcggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 141
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 141
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 142
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 142
Ser Tyr Ala Met Ser
1 5
<210> 143
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 143
Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 144
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 144
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 145
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 145
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 146
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 146
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 147
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 147
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 148
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 148
Ala Ala Trp Asp Asp Ser Leu Asn Asp Tyr Val Val
1 5 10
<210> 149
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 149
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 150
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 150
agctacgcca tgagc 15
<210> 151
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 151
gccatcggca caggcggcga tacctactat gccgactctg tgaagggc 48
<210> 152
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 152
agggacgact acaccagcag ggacgccttc gattat 36
<210> 153
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 153
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgactacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt cta 333
<210> 154
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 154
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 155
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 155
tacgacgacc tgcggcctag c 21
<210> 156
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 156
gccgcctggg acgacagcct gaacgactac gttgtg 36
<210> 157
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 157
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 158
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 158
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 159
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 159
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 160
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 160
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgactacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 161
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 161
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 162
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 162
Ser Tyr Ala Met Ser
1 5
<210> 163
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 163
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 164
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 164
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 165
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 165
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Ile Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 166
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 166
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 167
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 167
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 168
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 168
Ala Ala Trp Asp Asp Ser Leu Asn Asp Ile Val Val
1 5 10
<210> 169
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 169
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 170
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 170
agctacgcca tgagc 15
<210> 171
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 171
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 172
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 172
agggacgact acaccagcag ggacgccttc gattat 36
<210> 173
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 173
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgacatcgtt 300
gttttcggcg gaggcaccaa gctgaccgtt cta 333
<210> 174
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 174
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 175
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 175
tacgacgacc tgcggcctag c 21
<210> 176
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 176
gccgcctggg acgacagcct gaacgacatc gttgtt 36
<210> 177
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 177
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 178
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 178
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Ile Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 179
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 179
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 180
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 180
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgacatcgtt 300
gttttcggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 181
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 181
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 182
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 182
Ser Tyr Ala Met Ser
1 5
<210> 183
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 183
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 184
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 184
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 185
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 185
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 186
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 186
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 187
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 187
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 188
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 188
Ala Ala Trp Asp Asp Ser Leu Asn Val Tyr Pro Val
1 5 10
<210> 189
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 189
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 190
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 190
agctacgcca tgagc 15
<210> 191
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 191
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 192
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 192
agggacgact acaccagcag ggacgccttc gattat 36
<210> 193
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 193
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgtgtaccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 194
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 194
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 195
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 195
tacgacgacc tgcggcctag c 21
<210> 196
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 196
gccgcctggg acgacagcct gaacgtgtac cctgtt 36
<210> 197
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 197
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 198
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 198
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 199
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 199
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 200
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 200
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgtgtaccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 201
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 201
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 202
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 202
Ser Tyr Ala Met Ser
1 5
<210> 203
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 203
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 204
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 204
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 205
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 205
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Ile Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 206
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 206
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 207
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 207
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 208
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 208
His Ala Trp Asp Asp Ser Leu Asn Asp Ile Val Val
1 5 10
<210> 209
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 209
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 210
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 210
agctacgcca tgagc 15
<210> 211
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 211
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 212
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 212
agggacgact acaccagcag ggacgccttc gattat 36
<210> 213
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 213
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgacatcgtg 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 214
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 214
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 215
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 215
tacgacgacc tgcggcctag c 21
<210> 216
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 216
cacgcctggg acgacagcct gaacgacatc gtggtt 36
<210> 217
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 217
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 218
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 218
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Ile Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 219
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 219
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 220
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 220
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgacatcgtg 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 221
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 221
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 222
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 222
Ser Tyr Ala Met Ser
1 5
<210> 223
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 223
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 224
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 224
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 225
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 225
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 226
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 226
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 227
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 227
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 228
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 228
His Ala Trp Asp Asp Ser Leu Asn Asp Tyr Pro Val
1 5 10
<210> 229
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 229
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 230
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 230
agctacgcca tgagc 15
<210> 231
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 231
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 232
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 232
agggacgact acaccagcag ggacgccttc gattat 36
<210> 233
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 233
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgactaccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 234
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 234
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 235
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 235
tacgacgacc tgcggcctag c 21
<210> 236
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 236
cacgcctggg acgacagcct gaacgactac cctgtt 36
<210> 237
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 237
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 238
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 238
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 239
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 239
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 240
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 240
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgactaccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 241
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 241
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 242
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 242
Ser Tyr Ala Met Ser
1 5
<210> 243
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 243
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 244
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 244
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 245
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 245
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 246
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 246
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 247
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 247
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 248
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 248
His Ala Trp Asp Asp Ser Leu Asn Val Tyr Pro Val
1 5 10
<210> 249
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 249
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 250
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 250
agctacgcca tgagc 15
<210> 251
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 251
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 252
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 252
agggacgact acaccagcag ggacgccttc gattat 36
<210> 253
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 253
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgtgtaccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 254
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 254
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 255
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 255
tacgacgacc tgcggcctag c 21
<210> 256
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 256
cacgcctggg acgacagcct gaacgtgtac cctgtt 36
<210> 257
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 257
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 258
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 258
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 259
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 259
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 260
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 260
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgtgtaccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 261
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 261
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 262
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 262
Ser Tyr Ala Met Ser
1 5
<210> 263
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 263
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 264
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 264
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 265
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 265
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Ile Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 266
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 266
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 267
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 267
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 268
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 268
His Ala Trp Asp Asp Ser Leu Asn Val Ile Pro Val
1 5 10
<210> 269
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 269
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 270
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 270
agctacgcca tgagc 15
<210> 271
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 271
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 272
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 272
agggacgact acaccagcag ggacgccttc gattat 36
<210> 273
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 273
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgtgatccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 274
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 274
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 275
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 275
tacgacgacc tgcggcctag c 21
<210> 276
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 276
cacgcctggg acgacagcct gaacgtgatc cctgtt 36
<210> 277
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 277
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 278
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 278
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Ile Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 279
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 279
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttagc agctacgcca tgagctgggt ccgacaggct 120
cctggcaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 280
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 280
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgtgatccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 281
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 281
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 282
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 282
Ser Tyr Ala Met Leu
1 5
<210> 283
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 283
Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 284
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 284
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 285
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 285
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 286
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 286
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 287
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 287
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 288
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 288
Ala Ala Trp Asp Asp Ser Leu Asn Asp Tyr Val Val
1 5 10
<210> 289
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 289
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgctgtgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 290
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 290
agctacgcca tgctg 15
<210> 291
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 291
gccatcggca caggcggcga tacctactat gccgactctg tgaagggc 48
<210> 292
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 292
agggacgact acaccagcag ggacgccttc gattat 36
<210> 293
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 293
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgactacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt cta 333
<210> 294
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 294
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 295
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 295
tacgacgacc tgcggcctag c 21
<210> 296
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 296
gccgcctggg acgacagcct gaacgactac gttgtg 36
<210> 297
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 297
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 298
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 298
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 299
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 299
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgctgtgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 300
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 300
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgactacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 301
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 301
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 302
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 302
Ser Tyr Ala Met Leu
1 5
<210> 303
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 303
Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 304
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 304
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 305
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 305
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 306
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 306
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 307
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 307
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 308
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 308
Ala Ala Trp Asp Asp Ser Leu Asn Val Tyr Val Val
1 5 10
<210> 309
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 309
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgctgtgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 310
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 310
agctacgcca tgctg 15
<210> 311
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 311
gccatcggca caggcggcga tacctactat gccgactctg tgaagggc 48
<210> 312
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 312
agggacgact acaccagcag ggacgccttc gattat 36
<210> 313
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 313
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgtgtacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt cta 333
<210> 314
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 314
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 315
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 315
tacgacgacc tgcggcctag c 21
<210> 316
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 316
gccgcctggg acgacagcct gaacgtgtac gttgtg 36
<210> 317
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 317
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 318
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 318
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 319
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 319
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgctgtgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggcacag gcggcgatac ctactatgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 320
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 320
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgtgtacgtt 300
gtgtttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 321
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 321
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 322
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 322
Ser Tyr Ala Met Ser
1 5
<210> 323
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 323
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 324
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 324
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 325
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 325
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 326
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 326
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 327
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 327
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 328
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 328
His Ala Trp Asp Asp Ser Leu Asn Val Tyr Pro Val
1 5 10
<210> 329
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 329
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 330
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 330
agctacgcca tgagc 15
<210> 331
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 331
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 332
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 332
agggacgact acaccagcag ggacgccttc gattat 36
<210> 333
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 333
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgtgtaccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 334
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 334
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 335
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 335
tacgacgacc tgcggcctag c 21
<210> 336
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 336
cacgcctggg acgacagcct gaacgtgtac cctgtt 36
<210> 337
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 337
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 338
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 338
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys His Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Tyr Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 339
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 339
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 340
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 340
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ctattgtcac gcctgggacg acagcctgaa cgtgtaccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 341
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 341
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 342
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 342
Ser Tyr Ala Met Ser
1 5
<210> 343
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 343
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 344
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 344
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 345
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 345
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Ile Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 346
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 346
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 347
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 347
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 348
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 348
Ala Ala Trp Asp Asp Ser Leu Asn Asp Ile Pro Val
1 5 10
<210> 349
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 349
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 350
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 350
agctacgcca tgagc 15
<210> 351
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 351
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 352
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 352
agggacgact acaccagcag ggacgccttc gattat 36
<210> 353
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 353
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgacatccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 354
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 354
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 355
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 355
tacgacgacc tgcggcctag c 21
<210> 356
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 356
gccgcctggg acgacagcct gaacgacatc cctgtt 36
<210> 357
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 357
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 358
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 358
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Asp Ile Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 359
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 359
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 360
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 360
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgacatccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 361
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 361
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 362
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 362
Ser Tyr Ala Met Ser
1 5
<210> 363
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 363
Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 364
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 364
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr
1 5 10
<210> 365
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 365
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Ile Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 366
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 366
Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1 5 10
<210> 367
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 367
Tyr Asp Asp Leu Arg Pro Ser
1 5
<210> 368
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 368
Ala Ala Trp Asp Asp Ser Leu Asn Val Ile Pro Val
1 5 10
<210> 369
<211> 360
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 369
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
<210> 370
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 370
agctacgcca tgagc 15
<210> 371
<211> 48
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 371
gccatcggct atggcggcga tacctactac gccgactctg tgaagggc 48
<210> 372
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 372
agggacgact acaccagcag ggacgccttc gattat 36
<210> 373
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 373
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgtgatccct 300
gtttttggcg gaggcaccaa gctgaccgtt cta 333
<210> 374
<211> 39
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 374
agcggcagca gctccaacat cggcagcaac accgtgaac 39
<210> 375
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 375
tacgacgacc tgcggcctag c 21
<210> 376
<211> 36
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 376
gccgcctggg acgacagcct gaacgtgatc cctgtt 36
<210> 377
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 377
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Tyr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445
<210> 378
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 378
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Tyr Asp Asp Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Val Ile Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 379
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 379
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttttac agctacgcca tgagctgggt ccgacaggcc 120
cctggaaaag gccttgaatg ggtgtccgcc atcggctatg gcggcgatac ctactacgcc 180
gactctgtga agggcagatt caccatcagc cgggacaaca gcaagaacac cctgtacctg 240
cagatgaaca gcctgagagc cgaggacacc gccgtgtact attgcgccag aagggacgac 300
tacaccagca gggacgcctt cgattattgg ggccagggca cactggtcac cgtttcttca 360
gccagcacca agggccccag cgtgttccct ctggcccctt gtagcagaag caccagcgag 420
tctacagccg ccctgggctg cctcgtgaag gactactttc ccgagcccgt gaccgtgtcc 480
tggaactctg gcgctctgac aagcggcgtg cacacctttc cagccgtgct gcagagcagc 540
ggcctgtact ctctgagcag cgtcgtgaca gtgcccagca gcagcctggg caccaagacc 600
tacacctgta acgtggacca caagcccagc aacaccaagg tggacaagcg ggtggaatct 660
aagtacggcc ctccctgccc tccttgccca gcccctgaat ttctgggcgg accctccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccaggaagat cccgaggtgc agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cccagagagg aacagttcaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggg cctgcccagc tccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcctccaa gccaggaaga gatgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcagactg accgtggaca agagccggtg gcaggaaggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgtctctga gcctgggcaa g 1341
<210> 380
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 380
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caacatcggc agcaacaccg tgaactggta tcagcagctg 120
cctggcacag cccctaaact gctgatctac tacgacgacc tgcggcctag cggcgtgcca 180
gatagatttt ctggcagcaa gagcggcacc tctgccagcc tggctatttc tggactgcag 240
agcgaggacg aggccgacta ttattgtgcc gcctgggacg acagcctgaa cgtgatccct 300
gtttttggcg gaggcaccaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 381
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 381
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 382
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 382
Ser Tyr Glu Met Asn
1 5
<210> 383
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 383
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 384
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 384
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 385
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 385
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 386
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 386
Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 387
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 387
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 388
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 388
Ser Ser Tyr Ala Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 389
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 389
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 390
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 390
agctacgaga tgaac 15
<210> 391
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 391
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 392
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 392
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 393
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 393
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc cgatattggc gccggatacg acgtgcactg gtatcagcaa 120
ctgcctggca cagcccctaa gctgctgatc tacggcaaca gcaacagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgc agcagctacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 394
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 394
acaggcagca gctccgatat tggcgccgga tacgacgtgc ac 42
<210> 395
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 395
ggcaacagca acagacctag c 21
<210> 396
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 396
agcagctacg ctggccccaa tccttacgtg gtg 33
<210> 397
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 397
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 398
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 398
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 399
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 399
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 400
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 400
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc cgatattggc gccggatacg acgtgcactg gtatcagcaa 120
ctgcctggca cagcccctaa gctgctgatc tacggcaaca gcaacagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgc agcagctacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 401
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 401
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 402
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 402
Ser Tyr Glu Met Asn
1 5
<210> 403
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 403
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 404
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 404
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 405
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 405
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Ile
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 406
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 406
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 407
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 407
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 408
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 408
Gln Ser Tyr Ala Gly Ile Asn Pro Tyr Val Val
1 5 10
<210> 409
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 409
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 410
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 410
agctacgaga tgaac 15
<210> 411
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 411
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 412
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 412
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 413
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 413
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagagctacg ccggcatcaa cccctacgtg 300
gtgtttggcg gaggcaccaa gctgacagtt cta 333
<210> 414
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 414
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 415
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 415
ggcaacagca acagacccag c 21
<210> 416
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 416
cagagctacg ccggcatcaa cccctacgtg gtg 33
<210> 417
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 417
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 418
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 418
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Ile
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 419
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 419
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 420
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 420
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagagctacg ccggcatcaa cccctacgtg 300
gtgtttggcg gaggcaccaa gctgacagtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 421
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 421
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 422
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 422
Ser Tyr Glu Met Asn
1 5
<210> 423
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 423
Gly Ile Ser Trp Asn Ser Gly Trp Ile Gly Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 424
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 424
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 425
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 425
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 426
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 426
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 427
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 427
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 428
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 428
Gln Ser Tyr Ala Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 429
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 429
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgatttcagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcggctac 180
gccgatagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 430
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 430
agctacgaga tgaac 15
<210> 431
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 431
ggcatcagct ggaatagcgg ctggatcggc tacgccgata gcgtgaaggg c 51
<210> 432
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 432
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 433
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 433
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 434
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 434
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 435
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 435
ggcaacagca acagacccag c 21
<210> 436
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 436
cagtcttacg ctggccccaa tccttacgtg gtg 33
<210> 437
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 437
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 438
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 438
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 439
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 439
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgatttcagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcggctac 180
gccgatagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 440
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 440
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 441
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 441
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 442
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 442
Ser Tyr Glu Met Asn
1 5
<210> 443
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 443
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 444
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 444
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 445
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 445
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 446
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 446
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 447
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 447
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 448
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 448
Gln Ser Tyr Ala Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 449
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 449
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgatttcagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 450
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 450
agctacgaga tgaac 15
<210> 451
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 451
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 452
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 452
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 453
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 453
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 454
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 454
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 455
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 455
ggcaacagca acagacccag c 21
<210> 456
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 456
cagtcttacg ctggccccaa tccttacgtg gtg 33
<210> 457
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 457
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 458
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 458
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 459
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 459
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgatttcagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 460
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 460
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 461
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 461
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 462
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 462
Ser Tyr Glu Met Asn
1 5
<210> 463
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 463
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 464
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 464
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 465
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 465
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 466
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 466
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 467
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 467
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 468
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 468
Gln Ser Tyr Ala Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 469
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 469
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 470
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 470
agctacgaga tgaac 15
<210> 471
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 471
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 472
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 472
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 473
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 473
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 474
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 474
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 475
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 475
ggcaacagca acagacccag c 21
<210> 476
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 476
cagtcttacg ctggccccaa tccttacgtg gtg 33
<210> 477
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 477
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 478
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 478
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 479
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 479
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 480
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 480
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 481
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 481
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 482
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 482
Ser Tyr Glu Met Asn
1 5
<210> 483
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 483
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 484
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 484
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 485
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 485
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 486
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 486
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 487
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 487
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 488
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 488
Gln Ser Tyr Ala Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 489
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 489
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgacttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 490
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 490
agctacgaga tgaac 15
<210> 491
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 491
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 492
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 492
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 493
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 493
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 494
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 494
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 495
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 495
ggcaacagca acagacccag c 21
<210> 496
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 496
cagtcttacg ctggccccaa tccttacgtg gtg 33
<210> 497
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 497
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 498
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 498
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 499
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 499
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgacttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 500
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 500
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt cagtcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 501
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 501
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 502
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 502
Ser Tyr Glu Met Asn
1 5
<210> 503
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 503
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 504
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 504
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 505
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 505
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Ile
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 506
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 506
Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 507
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 507
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 508
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 508
Gln Ser Tyr Ala Gly Ile Asn Pro Tyr Val Val
1 5 10
<210> 509
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 509
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 510
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 510
agctacgaga tgaac 15
<210> 511
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 511
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 512
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 512
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 513
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 513
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc cgatattggc gccggatacg acgtgcactg gtatcagcaa 120
ctgcctggca cagcccctaa gctgctgatc tacggcaaca gcaacagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgt cagagctacg ccggcatcaa cccctacgtg 300
gtgtttggcg gaggcaccaa gctgacagtt cta 333
<210> 514
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 514
acaggcagca gctccgatat tggcgccgga tacgacgtgc ac 42
<210> 515
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 515
ggcaacagca acagacctag c 21
<210> 516
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 516
cagagctacg ccggcatcaa cccctacgtg gtg 33
<210> 517
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 517
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 518
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 518
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Ala Gly Ile
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 519
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 519
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 520
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 520
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc cgatattggc gccggatacg acgtgcactg gtatcagcaa 120
ctgcctggca cagcccctaa gctgctgatc tacggcaaca gcaacagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgt cagagctacg ccggcatcaa cccctacgtg 300
gtgtttggcg gaggcaccaa gctgacagtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 521
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 521
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 522
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 522
Ser Tyr Glu Met Asn
1 5
<210> 523
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 523
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 524
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 524
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 525
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 525
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Glu Gly Ile
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 526
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 526
Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 527
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 527
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 528
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 528
Ser Ser Tyr Glu Gly Ile Asn Pro Tyr Val Val
1 5 10
<210> 529
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 529
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgacttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 530
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 530
agctacgaga tgaac 15
<210> 531
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 531
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 532
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 532
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 533
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 533
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc cgatattggc gccggatacg acgtgcactg gtatcagcaa 120
ctgcctggca cagcccctaa gctgctgatc tacggcaaca gcaacagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgc agcagctacg agggcatcaa cccctacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 534
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 534
acaggcagca gctccgatat tggcgccgga tacgacgtgc ac 42
<210> 535
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 535
ggcaacagca acagacctag c 21
<210> 536
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 536
agcagctacg agggcatcaa cccctacgtg gtg 33
<210> 537
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 537
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 538
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 538
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Glu Gly Ile
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 539
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 539
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgacttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 540
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 540
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc cgatattggc gccggatacg acgtgcactg gtatcagcaa 120
ctgcctggca cagcccctaa gctgctgatc tacggcaaca gcaacagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgc agcagctacg agggcatcaa cccctacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 541
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 541
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 542
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 542
Ser Tyr Glu Met Asn
1 5
<210> 543
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 543
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 544
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 544
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 545
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 545
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Ala Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Glu Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 546
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 546
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 547
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 547
Gly Ala Ser Asn Arg Pro Ser
1 5
<210> 548
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 548
Ser Ser Tyr Glu Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 549
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 549
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgatttcagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 550
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 550
agctacgaga tgaac 15
<210> 551
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 551
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 552
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 552
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 553
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 553
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcgcca gcaatagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgc agcagctacg agggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 554
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 554
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 555
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 555
ggcgccagca atagacctag c 21
<210> 556
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 556
agcagctacg agggccccaa tccttacgtg gtg 33
<210> 557
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 557
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 558
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 558
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Ala Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Glu Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 559
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 559
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cgatttcagc agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 560
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 560
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcgcca gcaatagacc tagcggcgtg 180
cccgatagat tcagcggctc taagtctggc acaagcgcca gcctggccat tactggactg 240
caggccgaag atgaggccga ctactactgc agcagctacg agggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 561
<211> 123
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 561
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 562
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 562
Ser Tyr Glu Met Asn
1 5
<210> 563
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 563
Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 564
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 564
Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
1 5 10
<210> 565
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 565
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 566
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 566
Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 567
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 567
Gly Asn Ser Asn Arg Pro Ser
1 5
<210> 568
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 568
Ser Ser Tyr Ala Gly Pro Asn Pro Tyr Val Val
1 5 10
<210> 569
<211> 369
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 569
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttca 369
<210> 570
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 570
agctacgaga tgaac 15
<210> 571
<211> 51
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 571
ggcatcagct ggaatagcgg ctggatcgac tacgccgaca gcgtgaaggg c 51
<210> 572
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 572
agcggctaca gcagctcttg gtttgacccc gacttcgact at 42
<210> 573
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 573
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt agctcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt cta 333
<210> 574
<211> 42
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 574
acaggcagca gctccaatat cggagccggc tatgacgtgc ac 42
<210> 575
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 575
ggcaacagca acagacccag c 21
<210> 576
<211> 33
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 576
agctcttacg ctggccccaa tccttacgtg gtg 33
<210> 577
<211> 453
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 577
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Ser Tyr
20 25 30
Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Trp Ile Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Gly Tyr Ser Ser Ser Trp Phe Asp Pro Asp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
450
<210> 578
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 578
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Pro
85 90 95
Asn Pro Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 579
<211> 1359
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 579
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt caccttcgat agctacgaga tgaactgggt ccgacaggcc 120
cctggcaaag gccttgaatg ggtgtccggc atcagctgga atagcggctg gatcgactac 180
gccgacagcg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaagcggc 300
tacagcagct cttggtttga ccccgacttc gactattggg gccagggcac actggtcaca 360
gtctcttcag ccagcaccaa gggccccagc gtgttccctc tggcccctag cagcaagagc 420
acatctggcg gaacagccgc cctgggctgc ctcgtgaagg actactttcc cgagcccgtg 480
accgtgtcct ggaactctgg cgctctgaca agcggcgtgc acacctttcc agccgtgctg 540
cagagcagcg gcctgtactc tctgagcagc gtcgtgacag tgcccagcag ctctctgggc 600
acccagacct acatctgcaa cgtgaaccac aagcccagca acaccaaggt ggacaagaag 660
gtggaaccca agagctgcga caagacccac acctgtcccc cttgtcctgc ccccgaactg 720
ctgggaggcc cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatcagc 780
cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag 840
ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa 900
cagtacaaca gcacctaccg ggtggtgtcc gtgctgacag tgctgcacca ggactggctg 960
aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgagaaa 1020
accatcagca aggccaaggg ccagccccgc gaaccccagg tgtacacact gcccccaagc 1080
agggacgagc tgaccaagaa ccaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc 1140
tccgatatcg ccgtggaatg ggagagcaac ggccagcccg agaacaacta caagaccacc 1200
ccccctgtgc tggacagcga cggctcattc ttcctgtaca gcaagctgac cgtggacaag 1260
tcccggtggc agcagggcaa cgtgttcagc tgcagcgtga tgcacgaggc cctgcacaac 1320
cactacaccc agaagtccct gagcctgagc cctggcaag 1359
<210> 580
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 580
cagtctgttc tgacacagcc tccatctgtg tctggcgccc ctggacagag agtgaccatc 60
agctgtacag gcagcagctc caatatcgga gccggctatg acgtgcactg gtatcagcag 120
ctgcctggca cagcccctaa actgctgatc tacggcaaca gcaacagacc cagcggcgtg 180
cccgatagat tttccggctc taagagcggc acaagcgcca gcctggctat tactggactg 240
caggccgagg acgaggccga ctactactgt agctcttacg ctggccccaa tccttacgtg 300
gtgtttggcg gcggaacaaa gctgaccgtt ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 581
<211> 990
<212> PRT
<213> 智人(Homo sapiens)
<400> 581
His His His His His His Lys Asn Asn Val Pro Arg Leu Lys Leu Ser
1 5 10 15
Tyr Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu
20 25 30
Ala Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser
35 40 45
Arg Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asp Leu Val
50 55 60
Asn Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg
65 70 75 80
Arg Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala
85 90 95
Asn Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala
100 105 110
Cys Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Ile Gly
115 120 125
His His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asn Ser His Phe Glu
130 135 140
Asn Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser
145 150 155 160
Leu Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met
165 170 175
Gly Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile
180 185 190
Arg Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Lys Phe Ile
195 200 205
Ser Ala His Leu Ile Ser Glu Ser Asp Asn Pro Glu Asp Asp Lys Val
210 215 220
Tyr Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys
225 230 235 240
Ala Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly
245 250 255
His Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu
260 265 270
Ile Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu
275 280 285
Leu Gln Asp Val Phe Leu Met Asn Phe Lys Asp Pro Lys Asn Pro Val
290 295 300
Val Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala
305 310 315 320
Val Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro
325 330 335
Tyr Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly
340 345 350
Arg Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly
355 360 365
Gly Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala
370 375 380
Arg Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Met Asn Asn Arg
385 390 395 400
Pro Ile Val Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val
405 410 415
Val Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile
420 425 430
Gly Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu
435 440 445
Thr Trp Tyr Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe
450 455 460
Arg Glu Pro Thr Ala Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln
465 470 475 480
Gln Leu Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His
485 490 495
Arg Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg
500 505 510
Asp Pro Tyr Cys Ala Trp Asp Gly Ser Ala Cys Ser Arg Tyr Phe Pro
515 520 525
Thr Ala Lys Arg Ala Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro
530 535 540
Leu Thr His Cys Ser Asp Leu His His Asp Asn His His Gly His Ser
545 550 555 560
Pro Glu Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser Ser Thr Phe Leu
565 570 575
Glu Cys Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr Trp Gln Phe Gln
580 585 590
Arg Arg Asn Glu Glu Arg Lys Glu Glu Ile Arg Val Asp Asp His Ile
595 600 605
Ile Arg Thr Asp Gln Gly Leu Leu Leu Arg Ser Leu Gln Gln Lys Asp
610 615 620
Ser Gly Asn Tyr Leu Cys His Ala Val Glu His Gly Phe Ile Gln Thr
625 630 635 640
Leu Leu Lys Val Thr Leu Glu Val Ile Asp Thr Glu His Leu Glu Glu
645 650 655
Leu Leu His Lys Asp Asp Asp Gly Asp Gly Ser Lys Thr Lys Glu Met
660 665 670
Ser Asn Ser Met Thr Pro Ser Gln Lys Val Trp Tyr Arg Asp Phe Met
675 680 685
Gln Leu Ile Asn His Pro Asn Leu Asn Thr Met Asp Glu Phe Cys Glu
690 695 700
Gln Val Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln Arg Pro Gly His
705 710 715 720
Thr Pro Gly Asn Ser Asn Lys Trp Lys His Leu Gln Glu Asn Lys Lys
725 730 735
Gly Arg Asn Arg Arg Thr His Glu Phe Glu Arg Ala Pro Arg Ser Val
740 745 750
Asp Ile Glu Gly Arg Met Asp Pro Lys Ser Cys Asp Lys Thr His Thr
755 760 765
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
770 775 780
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
785 790 795 800
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
805 810 815
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
820 825 830
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
835 840 845
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
850 855 860
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
865 870 875 880
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
885 890 895
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
900 905 910
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
915 920 925
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
930 935 940
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
945 950 955 960
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
965 970 975
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
980 985 990
<210> 582
<211> 563
<212> PRT
<213> 智人
<400> 582
Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asp Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Ile Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asn Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Lys Phe Ile Ser
195 200 205
Ala His Leu Ile Ser Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Phe Lys Asp Pro Lys Asn Pro Val Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Met Asn Asn Arg Pro
385 390 395 400
Ile Val Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu Thr
435 440 445
Trp Tyr Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Ala Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ala Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Ala Arg Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 583
<211> 563
<212> PRT
<213> 小家鼠(Mus Musculus)(小鼠)
<400> 583
Asn Tyr Ala Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Glu Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Val Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Gln Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Val Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Ile Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Ala Arg Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 584
<211> 563
<212> PRT
<213> 褐家鼠(Rattus norvegicus)(大鼠)
<400> 584
Asn Tyr Ala Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Val Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Gln Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Val Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Ala Arg Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 585
<211> 563
<212> PRT
<213> 家犬(Canis lupus familiaris)(狗)
<400> 585
Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Ser Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Gln Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Ile Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Thr Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Pro Ile Ser Ala Met Glu Leu Ser Thr Lys Gln His Gln
465 470 475 480
Leu Tyr Ala Gly Ser Pro Ala Gly Leu Ala Gln Leu Pro Leu Gln Arg
485 490 495
Cys Ala Ala Tyr Gly Arg Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ala Ala Cys Ser Arg Tyr Phe Pro Ala
515 520 525
Ala Lys Ala Arg Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 586
<211> 563
<212> PRT
<213> 成束猴(Macaca fascicularis)(食蟹猴(Cynomolgus monkey))
<400> 586
Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Ile Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asn Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Phe Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Ile Gly Ser Thr Ala Gly Ile Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Ala Arg Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 587
<211> 563
<212> PRT
<213> 野猪(Sus scrofa)(猪)
<400> 587
Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Ile Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Thr Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Val Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Val Gly Ser Ala Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Ala Arg Thr Arg Ala Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 588
<211> 5
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (3)...(3)
<223> Xaa可以为任何天然存在的氨基酸
<220>
<221> misc_feature
<222> (5)...(5)
<223> Xaa可以为任何天然存在的氨基酸
<400> 588
Ser Tyr Xaa Met Xaa
1 5
<210> 589
<211> 5
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (5)...(5)
<223> Xaa可以为任何天然存在的氨基酸
<400> 589
Ser Tyr Ala Met Xaa
1 5
<210> 590
<211> 16
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (4)...(4)
<223> Xaa可以为任何天然存在的氨基酸
<220>
<221> misc_feature
<222> (15)...(15)
<223> Xaa可以为任何天然存在的氨基酸
<400> 590
Ala Ile Gly Xaa Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Xaa Gly
1 5 10 15
<210> 591
<211> 16
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (4)...(4)
<223> Xaa可以为任何天然存在的氨基酸
<400> 591
Ala Ile Gly Xaa Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15
<210> 592
<211> 17
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (8)...(8)
<223> Xaa可以为任何天然存在的氨基酸
<220>
<221> misc_feature
<222> (10)...(10)
<223> Xaa可以为任何天然存在的氨基酸
<400> 592
Gly Ile Ser Trp Asn Ser Gly Xaa Ile Xaa Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 593
<211> 17
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (10)...(10)
<223> Xaa可以为任何天然存在的氨基酸
<400> 593
Gly Ile Ser Trp Asn Ser Gly Trp Ile Xaa Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 594
<211> 12
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (12)...(12)
<223> Xaa可以为任何天然存在的氨基酸
<400> 594
Arg Asp Asp Tyr Thr Ser Arg Asp Ala Phe Asp Xaa
1 5 10
<210> 595
<211> 14
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (6)...(6)
<223> Xaa可以为任何天然存在的氨基酸
<400> 595
Thr Gly Ser Ser Ser Xaa Ile Gly Ala Gly Tyr Asp Val His
1 5 10
<210> 596
<211> 7
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (5)...(5)
<223> Xaa可以为任何天然存在的氨基酸
<400> 596
Tyr Asp Asp Leu Xaa Pro Ser
1 5
<210> 597
<211> 7
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (2)...(2)
<223> Xaa可以为任何天然存在的氨基酸
<400> 597
Gly Xaa Ser Asn Arg Pro Ser
1 5
<210> 598
<211> 12
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (1)...(1)
<223> Xaa可以为任何天然存在的氨基酸
<220>
<221> misc_feature
<222> (9)...(11)
<223> Xaa可以为任何天然存在的氨基酸
<400> 598
Xaa Ala Trp Asp Asp Ser Leu Asn Xaa Xaa Xaa Val
1 5 10
<210> 599
<211> 11
<212> PRT
<213> 人工
<220>
<223> 抗体序列
<220>
<221> misc_feature
<222> (1)...(1)
<223> Xaa可以为任何天然存在的氨基酸
<220>
<221> misc_feature
<222> (4)...(4)
<223> Xaa可以为任何天然存在的氨基酸
<220>
<221> misc_feature
<222> (6)...(6)
<223> Xaa可以为任何天然存在的氨基酸
<400> 599
Xaa Ser Tyr Xaa Gly Xaa Asn Pro Tyr Val Val
1 5 10
<210> 600
<211> 750
<212> PRT
<213> 智人
<400> 600
Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr Lys
1 5 10 15
Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala Asn
20 25 30
Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg Leu
35 40 45
Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asp Leu Val Asn Ile
50 55 60
Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg Asp
65 70 75 80
Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn Phe
85 90 95
Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys Gly
100 105 110
Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Ile Gly His His
115 120 125
Pro Glu Asp Asn Ile Phe Lys Leu Glu Asn Ser His Phe Glu Asn Gly
130 135 140
Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu Leu
145 150 155 160
Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly Arg
165 170 175
Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg Thr
180 185 190
Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Lys Phe Ile Ser Ala
195 200 205
His Leu Ile Ser Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr Phe
210 215 220
Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala Thr
225 230 235 240
His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His Arg
245 250 255
Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile Cys
260 265 270
Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu Gln
275 280 285
Asp Val Phe Leu Met Asn Phe Lys Asp Pro Lys Asn Pro Val Val Tyr
290 295 300
Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val Cys
305 310 315 320
Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr Ala
325 330 335
His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg Val
340 345 350
Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly Phe
355 360 365
Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg Ser
370 375 380
His Pro Ala Met Tyr Asn Pro Val Phe Pro Met Asn Asn Arg Pro Ile
385 390 395 400
Val Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val Asp
405 410 415
Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly Thr
420 425 430
Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu Thr Trp
435 440 445
Tyr Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg Glu
450 455 460
Pro Thr Ala Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln Leu
465 470 475 480
Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His Arg Cys
485 490 495
Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp Pro
500 505 510
Tyr Cys Ala Trp Asp Gly Ser Ala Cys Ser Arg Tyr Phe Pro Thr Ala
515 520 525
Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn Gly Asp Pro Leu Thr
530 535 540
His Cys Ser Asp Leu His His Asp Asn His His Gly His Ser Pro Glu
545 550 555 560
Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser Ser Thr Phe Leu Glu Cys
565 570 575
Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr Trp Gln Phe Gln Arg Arg
580 585 590
Asn Glu Glu Arg Lys Glu Glu Ile Arg Val Asp Asp His Ile Ile Arg
595 600 605
Thr Asp Gln Gly Leu Leu Leu Arg Ser Leu Gln Gln Lys Asp Ser Gly
610 615 620
Asn Tyr Leu Cys His Ala Val Glu His Gly Phe Ile Gln Thr Leu Leu
625 630 635 640
Lys Val Thr Leu Glu Val Ile Asp Thr Glu His Leu Glu Glu Leu Leu
645 650 655
His Lys Asp Asp Asp Gly Asp Gly Ser Lys Thr Lys Glu Met Ser Asn
660 665 670
Ser Met Thr Pro Ser Gln Lys Val Trp Tyr Arg Asp Phe Met Gln Leu
675 680 685
Ile Asn His Pro Asn Leu Asn Thr Met Asp Glu Phe Cys Glu Gln Val
690 695 700
Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln Arg Pro Gly His Thr Pro
705 710 715 720
Gly Asn Ser Asn Lys Trp Lys His Leu Gln Glu Asn Lys Lys Gly Arg
725 730 735
Asn Arg Arg Thr His Glu Phe Glu Arg Ala Pro Arg Ser Val
740 745 750
<210> 601
<211> 752
<212> PRT
<213> 小家鼠
<400> 601
Asn Tyr Ala Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Glu Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Val Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Gln Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Val Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Leu Gln His His Asp Asn His His Gly Pro Ser
545 550 555 560
Leu Glu Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser Ser Thr Phe Leu
565 570 575
Glu Cys Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr Trp Gln Phe Gln
580 585 590
Arg Arg Asn Glu Asp Arg Lys Glu Glu Ile Arg Met Gly Asp His Ile
595 600 605
Ile Arg Thr Glu Gln Gly Leu Leu Leu Arg Ser Leu Gln Lys Lys Asp
610 615 620
Ser Gly Asn Tyr Leu Cys His Ala Val Glu His Gly Phe Met Gln Thr
625 630 635 640
Leu Leu Lys Val Thr Leu Glu Val Ile Asp Thr Glu His Leu Glu Glu
645 650 655
Leu Leu His Lys Asp Asp Asp Gly Asp Gly Ser Lys Ile Lys Glu Met
660 665 670
Ser Ser Ser Met Thr Pro Ser Gln Lys Val Trp Tyr Arg Asp Phe Met
675 680 685
Gln Leu Ile Asn His Pro Asn Leu Asn Thr Met Asp Glu Phe Cys Glu
690 695 700
Gln Val Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln Arg Pro Gly His
705 710 715 720
Ser Gln Gly Ser Ser Asn Lys Trp Lys His Met Gln Glu Ser Lys Lys
725 730 735
Gly Arg Asn Arg Arg Thr His Glu Phe Glu Arg Ala Pro Arg Ser Val
740 745 750
<210> 602
<211> 772
<212> PRT
<213> 成束猴
<400> 602
Met Gly Trp Leu Thr Arg Ile Val Cys Leu Phe Trp Gly Val Leu Leu
1 5 10 15
Thr Ala Arg Ala Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu
20 25 30
Lys Leu Ser Tyr Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe
35 40 45
Asn Gly Leu Ala Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu
50 55 60
Glu Arg Ser Arg Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe
65 70 75 80
Asn Leu Val Asn Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser
85 90 95
Tyr Thr Arg Arg Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys
100 105 110
Glu Cys Ala Asn Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His
115 120 125
Leu Tyr Ala Cys Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile
130 135 140
Glu Ile Gly His His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asn Ser
145 150 155 160
His Phe Glu Asn Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu
165 170 175
Thr Ala Ser Leu Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala
180 185 190
Asp Phe Met Gly Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His
195 200 205
His Pro Ile Arg Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro
210 215 220
Arg Phe Ile Ser Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp
225 230 235 240
Asp Lys Val Tyr Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His
245 250 255
Ser Gly Lys Ala Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp
260 265 270
Phe Gly Gly His Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys
275 280 285
Ala Arg Leu Ile Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His
290 295 300
Phe Asp Glu Leu Gln Asp Val Phe Leu Met Asn Phe Lys Asp Pro Lys
305 310 315 320
Asn Pro Ile Val Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys
325 330 335
Gly Ser Ala Val Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe
340 345 350
Leu Gly Pro Tyr Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro
355 360 365
Tyr Gln Gly Arg Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys
370 375 380
Thr Phe Gly Gly Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile
385 390 395 400
Thr Phe Ala Arg Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile
405 410 415
Asn Asn Arg Pro Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr
420 425 430
Gln Ile Val Val Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val
435 440 445
Met Phe Ile Gly Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile
450 455 460
Pro Lys Glu Thr Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met
465 470 475 480
Thr Val Phe Arg Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr
485 490 495
Lys Gln Gln Gln Leu Tyr Ile Gly Ser Thr Ala Gly Ile Ala Gln Leu
500 505 510
Pro Leu His Arg Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys
515 520 525
Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg
530 535 540
Tyr Phe Pro Thr Ala Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn
545 550 555 560
Gly Asp Pro Leu Thr His Cys Ser Asp Leu Gln His His Asp Asn His
565 570 575
His Gly His Ser Pro Glu Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser
580 585 590
Ser Thr Phe Leu Glu Cys Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr
595 600 605
Trp Gln Phe Gln Arg Arg Asn Glu Glu Arg Lys Glu Glu Ile Arg Val
610 615 620
Asp Asp His Ile Ile Arg Thr Asp Gln Gly Leu Leu Leu Arg Ser Leu
625 630 635 640
Gln Arg Lys Asp Ser Gly Ser Tyr Leu Cys His Ala Val Glu His Gly
645 650 655
Phe Ile Gln Thr Leu Leu Lys Val Thr Leu Glu Val Ile Asp Thr Glu
660 665 670
His Leu Glu Glu Leu Leu His Lys Asp Asp Asp Gly Asp Gly Ser Lys
675 680 685
Thr Lys Glu Met Ser Asn Ser Met Thr Pro Ser Gln Lys Val Trp Tyr
690 695 700
Arg Asp Phe Met Gln Leu Ile Asn His Pro Asn Leu Asn Thr Met Asp
705 710 715 720
Glu Phe Cys Glu Gln Val Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln
725 730 735
Arg Pro Gly His Thr Gln Gly Asn Ser Asn Lys Trp Lys His Leu Gln
740 745 750
Glu Asn Lys Lys Gly Arg Asn Arg Arg Thr His Glu Phe Glu Arg Ala
755 760 765
Pro Arg Ser Val
770
<210> 603
<211> 752
<212> PRT
<213> 褐家鼠
<400> 603
Asn Tyr Ala Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile Glu Val Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Gln Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Val Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Ile Gly Ser Thr Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Leu Gln His His Asp Asn His His Gly His Ser
545 550 555 560
Leu Glu Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser Ser Thr Phe Leu
565 570 575
Glu Cys Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr Trp Gln Phe Gln
580 585 590
Arg Arg Asn Glu Asp Arg Lys Glu Glu Ile Arg Val Gly Asp His Ile
595 600 605
Ile Arg Thr Glu Gln Gly Leu Leu Leu Arg Ser Leu Gln Lys Lys Asp
610 615 620
Ser Gly Asn Tyr Leu Cys His Ala Val Glu His Gly Phe Met Gln Thr
625 630 635 640
Leu Leu Lys Val Thr Leu Glu Val Ile Asp Thr Glu His Leu Glu Glu
645 650 655
Leu Leu His Lys Asp Asp Asp Gly Asp Gly Ser Lys Thr Lys Glu Met
660 665 670
Ser Ser Ser Met Thr Pro Ser Gln Lys Val Trp Tyr Arg Asp Phe Met
675 680 685
Gln Leu Ile Asn His Pro Asn Leu Asn Thr Met Asp Glu Phe Cys Glu
690 695 700
Gln Val Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln Arg Pro Gly His
705 710 715 720
Ser Gln Gly Ser Ser Asn Lys Trp Lys His Met Gln Glu Ser Lys Lys
725 730 735
Gly Arg Asn Arg Arg Thr His Glu Phe Glu Arg Ala Pro Arg Ser Val
740 745 750
<210> 604
<211> 772
<212> PRT
<213> 野猪
<400> 604
Met Gly Trp Phe Ser Arg Ile Val Cys Leu Phe Trp Gly Val Leu Leu
1 5 10 15
Thr Ala Arg Ala Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu
20 25 30
Lys Leu Ser Tyr Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe
35 40 45
Asn Gly Leu Ala Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu
50 55 60
Glu Arg Ser Arg Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe
65 70 75 80
Asn Leu Val Asn Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser
85 90 95
Tyr Thr Arg Arg Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Lys
100 105 110
Glu Cys Ala Asn Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His
115 120 125
Leu Tyr Ala Cys Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile
130 135 140
Glu Ile Gly His His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asp Ser
145 150 155 160
His Phe Glu Asn Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu
165 170 175
Thr Ala Ser Leu Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala
180 185 190
Asp Phe Met Gly Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His
195 200 205
His Pro Ile Arg Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro
210 215 220
Arg Phe Ile Ser Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp
225 230 235 240
Asp Lys Val Tyr Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His
245 250 255
Thr Gly Lys Ala Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp
260 265 270
Phe Gly Gly His Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys
275 280 285
Ala Arg Leu Ile Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His
290 295 300
Phe Asp Glu Leu Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys
305 310 315 320
Asn Pro Val Val Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys
325 330 335
Gly Ser Ala Val Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe
340 345 350
Leu Gly Pro Tyr Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro
355 360 365
Tyr Gln Gly Arg Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys
370 375 380
Thr Phe Gly Gly Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile
385 390 395 400
Thr Phe Ala Arg Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile
405 410 415
Asn Asn Arg Pro Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr
420 425 430
Gln Ile Val Val Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val
435 440 445
Met Phe Ile Gly Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile
450 455 460
Pro Lys Glu Thr Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met
465 470 475 480
Thr Val Phe Arg Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr
485 490 495
Lys Gln Gln Gln Leu Tyr Val Gly Ser Ala Ala Gly Val Ala Gln Leu
500 505 510
Pro Leu His Arg Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys
515 520 525
Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg
530 535 540
Tyr Phe Pro Thr Ala Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn
545 550 555 560
Gly Asp Pro Leu Thr His Cys Ser Asp Leu Gln His His Asp Asn His
565 570 575
Arg Gly His Asn Phe Glu Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser
580 585 590
Ser Thr Phe Leu Glu Cys Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr
595 600 605
Trp Gln Phe Gln Arg Arg Asn Glu Glu Arg Lys Glu Glu Ile Arg Val
610 615 620
Asp Asp His Ile Ile Arg Thr Glu Gln Gly Leu Leu Leu Arg Ser Leu
625 630 635 640
Gln Arg Lys Asp Ser Gly Ser Tyr Leu Cys His Ala Val Glu His Gly
645 650 655
Phe Met Gln Thr Leu Leu Lys Val Thr Leu Glu Val Ile Asp Thr Glu
660 665 670
His Leu Glu Glu Leu Leu His Lys Asp Asp Asp Gly Asp Ser Ser Lys
675 680 685
Thr Lys Glu Met Ser Asn Ser Met Thr Pro Ser Gln Lys Ile Trp Tyr
690 695 700
Arg Asp Phe Met Gln Leu Ile Asn His Pro Asn Leu Asn Thr Met Asp
705 710 715 720
Glu Phe Cys Glu Gln Val Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln
725 730 735
Arg Pro Gly His Thr Gln Gly Asn Ser Asn Lys Trp Lys His Leu Gln
740 745 750
Glu Asn Lys Lys Cys Arg Asn Arg Arg Thr His Glu Phe Glu Arg Ala
755 760 765
Pro Arg Ser Val
770
<210> 605
<211> 772
<212> PRT
<213> 家犬
<400> 605
Met Gly Trp Leu Ala Arg Ile Ala Cys Leu Phe Trp Gly Val Leu Leu
1 5 10 15
Thr Ala Thr Ala Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu
20 25 30
Lys Leu Ser Tyr Lys Glu Met Leu Glu Ser Asn Ser Val Ile Thr Phe
35 40 45
Asn Gly Leu Ala Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu
50 55 60
Glu Arg Ser Arg Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe
65 70 75 80
Asn Leu Val Asn Ile Lys Asp Phe Gln Lys Ile Val Trp Pro Val Ser
85 90 95
Tyr Thr Arg Arg Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Gln Lys
100 105 110
Glu Cys Ala Asn Phe Ile Lys Val Leu Lys Ala Tyr Asn Gln Thr His
115 120 125
Leu Tyr Ala Cys Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Ile
130 135 140
Glu Ile Gly His His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asp Ser
145 150 155 160
His Phe Glu Asn Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu
165 170 175
Thr Ala Ser Leu Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala
180 185 190
Asp Phe Met Gly Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly His His
195 200 205
His Pro Ile Arg Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro
210 215 220
Arg Phe Ile Ser Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp
225 230 235 240
Asp Lys Val Tyr Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His
245 250 255
Thr Gly Lys Ala Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp
260 265 270
Phe Gly Gly His Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys
275 280 285
Ala Arg Leu Ile Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His
290 295 300
Phe Asp Glu Leu Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys
305 310 315 320
Asn Pro Ile Val Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Lys
325 330 335
Gly Ser Ala Val Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe
340 345 350
Leu Gly Pro Tyr Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro
355 360 365
Tyr Gln Gly Arg Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys
370 375 380
Thr Phe Gly Gly Phe Asp Ser Thr Lys Asp Leu Pro Asp Asp Val Ile
385 390 395 400
Thr Phe Ala Arg Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile
405 410 415
Asn Asn Arg Pro Ile Met Ile Lys Thr Asp Val Asn Tyr Gln Phe Thr
420 425 430
Gln Ile Val Val Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val
435 440 445
Met Phe Ile Gly Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile
450 455 460
Pro Lys Glu Thr Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met
465 470 475 480
Thr Val Phe Arg Glu Pro Thr Pro Ile Ser Ala Met Glu Leu Ser Thr
485 490 495
Lys Gln His Gln Leu Tyr Ala Gly Ser Pro Ala Gly Leu Ala Gln Leu
500 505 510
Pro Leu Gln Arg Cys Ala Ala Tyr Gly Arg Ala Cys Ala Glu Cys Cys
515 520 525
Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Ala Ala Cys Ser Arg
530 535 540
Tyr Phe Pro Ala Ala Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn
545 550 555 560
Gly Asp Pro Leu Thr His Cys Ser Asp Leu Gln His His Asp Asn His
565 570 575
His Ser His Ser Leu Glu Glu Arg Ile Ile Tyr Gly Val Glu Asn Ser
580 585 590
Ser Thr Phe Leu Glu Cys Ser Pro Lys Ser Gln Arg Ala Leu Val Tyr
595 600 605
Trp Gln Phe Gln Arg Arg Asn Glu Glu Arg Lys Glu Glu Ile Arg Val
610 615 620
Asp Asp His Ile Ile Arg Thr Glu Gln Gly Leu Leu Leu Arg Ser Leu
625 630 635 640
Gln Arg Lys Asp Ser Gly Asn Tyr Leu Cys His Ala Val Glu His Gly
645 650 655
Phe Met Gln Thr Leu Leu Lys Val Thr Leu Glu Val Ile Asp Thr Glu
660 665 670
His Leu Glu Glu Leu Leu His Lys Asp Asp Asp Gly Asp Gly Ser Lys
675 680 685
Thr Lys Glu Ile Ser Asn Ser Met Thr Pro Ser Gln Lys Val Trp Tyr
690 695 700
Arg Asp Phe Met Gln Leu Ile Asn His Pro Asn Leu Asn Thr Met Asp
705 710 715 720
Glu Phe Cys Glu Gln Val Trp Lys Arg Asp Arg Lys Gln Arg Arg Gln
725 730 735
Arg Pro Gly His Thr Gln Gly Asn Ser Asn Lys Trp Lys His Leu Gln
740 745 750
Glu Asn Lys Lys Gly Arg Asn Arg Arg Thr His Glu Phe Glu Arg Ala
755 760 765
Pro Arg Ser Val
770
<210> 800
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 800
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 801
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 801
Ser Tyr Tyr Met Ser
1 5
<210> 802
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 802
Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Asp
<210> 803
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 803
Gly Gly Gln Gly Ala Met Asp Tyr
1 5
<210> 804
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 804
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 805
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 805
Arg Ala Ser Gln Ser Ile Gly Asp Tyr Leu His
1 5 10
<210> 806
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 806
Tyr Ala Ser Gln Ser Ile Ser
1 5
<210> 807
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 807
Gln Gln Gly Tyr Ser Phe Pro Tyr Thr
1 5
<210> 808
<211> 351
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 808
gaagtgcagc tggtggaatc tggcggagga ctggttcaac ctggcggctc tctgagactg 60
tcttgtgccg ccagcggctt caccttcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc tccagagaca acagcaagaa caccctgtac 240
ctgcagatga gcagcctgag agccgaggat accgccgtgt actactgtgt tagaggcgga 300
cagggcgcca tggattattg gggccaggga accacagtga ccgtgtcatc a 351
<210> 809
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 809
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gattaagtac gccagccagt ccatcagcgg catccctgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccatcaccag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa a 321
<210> 810
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 810
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 811
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 811
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 812
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 812
gaagtgcagc tggtggaatc tggcggagga ctggttcaac ctggcggctc tctgagactg 60
tcttgtgccg ccagcggctt caccttcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc tccagagaca acagcaagaa caccctgtac 240
ctgcagatga gcagcctgag agccgaggat accgccgtgt actactgtgt tagaggcgga 300
cagggcgcca tggattattg gggccaggga accacagtga ccgtgtcatc agccagcacc 360
aagggcccca gcgtgttccc tctggcccct agcagcaaga gcacatctgg cggaacagcc 420
gccctgggct gcctcgtgaa ggactacttt cccgagcccg tgaccgtgtc ctggaactct 480
ggcgctctga caagcggcgt gcacaccttt ccagccgtgc tgcagagcag cggcctgtac 540
tctctgagca gcgtcgtgac agtgcccagc agctctctgg gcacccagac ctacatctgc 600
aacgtgaacc acaagcccag caacaccaag gtggacaaga aggtggaacc caagagctgc 660
gacaagaccc acacctgtcc cccttgtcct gcccccgaac tgctgggagg cccttccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccacgaggac cctgaagtga agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cctagagagg aacagtacaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggc cctgcctgcc cccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcccccaa gcagggacga gctgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcaagctg accgtggaca agtcccggtg gcagcagggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgagcctga gccctggcaa g 1341
<210> 813
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 813
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gattaagtac gccagccagt ccatcagcgg catccctgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccatcaccag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa acgaaccgtg gccgctccca gcgtgttcat cttcccacct 360
agcgacgagc agctgaagtc cggcacagcc tctgtcgtgt gcctgctgaa caacttctac 420
ccccgcgagg ccaaggtgca gtggaaggtg gacaatgccc tgcagagcgg caacagccag 480
gaaagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtctagcc ccgtgaccaa gagcttcaac cggggcgagt gt 642
<210> 814
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 814
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 815
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 815
Ser Tyr Tyr Met Ser
1 5
<210> 816
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 816
Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Asp
<210> 817
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 817
Gly Gly Gln Gly Ala Met Asp Tyr
1 5
<210> 818
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 818
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 819
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 819
Arg Ala Ser Gln Ser Ile Gly Asp Tyr Leu His
1 5 10
<210> 820
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 820
Tyr Ala Ser Gln Ser Ile Ser
1 5
<210> 821
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 821
Gln Gln Gly Tyr Ser Phe Pro Tyr Thr
1 5
<210> 822
<211> 351
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 822
gaagtgcagc tggtggaatc tggcggagga ctggttcaac ctggcggctc tctgagactg 60
tcttgtgccg cctctggctt cccattcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga gcagcctgag agccgaggat accgccgtgt actactgtgt tagaggcgga 300
cagggcgcca tggattattg gggccaggga accacagtga ccgtgtcatc a 351
<210> 823
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 823
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gattaagtac gccagccagt ccatcagcgg catccctgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccatcaccag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa a 321
<210> 824
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 824
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 825
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 825
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 826
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 826
gaagtgcagc tggtggaatc tggcggagga ctggttcaac ctggcggctc tctgagactg 60
tcttgtgccg cctctggctt cccattcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga gcagcctgag agccgaggat accgccgtgt actactgtgt tagaggcgga 300
cagggcgcca tggattattg gggccaggga accacagtga ccgtgtcatc agccagcacc 360
aagggcccca gcgtgttccc tctggcccct agcagcaaga gcacatctgg cggaacagcc 420
gccctgggct gcctcgtgaa ggactacttt cccgagcccg tgaccgtgtc ctggaactct 480
ggcgctctga caagcggcgt gcacaccttt ccagccgtgc tgcagagcag cggcctgtac 540
tctctgagca gcgtcgtgac agtgcccagc agctctctgg gcacccagac ctacatctgc 600
aacgtgaacc acaagcccag caacaccaag gtggacaaga aggtggaacc caagagctgc 660
gacaagaccc acacctgtcc cccttgtcct gcccccgaac tgctgggagg cccttccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccacgaggac cctgaagtga agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cctagagagg aacagtacaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggc cctgcctgcc cccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcccccaa gcagggacga gctgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcaagctg accgtggaca agtcccggtg gcagcagggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgagcctga gccctggcaa g 1341
<210> 827
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 827
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gattaagtac gccagccagt ccatcagcgg catccctgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccatcaccag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa acgaaccgtg gccgctccca gcgtgttcat cttcccacct 360
agcgacgagc agctgaagtc cggcacagcc tctgtcgtgt gcctgctgaa caacttctac 420
ccccgcgagg ccaaggtgca gtggaaggtg gacaatgccc tgcagagcgg caacagccag 480
gaaagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtctagcc ccgtgaccaa gagcttcaac cggggcgagt gt 642
<210> 828
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 828
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Leu Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Lys Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 829
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 829
Ser Tyr Tyr Met Ser
1 5
<210> 830
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 830
Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Asp
<210> 831
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 831
Gly Gly Gln Gly Ala Met Asp Tyr
1 5
<210> 832
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 832
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 833
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 833
Arg Ala Ser Gln Ser Ile Gly Asp Tyr Leu His
1 5 10
<210> 834
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 834
Tyr Ala Ser Gln Ser Ile Ser
1 5
<210> 835
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 835
Gln Gln Gly Tyr Ser Phe Pro Tyr Thr
1 5
<210> 836
<211> 351
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 836
gaagtgcagc tggtggaatc tggcggagga ctggttcagc tcggcggatc tctgagactg 60
tcttgtgccg ccagcggctt caccttcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc tccagagaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgt gaaaggtgga 300
cagggcgcca tggactattg gggccaggga acaacagtga ccgtgtcctc a 351
<210> 837
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 837
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gatctactat gccagccagt ccatcagcgg catccccgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccataagcag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa a 321
<210> 838
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 838
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Leu Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Lys Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 839
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 839
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 840
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 840
gaagtgcagc tggtggaatc tggcggagga ctggttcagc tcggcggatc tctgagactg 60
tcttgtgccg ccagcggctt caccttcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc tccagagaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgt gaaaggtgga 300
cagggcgcca tggactattg gggccaggga acaacagtga ccgtgtcctc agccagcacc 360
aagggcccca gcgtgttccc tctggcccct agcagcaaga gcacatctgg cggaacagcc 420
gccctgggct gcctcgtgaa ggactacttt cccgagcccg tgaccgtgtc ctggaactct 480
ggcgctctga caagcggcgt gcacaccttt ccagccgtgc tgcagagcag cggcctgtac 540
tctctgagca gcgtcgtgac agtgcccagc agctctctgg gcacccagac ctacatctgc 600
aacgtgaacc acaagcccag caacaccaag gtggacaaga aggtggaacc caagagctgc 660
gacaagaccc acacctgtcc cccttgtcct gcccccgaac tgctgggagg cccttccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccacgaggac cctgaagtga agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cctagagagg aacagtacaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggc cctgcctgcc cccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcccccaa gcagggacga gctgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcaagctg accgtggaca agtcccggtg gcagcagggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgagcctga gccctggcaa g 1341
<210> 841
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 841
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gatctactat gccagccagt ccatcagcgg catccccgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccataagcag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa acgaaccgtg gccgctccca gcgtgttcat cttcccacct 360
agcgacgagc agctgaagtc cggcacagcc tctgtcgtgt gcctgctgaa caacttctac 420
ccccgcgagg ccaaggtgca gtggaaggtg gacaatgccc tgcagagcgg caacagccag 480
gaaagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtctagcc ccgtgaccaa gagcttcaac cggggcgagt gt 642
<210> 842
<211> 117
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 842
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Leu Gln Leu Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asn
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Lys Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 843
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 843
Ser Tyr Tyr Met Ser
1 5
<210> 844
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 844
Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val Lys
1 5 10 15
Asp
<210> 845
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 845
Gly Gly Gln Gly Ala Met Asp Tyr
1 5
<210> 846
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 846
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 847
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 847
Arg Ala Ser Gln Ser Ile Gly Asp Tyr Leu His
1 5 10
<210> 848
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 848
Tyr Ala Ser Gln Ser Ile Ser
1 5
<210> 849
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 849
Gln Gln Gly Tyr Ser Phe Pro Tyr Thr
1 5
<210> 850
<211> 351
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 850
gaagtgcagc tggtggaatc tggcggagga ctgctgcagc ttggcggatc tctgagactg 60
tcttgtgccg ccagcggctt caccttcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc tccagagaca acagcaagaa caccctgaac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgt gaaaggtgga 300
cagggcgcca tggactattg gggccaggga acaacagtga ccgtgtcctc a 351
<210> 851
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 851
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gattaagtac gccagccagt ccatcagcgg catccctgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccataagcag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa a 321
<210> 852
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 852
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Leu Gln Leu Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ile Lys Ser Gly Gly Tyr Ala Tyr Tyr Pro Asp Ser Val
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asn
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Lys Gly Gly Gln Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 853
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 853
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Asp Tyr
20 25 30
Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 854
<211> 1341
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 854
gaagtgcagc tggtggaatc tggcggagga ctgctgcagc ttggcggatc tctgagactg 60
tcttgtgccg ccagcggctt caccttcagc agctactaca tgagctgggt ccgacaggcc 120
cctggcaaag gacttgaatg ggtgtccacc atcatcaaga gcggcggcta cgcctactat 180
cccgacagcg tgaaggaccg gttcaccatc tccagagaca acagcaagaa caccctgaac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgt gaaaggtgga 300
cagggcgcca tggactattg gggccaggga acaacagtga ccgtgtcctc agccagcacc 360
aagggcccca gcgtgttccc tctggcccct agcagcaaga gcacatctgg cggaacagcc 420
gccctgggct gcctcgtgaa ggactacttt cccgagcccg tgaccgtgtc ctggaactct 480
ggcgctctga caagcggcgt gcacaccttt ccagccgtgc tgcagagcag cggcctgtac 540
tctctgagca gcgtcgtgac agtgcccagc agctctctgg gcacccagac ctacatctgc 600
aacgtgaacc acaagcccag caacaccaag gtggacaaga aggtggaacc caagagctgc 660
gacaagaccc acacctgtcc cccttgtcct gcccccgaac tgctgggagg cccttccgtg 720
ttcctgttcc ccccaaagcc caaggacacc ctgatgatca gccggacccc cgaagtgacc 780
tgcgtggtgg tggatgtgtc ccacgaggac cctgaagtga agttcaattg gtacgtggac 840
ggcgtggaag tgcacaacgc caagaccaag cctagagagg aacagtacaa cagcacctac 900
cgggtggtgt ccgtgctgac agtgctgcac caggactggc tgaacggcaa agagtacaag 960
tgcaaggtgt ccaacaaggc cctgcctgcc cccatcgaga aaaccatcag caaggccaag 1020
ggccagcccc gcgaacccca ggtgtacaca ctgcccccaa gcagggacga gctgaccaag 1080
aaccaggtgt ccctgacctg tctcgtgaaa ggcttctacc cctccgatat cgccgtggaa 1140
tgggagagca acggccagcc cgagaacaac tacaagacca ccccccctgt gctggacagc 1200
gacggctcat tcttcctgta cagcaagctg accgtggaca agtcccggtg gcagcagggc 1260
aacgtgttca gctgcagcgt gatgcacgag gccctgcaca accactacac ccagaagtcc 1320
ctgagcctga gccctggcaa g 1341
<210> 855
<211> 642
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 855
gagattgtgc tgacacagtc tcccgccaca ctgtctctta gccctggcga aagagccaca 60
ctgagctgta gagccagcca gagcatcggc gattacctgc actggtatca gcagaagcct 120
ggacaggccc ctcggctgct gattaagtac gccagccagt ccatcagcgg catccctgcc 180
agattttctg gcagcggctc tggcaccgat ttcaccctga ccataagcag cctggaacct 240
gaggacttcg ccgtgtacta ctgccagcag ggctacagct tcccctacac atttggcgga 300
ggcaccaagc tggaaatcaa acgaaccgtg gccgctccca gcgtgttcat cttcccacct 360
agcgacgagc agctgaagtc cggcacagcc tctgtcgtgt gcctgctgaa caacttctac 420
ccccgcgagg ccaaggtgca gtggaaggtg gacaatgccc tgcagagcgg caacagccag 480
gaaagcgtga ccgagcagga cagcaaggac tccacctaca gcctgagcag caccctgacc 540
ctgagcaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac ccaccagggc 600
ctgtctagcc ccgtgaccaa gagcttcaac cggggcgagt gt 642
<210> 856
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 856
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
20 25 30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Thr Glu Gly Ser Gly Val Gly Thr Ser Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Met Leu Gly Gly Gly Asn Pro Leu Asp Tyr Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 857
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 857
Ser Tyr Ala Val His
1 5
<210> 858
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 858
Ser Thr Glu Gly Ser Gly Val Gly Thr Ser Tyr Thr Asp Ser Val Lys
1 5 10 15
Gly
<210> 859
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 859
Met Leu Gly Gly Gly Asn Pro Leu Asp Tyr Leu Asp Tyr
1 5 10
<210> 860
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 860
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Leu Gly Glu Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Tyr Ser Asp Phe Arg Pro Ser Gly Val Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser
85 90 95
Leu Ser Ser Gln Val Phe Gly Gly Gly Thr Gln Val Thr Val Leu
100 105 110
<210> 861
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 861
Ser Gly Ser Ser Ser Asn Leu Gly Glu Gly Tyr Asp Val His
1 5 10
<210> 862
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 862
Tyr Ser Asp Phe Arg Pro Ser
1 5
<210> 863
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 863
Ala Ala Trp Asp Asp Ser Leu Ser Ser Gln Val
1 5 10
<210> 864
<211> 366
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 864
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttaga agctatgccg tgcactgggt ccgacaggcc 120
cctggaaaag gactggaatg ggtgtccagc accgaaggct ctggcgtggg cacaagctac 180
accgattctg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaatgctc 300
ggcggaggca accctctgga ctacctggat tattggggcc agggcaccct ggtcacagtc 360
tcttca 366
<210> 865
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 865
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caatctcggc gagggctatg acgtgcactg gtatcagcag 120
ctgcctggca aggcccctaa actgctgatc tactacagcg acttcagacc cagcggcgtg 180
tccgatagat tcagcggctc taagagcggc acatctgcca gcctggccat ctctggactg 240
cagagcgaag atgaggccga ctactattgc gccgcctggg atgatagcct gagcagccaa 300
gtttttggcg gcggaaccca agtgaccgtg cta 333
<210> 866
<211> 452
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 866
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
20 25 30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Thr Glu Gly Ser Gly Val Gly Thr Ser Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Met Leu Gly Gly Gly Asn Pro Leu Asp Tyr Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
115 120 125
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
130 135 140
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
165 170 175
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
180 185 190
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
195 200 205
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
210 215 220
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
225 230 235 240
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
245 250 255
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
260 265 270
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
275 280 285
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
290 295 300
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
305 310 315 320
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
325 330 335
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
340 345 350
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
355 360 365
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
370 375 380
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
385 390 395 400
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
405 410 415
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
420 425 430
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
435 440 445
Ser Pro Gly Lys
450
<210> 867
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 867
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Leu Gly Glu Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Tyr Ser Asp Phe Arg Pro Ser Gly Val Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser
85 90 95
Leu Ser Ser Gln Val Phe Gly Gly Gly Thr Gln Val Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 868
<211> 1356
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 868
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttaga agctatgccg tgcactgggt ccgacaggcc 120
cctggaaaag gactggaatg ggtgtccagc accgaaggct ctggcgtggg cacaagctac 180
accgattctg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaatgctc 300
ggcggaggca accctctgga ctacctggat tattggggcc agggcaccct ggtcacagtc 360
tcttcagcca gcaccaaggg ccccagcgtg ttccctctgg cccctagcag caagagcaca 420
tctggcggaa cagccgccct gggctgcctc gtgaaggact actttcccga gcccgtgacc 480
gtgtcctgga actctggcgc tctgacaagc ggcgtgcaca cctttccagc cgtgctgcag 540
agcagcggcc tgtactctct gagcagcgtc gtgacagtgc ccagcagctc tctgggcacc 600
cagacctaca tctgcaacgt gaaccacaag cccagcaaca ccaaggtgga caagaaggtg 660
gaacccaaga gctgcgacaa gacccacacc tgtccccctt gtcctgcccc cgaactgctg 720
ggaggccctt ccgtgttcct gttcccccca aagcccaagg acaccctgat gatcagccgg 780
acccccgaag tgacctgcgt ggtggtggat gtgtcccacg aggaccctga agtgaagttc 840
aattggtacg tggacggcgt ggaagtgcac aacgccaaga ccaagcctag agaggaacag 900
tacaacagca cctaccgggt ggtgtccgtg ctgacagtgc tgcaccagga ctggctgaac 960
ggcaaagagt acaagtgcaa ggtgtccaac aaggccctgc ctgcccccat cgagaaaacc 1020
atcagcaagg ccaagggcca gccccgcgaa ccccaggtgt acacactgcc cccaagcagg 1080
gacgagctga ccaagaacca ggtgtccctg acctgtctcg tgaaaggctt ctacccctcc 1140
gatatcgccg tggaatggga gagcaacggc cagcccgaga acaactacaa gaccaccccc 1200
cctgtgctgg acagcgacgg ctcattcttc ctgtacagca agctgaccgt ggacaagtcc 1260
cggtggcagc agggcaacgt gttcagctgc agcgtgatgc acgaggccct gcacaaccac 1320
tacacccaga agtccctgag cctgagccct ggcaag 1356
<210> 869
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 869
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caatctcggc gagggctatg acgtgcactg gtatcagcag 120
ctgcctggca aggcccctaa actgctgatc tactacagcg acttcagacc cagcggcgtg 180
tccgatagat tcagcggctc taagagcggc acatctgcca gcctggccat ctctggactg 240
cagagcgaag atgaggccga ctactattgc gccgcctggg atgatagcct gagcagccaa 300
gtttttggcg gcggaaccca agtgaccgtg ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 870
<211> 122
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 870
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
20 25 30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Thr Glu Gly Ser Gly Val Gly Thr Ser Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Met Leu Gly Gly Gly Asn Pro Leu Asp Tyr Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 871
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 871
Ser Tyr Ala Val His
1 5
<210> 872
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 872
Ser Thr Glu Gly Ser Gly Val Gly Thr Ser Tyr Thr Asp Ser Val Lys
1 5 10 15
Gly
<210> 873
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 873
Met Leu Gly Gly Gly Asn Pro Leu Asp Tyr Leu Asp Tyr
1 5 10
<210> 874
<211> 111
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 874
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Leu Gly Glu Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Tyr Ser Asp Phe Arg Pro Ser Gly Val Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser
85 90 95
Leu Ser Ser Gln Val Phe Gly Gly Gly Thr Gln Val Thr Val Leu
100 105 110
<210> 875
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 875
Ser Gly Ser Ser Ser Asn Leu Gly Glu Gly Tyr Asp Val His
1 5 10
<210> 876
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 876
Tyr Ser Asp Phe Arg Pro Ser
1 5
<210> 877
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 877
Ala Ala Trp Asp Asp Ser Leu Ser Ser Gln Val
1 5 10
<210> 878
<211> 366
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 878
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttaga agctatgccg tgcactgggt ccgacaggcc 120
cctggaaaag gactggaatg ggtgtccagc accgaaggct ctggcgtggg cacaagctac 180
accgattctg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaatgctc 300
ggcggaggca accctctgga ctacctggat tattggggcc agggcaccct ggtcacagtc 360
tcttca 366
<210> 879
<211> 333
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 879
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caatctcggc gagggctatg acgtgcactg gtatcagcag 120
ctgcctggca aggcccctaa actgctgatc tactacagcg acttcagacc cagcggcgtg 180
tccgatagat tcagcggctc taagagcggc acatctgcca gcctggccat ctctggactg 240
cagagcgaag atgaggccga ctactattgc gccgcctggg atgatagcct gagcagccaa 300
gtttttggcg gcggaaccca agtgaccgtg cta 333
<210> 880
<211> 251
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 880
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
20 25 30
Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Thr Glu Gly Ser Gly Val Gly Thr Ser Tyr Thr Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Met Leu Gly Gly Gly Asn Pro Leu Asp Tyr Leu Asp Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
115 120 125
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
130 135 140
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
165 170 175
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
180 185 190
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
195 200 205
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
210 215 220
Cys Ala Ala Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Ser
225 230 235 240
Gly Ser Ala Ala Ala His His His His His His
245 250
<210> 881
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗体序列
<400> 881
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Leu Gly Glu Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Tyr Ser Asp Phe Arg Pro Ser Gly Val Ser Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser
85 90 95
Leu Ser Ser Gln Val Phe Gly Gly Gly Thr Gln Val Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
<210> 882
<211> 753
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 882
gaagttcagc tgctggaatc tggcggcgga ctggttcaac ctggcggatc tctgagactg 60
agctgtgccg ccagcggctt cacctttaga agctatgccg tgcactgggt ccgacaggcc 120
cctggaaaag gactggaatg ggtgtccagc accgaaggct ctggcgtggg cacaagctac 180
accgattctg tgaagggcag attcaccatc agccgggaca acagcaagaa caccctgtac 240
ctgcagatga acagcctgag agccgaggac accgccgtgt actactgtgc cagaatgctc 300
ggcggaggca accctctgga ctacctggat tattggggcc agggcaccct ggtcacagtc 360
tcttcagcct ccaccaaggg cccatcggtg ttccccctgg caccctcctc caagagcacc 420
tctgggggca cagcggccct gggctgcctg gtcaaggact acttccccga accggtgacg 480
gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttcccggc tgtcctacag 540
tcctcaggac tctactccct cagcagcgtg gtgaccgtgc cctccagcag cttgggcacc 600
cagacctaca tctgcaacgt gaatcacaag cccagcaaca ccaaggtgga caagaaagtt 660
gagcccaaat cttgtgcagc gggttctgaa caaaaactca tctcagaaga ggatctgtct 720
ggatcagcgg ccgcccatca tcatcatcat cat 753
<210> 883
<211> 651
<212> DNA
<213> 人工序列
<220>
<223> 抗体序列
<400> 883
cagtctgttc tgacacagcc tcctagcgcc tctggcacac ctggacagag agtgaccatc 60
agctgtagcg gcagcagctc caatctcggc gagggctatg acgtgcactg gtatcagcag 120
ctgcctggca aggcccctaa actgctgatc tactacagcg acttcagacc cagcggcgtg 180
tccgatagat tcagcggctc taagagcggc acatctgcca gcctggccat ctctggactg 240
cagagcgaag atgaggccga ctactattgc gccgcctggg atgatagcct gagcagccaa 300
gtttttggcg gcggaaccca agtgaccgtg ctaggccagc ctaaagccgc ccctagcgtg 360
accctgttcc ctccaagcag cgaggaactg caggccaaca aggccaccct cgtgtgcctg 420
atcagcgact tctatcctgg cgccgtgacc gtggcctgga aggccgatag ctctcctgtg 480
aaggccggcg tggaaaccac cacccctagc aagcagagca acaacaaata cgccgccagc 540
agctacctga gcctgacccc cgagcagtgg aagtcccaca gatcctacag ctgccaagtg 600
acccacgagg gcagcaccgt ggaaaagaca gtggccccta ccgagtgcag c 651
<210> 884
<211> 563
<212> PRT
<213> 穴兔(Oryctolagus cuniculus)(兔)
<400> 884
Asn Tyr Gln Asn Gly Lys Asn Asn Val Pro Arg Leu Lys Leu Ser Tyr
1 5 10 15
Lys Glu Met Leu Glu Ser Asn Asn Val Ile Thr Phe Asn Gly Leu Ala
20 25 30
Asn Ser Ser Ser Tyr His Thr Phe Leu Leu Asp Glu Glu Arg Ser Arg
35 40 45
Leu Tyr Val Gly Ala Lys Asp His Ile Phe Ser Phe Asn Leu Val Asn
50 55 60
Ile Lys Asp Phe Gln Lys Ile Ala Trp Pro Val Ser Tyr Thr Arg Arg
65 70 75 80
Asp Glu Cys Lys Trp Ala Gly Lys Asp Ile Leu Arg Glu Cys Ala Asn
85 90 95
Phe Ile Lys Val Leu Lys Val Tyr Asn Gln Thr His Leu Tyr Ala Cys
100 105 110
Gly Thr Gly Ala Phe His Pro Ile Cys Thr Tyr Val Gly Ile Gly His
115 120 125
His Pro Glu Asp Asn Ile Phe Lys Leu Glu Asp Ser His Phe Glu Asn
130 135 140
Gly Arg Gly Lys Ser Pro Tyr Asp Pro Lys Leu Leu Thr Ala Ser Leu
145 150 155 160
Leu Ile Asp Gly Glu Leu Tyr Ser Gly Thr Ala Ala Asp Phe Met Gly
165 170 175
Arg Asp Phe Ala Ile Phe Arg Thr Leu Gly Gln His His Pro Ile Arg
180 185 190
Thr Glu Gln His Asp Ser Arg Trp Leu Asn Asp Pro Arg Phe Ile Ser
195 200 205
Ala His Leu Ile Pro Glu Ser Asp Asn Pro Glu Asp Asp Lys Val Tyr
210 215 220
Phe Phe Phe Arg Glu Asn Ala Ile Asp Gly Glu His Ser Gly Lys Ala
225 230 235 240
Thr His Ala Arg Ile Gly Gln Ile Cys Lys Asn Asp Phe Gly Gly His
245 250 255
Arg Ser Leu Val Asn Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ile
260 265 270
Cys Ser Val Pro Gly Pro Asn Gly Ile Asp Thr His Phe Asp Glu Leu
275 280 285
Gln Asp Val Phe Leu Met Asn Ser Lys Asp Pro Lys Asn Pro Ile Val
290 295 300
Tyr Gly Val Phe Thr Thr Ser Ser Asn Ile Phe Arg Gly Ser Ala Val
305 310 315 320
Cys Met Tyr Ser Met Ser Asp Val Arg Arg Val Phe Leu Gly Pro Tyr
325 330 335
Ala His Arg Asp Gly Pro Asn Tyr Gln Trp Val Pro Phe Gln Gly Arg
340 345 350
Val Pro Tyr Pro Arg Pro Gly Thr Cys Pro Ser Lys Thr Phe Gly Gly
355 360 365
Phe Glu Ser Thr Lys Asp Leu Pro Asp Asp Val Ile Thr Phe Ala Arg
370 375 380
Ser His Pro Ala Met Tyr Asn Pro Val Phe Pro Ile Asn Asn Arg Pro
385 390 395 400
Ile Met Val Lys Thr Asp Val Asn Tyr Gln Phe Thr Gln Ile Val Val
405 410 415
Asp Arg Val Asp Ala Glu Asp Gly Gln Tyr Asp Val Met Phe Ile Gly
420 425 430
Thr Asp Val Gly Thr Val Leu Lys Val Val Ser Ile Pro Lys Glu Thr
435 440 445
Trp His Asp Leu Glu Glu Val Leu Leu Glu Glu Met Thr Val Phe Arg
450 455 460
Glu Pro Thr Thr Ile Ser Ala Met Glu Leu Ser Thr Lys Gln Gln Gln
465 470 475 480
Leu Tyr Val Gly Ser Ala Ala Gly Val Ala Gln Leu Pro Leu His Arg
485 490 495
Cys Asp Ile Tyr Gly Lys Ala Cys Ala Glu Cys Cys Leu Ala Arg Asp
500 505 510
Pro Tyr Cys Ala Trp Asp Gly Ser Ser Cys Ser Arg Tyr Phe Pro Thr
515 520 525
Ala Lys Arg Arg Thr Arg Arg Gln Asp Ile Arg Asn Gly Asp Pro Leu
530 535 540
Thr His Cys Ser Asp Gly Gly Ile Glu Gly Arg Met Asp His His His
545 550 555 560
His His His
<210> 885
<211> 1689
<212> DNA
<213> 穴兔(兔)
<400> 885
aactatcaga acggcaagaa caacgtgccc cggctgaagc tgagctacaa agagatgctg 60
gaaagcaaca acgtgatcac cttcaacggc ctggccaaca gcagcagcta ccacaccttt 120
ctgctggacg aggaacggtc cagactgtac gtgggagcca aggaccacat cttcagcttc 180
aacctggtca acatcaagga cttccagaaa atcgcctggc ctgtgtccta caccagacgg 240
gatgagtgta aatgggccgg caaggacatc ctgagagagt gcgccaactt catcaaggtg 300
ctgaaggtgt acaatcagac ccacctgtac gcctgtggca ccggcgcttt tcaccctatc 360
tgtacctatg tcggcatcgg ccaccatcct gaggacaata tcttcaagct cgaggacagc 420
cacttcgaga acggcagagg caagagcccc tacgatccca aactgctgac agcctctctg 480
ctgatcgacg gcgagctgta ttctggcaca gccgccgatt tcatgggcag agacttcgcc 540
atcttcagaa ccctgggcca gcatcacccc atcagaaccg agcagcacga cagcagatgg 600
ctgaacgacc ccagattcat cagcgcccat ctgatccccg agagcgacaa ccccgaggac 660
gacaaggtgt acttcttctt ccgggaaaac gccatcgacg gggagcactc tggaaaagcc 720
acacacgcca gaatcggcca gatctgcaag aacgacttcg gcggccacag atccctcgtg 780
aacaagtgga ccaccttcct gaaggcccgg ctgatctgtt ctgtgcccgg acctaatggc 840
atcgataccc acttcgacga gctgcaggac gtgttcctga tgaacagcaa ggaccccaag 900
aatcccatcg tgtacggcgt gttcaccacc agcagcaaca tctttagagg cagcgccgtg 960
tgcatgtaca gcatgtccga tgtgcggaga gtgtttctgg gcccctacgc tcacagagat 1020
ggccccaatt atcagtgggt gccattccag ggcagagtgc cctatcctag acctggcacc 1080
tgtcctagca agacctttgg cggcttcgag agcaccaagg acctgcctga cgatgtgatt 1140
accttcgcca gatctcaccc cgccatgtac aaccctgtgt tccccatcaa caacaggccc 1200
atcatggtca agaccgacgt gaactaccag ttcacccaga tcgtggtgga cagagtggat 1260
gccgaggacg gccagtacga cgtgatgttc atcggcaccg atgtgggcac cgtgctgaaa 1320
gtggtgtcta tccccaaaga gacatggcac gacctggaag aggtgctgct ggaagagatg 1380
accgtgttca gagagcccac caccatctcc gccatggaac tgagcacaaa acagcaacag 1440
ctgtatgtgg gctccgccgc tggtgttgct caactgcctc tgcacagatg cgacatctac 1500
ggcaaagcct gcgccgagtg ttgcctggcc agagatcctt actgtgcctg ggatggcagc 1560
agctgcagca gatactttcc caccgccaag cggagaacca gacggcagga tatcagaaac 1620
ggcgaccctc tgacacactg cagcgacggt ggcatcgagg gccgcatgga tcatcatcat 1680
caccatcat 1689
Claims (30)
1.结合人Sema3A的分离的抗体或其抗原结合片段,其中所述分离的抗体或其抗原结合片段
i)结合序列为SEQ ID NO:600的人Sema3A,解离常数(KD)≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM;
ii)与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,特别是其中所述分离的抗体或其抗原结合片段以≤50nM、≤20nM、≤10nM、≤1nM或≤0.1nM的解离常数(KD)结合小鼠、食蟹猴、大鼠、猪和/或狗Sema3A;
iii)结合序列为SEQ ID NO:600的人Sema3A,其结合活性经表面等离子共振(SPR)测定为≥60%、≥70%、≥80%或≥90%;
iv)在体外肾小球膜细胞迁移检测中抑制序列为SEQ ID NO:600的人Sema3A的活性,EC50≤10nM、≤5nM、≤2.5nM或≤1nM;
v)在体外生长锥塌陷检测中抑制序列为SEQ ID NO:600的人
Sema3A的活性,EC50≤50nM、≤25nM、≤10nM或≤5nM;
和/或
vi)在体外HUVEC排斥检测中抑制序列为SEQ ID NO:600的人
Sema3A的活性,EC50≤1nM或≤0.3nM、≤0.1nM、≤0.07nM、
≤0.06nM。
2.根据权利要求1所述的分离的抗体或抗原结合片段,其中所述分离的抗体或其抗原结合片段与小鼠、食蟹猴、大鼠、猪和/或狗Sema3A交叉反应,尤其是对小鼠、食蟹猴、大鼠、猪和/或狗Sema3A的亲和力比对人Sema3A的亲和力差小于100倍,特别地小于50倍,更特别地小于25倍,甚至更特别地小于10倍并且最特别地小于5倍。
3.根据权利要求1或2所述的分离的抗体或抗原结合片段,其中所述分离的抗体或其抗原结合片段与人Sema3B、Sema3C、Sema3D、Sema3E、Sema3F和/或Sema3G无显著交叉反应,特别地其中所述分离的抗体或其抗原结合片段与人Sema3G无显著交叉反应。
4.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其中所述分离的抗体或其抗原结合片段抑制Sema3A诱导的白蛋白尿和/或蛋白尿。
5.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其中所述分离的抗体或其抗原结合片段抑制Sema3A诱导的纤维化。
6.一种分离的抗体或其抗原结合片段,其与根据前述权利要求中任一项所述的分离的抗体或抗原结合片段竞争结合Sema3A,且其中所述分离的抗体或抗原结合片段不与包含i)SEQ ID NO:800和NO:804或ii)NO:810和NO:811的抗体竞争结合Sema3A。
7.根据权利要求1或2中任一项所述的分离的抗体或抗原结合片段,其包含
i)与SEQ ID NO:141至少90%、至少95%、至少98%、至少99%或100%一致的重链可变结构域以及与SEQ ID NO:145至少90%、至少95%、至少98%、至少99%或100%一致的轻链可变结构域;或
ii)与SEQ ID NO:61至少90%、至少95%、至少98%、至少99%或100%一致的重链可变结构域以及与SEQ ID NO:65至少90%、至少95%、至少98%、至少99%或100%一致的轻链可变结构域。
8.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其包含
i)a)包含含有序列RDDYTSRDAFDX(SEQ ID NO:594)的H-CDR3的重链抗原结合区,其中X选自Y和V,特别地其中X为Y;和b)包含含有序列X1AWDDSLNX2X3X4V(SEQ ID NO:598)的L-CDR3的轻链抗原结合区,其中X1选自A和H;其中X2选自V、D和G,特别地其中X2选自V和D;其中X3选自I和Y;并且其中X4选自P和V;或
ii)a)包含含有序列SGYSSSWFDPDFDY(SEQ ID NO:64)的H-CDR3的重链抗原结合区;和b)包含含有序列X1SYX2GX3NPYVV(SEQ ID NO:599)的L-CDR3的轻链抗原结合区,其中X1选自S和Q;其中X2选自E和A;并且其中X3选自P、I和S,特别地其中X3选自P和I。
9.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其包含
i)a)包含含有序列SYX1MX2(SEQ ID NO:588)的H-CDR1的重链抗原结合区,其中X1选自G和A并且其中X2选自H、S和L;特别是含有序列SYAMX(SEQ ID NO:589)的H-CDR1,其中X选自S和L;含有序列AIGX1GGDTYYADSVX2G(SEQ ID NO:590)的H-CDR2,其中X1选自T和Y,并且其中X2选自K和M;特别是含有序列AIGXGGDTYYADSVKG(SEQ ID NO:591)的H-CDR2,其中X选自T和Y;和含有序列RDDYTSRDAFDX(SEQ ID NO:594)的H-CDR3,其中X选自Y和V,特别地其中X为Y;和b)包含含有序列SGSSSNIGSNTVN(SEQ ID NO:46)的L-CDR1的轻链抗原结合区;含有序列YDDLXPS(SEQ ID NO:596)的L-CDR2,其中X选自L和R;特别是含有序列YDDLRPS(SEQ ID NO:127)的L-CDR2;和含有序列X1AWDDSLNX2X3X4V(SEQ ID NO:598)的L-CDR3,其中X1选自A和H;其中X2选自V、D和G,特别地其中X2选自V和D;其中X3选自I和Y;并且其中X4选自P和V;或
ii)a)包含含有序列SYEMN(SEQ ID NO:62)的H-CDR1的重链抗原结合区;含有序列GISWNSGX1IX2YADSVKG(SEQ ID NO:592)的H-CDR2,其中X1选自W和S并且X2选自G和D;特别是含有序列GISWNSGWIXYADSVKG(SEQ ID NO:593)的H-CDR2,其中X选自G和D;和含有序列SGYSSSWFDPDFDY(SEQ ID NO:64)的H-CDR3;和b)包含含有序列TGSSSXIGAGYDVH(SEQ IDNO:595)的L-CDR1的轻链抗原结合区,其中X选自N和D;含有序列GXSNRPS(SEQ ID NO:597)的L-CDR2,其中X选自N和A;和含有序列X1SYX2GX3NPYVV(SEQ ID NO:599)的L-CDR3,其中X1选自S和Q;其中X2选自E和A;并且其中X3选自P、I和S,特别地其中X3选自P和I。
10.根据权利要求8所述的分离的抗体或抗原结合片段,其中根据权利要求8的选项i)所述分离的抗体或抗原结合片段中与H-CDR1在其5’端直接相邻的氨基酸残基为S或Y;或其中根据权利要求8的选项ii)所述分离的抗体或抗原结合片段中与H-CDR1在其5’端直接相邻的三个氨基酸残基为X1FX2,其中X1选自T和D并且X2选自S和D。
11.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其包含
i)包含含有SEQ ID NO:42的H-CDR1、含有SEQ ID NO:43的H-CDR2和含有SEQ ID NO:44的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:46的L-CDR1、含有SEQ ID NO:47的L-CDR2和含有SEQ ID NO:48的L-CDR3的轻链抗原结合区;或
ii)包含含有SEQ ID NO:62的H-CDR1、含有SEQ ID NO:63的H-CDR2和含有SEQ ID NO:64的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:66的L-CDR1、含有SEQ ID NO:67的L-CDR2和含有SEQ ID NO:68的L-CDR3的轻链抗原结合区;或
iii)包含含有SEQ ID NO:102的H-CDR1、含有SEQ ID NO:103的H-CDR2和含有SEQ IDNO:104的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:106的L-CDR1、含有SEQ IDNO:107的L-CDR2和含有SEQ ID NO:108的L-CDR3的轻链抗原结合区;或
iv)包含含有SEQ ID NO:122的H-CDR1、含有SEQ ID NO:123的H-CDR2和含有SEQ IDNO:124的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:126的L-CDR1、含有SEQ IDNO:127的L-CDR2和含有SEQ ID NO:128的L-CDR3的轻链抗原结合区;或
v)包含含有SEQ ID NO:142的H-CDR1、含有SEQ ID NO:143的H-CDR2和含有SEQ ID NO:144的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:146的L-CDR1、含有SEQ ID NO:147的L-CDR2和含有SEQ ID NO:148的L-CDR3的轻链抗原结合区;或
vi)包含含有SEQ ID NO:162的H-CDR1、含有SEQ ID NO:163的H-CDR2和含有SEQ IDNO:164的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:166的L-CDR1、含有SEQ IDNO:167的L-CDR2和含有SEQ ID NO:168的L-CDR3的轻链抗原结合区;或
vii)包含含有SEQ ID NO:182的H-CDR1、含有SEQ ID NO:183的H-CDR2和含有SEQ IDNO:184的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:186的L-CDR1、含有SEQ IDNO:187的L-CDR2和含有SEQ ID NO:188的L-CDR3的轻链抗原结合区;或
viii)包含含有SEQ ID NO:202的H-CDR1、含有SEQ ID NO:203的H-CDR2和含有SEQ IDNO:204的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:206的L-CDR1、含有SEQ IDNO:207的L-CDR2和含有SEQ ID NO:208的L-CDR3的轻链抗原结合区;或
ix)包含含有SEQ ID NO:222的H-CDR1、含有SEQ ID NO:223的H-CDR2和含有SEQ IDNO:224的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:226的L-CDR1、含有SEQ IDNO:227的L-CDR2和含有SEQ ID NO:228的L-CDR3的轻链抗原结合区;或
x)包含含有SEQ ID NO:242的H-CDR1、含有SEQ ID NO:243的H-CDR2和含有SEQ ID NO:244的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:246的L-CDR1、含有SEQ ID NO:247的L-CDR2和含有SEQ ID NO:248的L-CDR3的轻链抗原结合区;或
xi)包含含有SEQ ID NO:262的H-CDR1、含有SEQ ID NO:263的H-CDR2和含有SEQ IDNO:264的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:266的L-CDR1、含有SEQ IDNO:267的L-CDR2和含有SEQ ID NO:268的L-CDR3的轻链抗原结合区;或
xii)包含含有SEQ ID NO:282的H-CDR1、含有SEQ ID NO:283的H-CDR2和含有SEQ IDNO:284的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:286的L-CDR1、含有SEQ IDNO:287的L-CDR2和含有SEQ ID NO:288的L-CDR3的轻链抗原结合区;或
xiii)包含含有SEQ ID NO:302的H-CDR1、含有SEQ ID NO:303的H-CDR2和含有SEQ IDNO:304的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:306的L-CDR1、含有SEQ IDNO:307的L-CDR2和含有SEQ ID NO:308的L-CDR3的轻链抗原结合区;或
xiv)包含含有SEQ ID NO:322的H-CDR1、含有SEQ ID NO:323的H-CDR2和含有SEQ IDNO:324的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:326的L-CDR1、含有SEQ IDNO:327的L-CDR2和含有SEQ ID NO:328的L-CDR3的轻链抗原结合区;或
xv)包含含有SEQ ID NO:342的H-CDR1、含有SEQ ID NO:343的H-CDR2和含有SEQ IDNO:344的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:346的L-CDR1、含有SEQ IDNO:347的L-CDR2和含有SEQ ID NO:348的L-CDR3的轻链抗原结合区;或
xvi)包含含有SEQ ID NO:362的H-CDR1、含有SEQ ID NO:363的H-CDR2和含有SEQ IDNO:364的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:366的L-CDR1、含有SEQ IDNO:367的L-CDR2和含有SEQ ID NO:368的L-CDR3的轻链抗原结合区;或
xvii)包含含有SEQ ID NO:382的H-CDR1、含有SEQ ID NO:383的H-CDR2和含有SEQ IDNO:384的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:386的L-CDR1、含有SEQ IDNO:387的L-CDR2和含有SEQ ID NO:388的L-CDR3的轻链抗原结合区;或
xviii)包含含有SEQ ID NO:402的H-CDR1、含有SEQ ID NO:403的H-CDR2和含有SEQ IDNO:404的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:406的L-CDR1、含有SEQ IDNO:407的L-CDR2和含有SEQ ID NO:408的L-CDR3的轻链抗原结合区;或
xix)包含含有SEQ ID NO:422的H-CDR1、含有SEQ ID NO:423的H-CDR2和含有SEQ IDNO:424的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:426的L-CDR1、含有SEQ IDNO:427的L-CDR2和含有SEQ ID NO:428的L-CDR3的轻链抗原结合区;或
xx)包含含有SEQ ID NO:442的H-CDR1、含有SEQ ID NO:443的H-CDR2和含有SEQ IDNO:444的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:446的L-CDR1、含有SEQ IDNO:447的L-CDR2和含有SEQ ID NO:448的L-CDR3的轻链抗原结合区;或
xxi)包含含有SEQ ID NO:462的H-CDR1、含有SEQ ID NO:463的H-CDR2和含有SEQ IDNO:464的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:466的L-CDR1、含有SEQ IDNO:467的L-CDR2和含有SEQ ID NO:468的L-CDR3的轻链抗原结合区;或
xxii)包含含有SEQ ID NO:482的H-CDR1、含有SEQ ID NO:483的H-CDR2和含有SEQ IDNO:484的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:486的L-CDR1、含有SEQ IDNO:487的L-CDR2和含有SEQ ID NO:488的L-CDR3的轻链抗原结合区;或
xxiii)包含含有SEQ ID NO:502的H-CDR1、含有SEQ ID NO:503的H-CDR2和含有SEQ IDNO:504的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:506的L-CDR1、含有SEQ IDNO:507的L-CDR2和含有SEQ ID NO:508的L-CDR3的轻链抗原结合区;或
xxiv)包含含有SEQ ID NO:522的H-CDR1、含有SEQ ID NO:523的H-CDR2和含有SEQ IDNO:524的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:526的L-CDR1、含有SEQ IDNO:527的L-CDR2和含有SEQ ID NO:528的L-CDR3的轻链抗原结合区;或
xxv)包含含有SEQ ID NO:542的H-CDR1、含有SEQ ID NO:543的H-CDR2和含有SEQ IDNO:544的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:546的L-CDR1、含有SEQ IDNO:547的L-CDR2和含有SEQ ID NO:548的L-CDR3的轻链抗原结合区;或
xxvi)包含含有SEQ ID NO:562的H-CDR1、含有SEQ ID NO:563的H-CDR2和含有SEQ IDNO:564的H-CDR3的重链抗原结合区以及包含含有SEQ ID NO:566的L-CDR1、含有SEQ IDNO:567的L-CDR2和含有SEQ ID NO:568的L-CDR3的轻链抗原结合区。
12.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其包含
i)含有SEQ ID NO:41的可变重链结构域和含有SEQ ID NO:45的可变轻链结构域;或
ii)含有SEQ ID NO:61的可变重链结构域和含有SEQ ID NO:65的可变轻链结构域;或
iii)含有SEQ ID NO:101的可变重链结构域和含有SEQ ID NO:105的可变轻链结构域;或
iv)含有SEQ ID NO:121的可变重链结构域和含有SEQ ID NO:125的可变轻链结构域;或
v)含有SEQ ID NO:141的可变重链结构域和含有SEQ ID NO:145的可变轻链结构域;或
vi)含有SEQ ID NO:161的可变重链结构域和含有SEQ ID NO:165的可变轻链结构域;或
vii)含有SEQ ID NO:181的可变重链结构域和含有SEQ ID NO:185的可变轻链结构域;或
viii)含有SEQ ID NO:201的可变重链结构域和含有SEQ ID NO:205的可变轻链结构域;或
ix)含有SEQ ID NO:221的可变重链结构域和含有SEQ ID NO:225的可变轻链结构域;或
x)含有SEQ ID NO:241的可变重链结构域和含有SEQ ID NO:245的可变轻链结构域;或
xi)含有SEQ ID NO:261的可变重链结构域和含有SEQ ID NO:265的可变轻链结构域;或
xii)含有SEQ ID NO:281的可变重链结构域和含有SEQ ID NO:285的可变轻链结构域;或
xiii)含有SEQ ID NO:301的可变重链结构域和含有SEQ ID NO:305的可变轻链结构域;或
xiv)含有SEQ ID NO:321的可变重链结构域和含有SEQ ID NO:325的可变轻链结构域;或
xv)含有SEQ ID NO:341的可变重链结构域和含有SEQ ID NO:345的可变轻链结构域;或
xvi)含有SEQ ID NO:361的可变重链结构域和含有SEQ ID NO:365的可变轻链结构域;或
xvii)含有SEQ ID NO:381的可变重链结构域和含有SEQ ID NO:385的可变轻链结构域;或
xviii)含有SEQ ID NO:401的可变重链结构域和含有SEQ ID NO:405的可变轻链结构域;或
xix)含有SEQ ID NO:421的可变重链结构域和含有SEQ ID NO:425的可变轻链结构域;或
xx)含有SEQ ID NO:441的可变重链结构域和含有SEQ ID NO:445的可变轻链结构域;或
xxi)含有SEQ ID NO:461的可变重链结构域和含有SEQ ID NO:465的可变轻链结构域;或
xxii)含有SEQ ID NO:481的可变重链结构域和含有SEQ ID NO:485的可变轻链结构域;或
xxiii)含有SEQ ID NO:501的可变重链结构域和含有SEQ ID NO:505的可变轻链结构域;或
xxiv)含有SEQ ID NO:521的可变重链结构域和含有SEQ ID NO:525的可变轻链结构域;或
xxv)含有SEQ ID NO:541的可变重链结构域和含有SEQ ID NO:545的可变轻链结构域;或
xxvi)含有SEQ ID NO:561的可变重链结构域和含有SEQ ID NO:565的可变轻链结构域。
13.根据前述权利要求中任一项所述的分离的抗体,其为IgG抗体,特别是IgG1或IgG4抗体。
14.根据前述权利要求中任一项所述的分离的抗体,其包含
i)含有SEQ ID NO:57的重链和含有SEQ ID NO:58的轻链;或
ii)含有SEQ ID NO:77的重链和含有SEQ ID NO:78的轻链;或
iii)含有SEQ ID NO:117的重链和含有SEQ ID NO:118的轻链;或
iv)含有SEQ ID NO:137的重链和含有SEQ ID NO:138的轻链;或
v)含有SEQ ID NO:157的重链和含有SEQ ID NO:158的轻链;或
vi)含有SEQ ID NO:177的重链和含有SEQ ID NO:178的轻链;或
vii)含有SEQ ID NO:197的重链和含有SEQ ID NO:198的轻链;或
viii)含有SEQ ID NO:217的重链和含有SEQ ID NO:218的轻链;
或
ix)含有SEQ ID NO:237的重链和含有SEQ ID NO:238的轻链;或
x)含有SEQ ID NO:257的重链和含有SEQ ID NO:258的轻链;或
xi)含有SEQ ID NO:277的重链和含有SEQ ID NO:278的轻链;或
xii)含有SEQ ID NO:297的重链和含有SEQ ID NO:298的轻链;或
xiii)含有SEQ ID NO:317的重链和含有SEQ ID NO:318的轻链;
或
xiv)含有SEQ ID NO:337的重链和含有SEQ ID NO:338的轻链;
或
xv)含有SEQ ID NO:357的重链和含有SEQ ID NO:358的轻链;或
xvi)含有SEQ ID NO:377的重链和含有SEQ ID NO:378的轻链;
或
xvii)含有SEQ ID NO:397的重链和含有SEQ ID NO:398的轻链;
或
xviii)含有SEQ ID NO:417的重链和含有SEQ ID NO:418的轻链;
或
xix)含有SEQ ID NO:437的重链和含有SEQ ID NO:438的轻链;
或
xx)含有SEQ ID NO:457的重链和含有SEQ ID NO:458的轻链;或
xxi)含有SEQ ID NO:477的重链和含有SEQ ID NO:478的轻链;
或
xxii)含有SEQ ID NO:497的重链和含有SEQ ID NO:498的轻链;
或
xxiii)含有SEQ ID NO:517的重链和含有SEQ ID NO:518的轻链;
或
xxiv)含有SEQ ID NO:537的重链和含有SEQ ID NO:538的轻链;
或
xxv)含有SEQ ID NO:557的重链和含有SEQ ID NO:558的轻链;
或
xxvi)含有SEQ ID NO:577的重链和含有SEQ ID NO:578的轻链。
15.根据前述权利要求中任一项所述的抗原结合片段,其为scFv、Fab、Fab’片段或F(ab’)2片段。
16.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其为单克隆抗体或其抗原结合片段。
17.根据前述权利要求中任一项所述的分离的抗体或抗原结合片段,其为人的、人源化的或嵌合的抗体或其抗原结合片段。
18.一种分离的抗体或其抗原结合片段,其与根据前述权利要求中任一项所述的分离的抗体或抗原结合片段竞争结合人Sema3A。
19.一种抗体偶联物,其包含根据前述权利要求中任一项所述的分离的抗体或抗原结合片段。
20.一种分离的核酸序列,其编码根据权利要求1至17中任一项所述的抗体或抗原结合片段。
21.一种载体,其包含根据权利要求19所述的核酸序列。
22.一种分离的细胞,其表达根据权利要求1至17中任一项所述的抗体或抗原结合片段和/或包含根据权利要求19所述的核酸或根据权利要求20所述的载体。
23.根据权利要求21所述的分离的细胞,其中所述细胞为原核或真核细胞。
24.一种生产根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段的方法,其包括培养根据权利要求21或22中任一项所述的细胞和任选地纯化抗体或其抗原结合片段。
25.一种药物组合物,其包含根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段或根据权利要求18所述的抗体偶联物。
26.根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段或根据权利要求18所述的偶联物或根据权利要求24所述的药物组合物,其用作药物。
27.根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段或根据权利要求18所述的抗体偶联物,其用作诊断试剂。
28.根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段或根据权利要求18所述的偶联物或根据权利要求24所述的药物组合物,其用于治疗和/或预防i)肾脏病,尤其是急性和慢性肾脏病、糖尿病肾病、Alport综合征、急性和慢性肾功能衰竭、多囊肾病(PCKD)和抗利尿激素分泌不当综合征(SIADH);ii)肾功能不全的后遗症,尤其是肺水肿、心力衰竭、尿毒症、贫血、电解质紊乱例如高钾血症和低钠血症以及骨骼和碳水化合物代谢紊乱;iii)血管通透性过高、糖尿病视网膜病变、血视网膜屏障受损、黄斑水肿尤其是年龄相关性黄斑水肿、非增殖性年龄相关性黄斑水肿和非增殖性糖尿病性黄斑水肿;iv)中枢或外周神经系统疾病尤其是神经病理性疼痛、脊髓损伤、多发性硬化、创伤性脑损伤、脑水肿和神经退行性疾病尤其是阿尔兹海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化、进行性核上性麻痹、黑质变性、Shy-Drager综合征、橄榄-脑桥-小脑萎缩和脊髓小脑变性;或v)癌症,尤其是肠癌、结直肠癌、肺癌、乳腺癌、脑癌、黑色素瘤、肾细胞癌、白血病、淋巴瘤、T细胞淋巴瘤、胃癌、胰腺癌、宫颈癌、子宫内膜癌、卵巢癌、食管癌、肝癌、头颈部鳞状细胞癌、皮肤癌、泌尿道癌、前列腺癌、绒毛膜癌、咽癌和喉癌。
29.根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段或根据权利要求18所述的偶联物或根据权利要求24所述的药物组合物,其与一种或多种其他治疗活性化合物同时、分别或依次联合使用。
30.一种试剂盒,其包含根据权利要求1至17中任一项所述的分离的抗体或抗原结合片段或根据权利要求18所述的偶联物,和使用说明书。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21165960.2 | 2021-03-30 | ||
EP21165960 | 2021-03-30 | ||
PCT/EP2022/058123 WO2022207554A1 (en) | 2021-03-30 | 2022-03-28 | Anti-sema3a antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117396504A true CN117396504A (zh) | 2024-01-12 |
Family
ID=75302351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280038261.5A Pending CN117396504A (zh) | 2021-03-30 | 2022-03-28 | 抗Sema3A抗体及其用途 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20220389096A1 (zh) |
EP (1) | EP4314047A1 (zh) |
JP (1) | JP2024512633A (zh) |
KR (1) | KR20230162800A (zh) |
CN (1) | CN117396504A (zh) |
AR (1) | AR125240A1 (zh) |
AU (1) | AU2022251786A1 (zh) |
BR (1) | BR112023018061A2 (zh) |
CA (1) | CA3215274A1 (zh) |
IL (1) | IL307233A (zh) |
MX (1) | MX2023011619A (zh) |
PE (1) | PE20240357A1 (zh) |
TW (1) | TW202304975A (zh) |
WO (1) | WO2022207554A1 (zh) |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP2301966A1 (en) | 2002-12-16 | 2011-03-30 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
LT2348051T (lt) | 2003-11-05 | 2019-02-25 | Roche Glycart Ag | Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN101720368A (zh) | 2007-03-09 | 2010-06-02 | 中国抗体制药有限公司 | 储备多样性最大化的功能性人化抗体文库之构建及应用 |
DK2955195T3 (da) | 2013-02-06 | 2019-05-06 | Univ Yokohama City | Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme |
CN108290942B (zh) * | 2015-10-27 | 2021-08-27 | 社会福祉法人三星生命公益财团 | 与人及小鼠信号素3a交联的抗体及其用途 |
MA55872A (fr) * | 2019-05-09 | 2022-03-16 | Boehringer Ingelheim Int | Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires |
WO2020261281A1 (en) * | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
-
2022
- 2022-03-28 PE PE2023002753A patent/PE20240357A1/es unknown
- 2022-03-28 BR BR112023018061A patent/BR112023018061A2/pt unknown
- 2022-03-28 WO PCT/EP2022/058123 patent/WO2022207554A1/en active Application Filing
- 2022-03-28 AU AU2022251786A patent/AU2022251786A1/en active Pending
- 2022-03-28 CA CA3215274A patent/CA3215274A1/en active Pending
- 2022-03-28 IL IL307233A patent/IL307233A/en unknown
- 2022-03-28 CN CN202280038261.5A patent/CN117396504A/zh active Pending
- 2022-03-28 US US17/706,543 patent/US20220389096A1/en active Pending
- 2022-03-28 EP EP22713427.7A patent/EP4314047A1/en active Pending
- 2022-03-28 KR KR1020237036770A patent/KR20230162800A/ko unknown
- 2022-03-28 JP JP2023560024A patent/JP2024512633A/ja active Pending
- 2022-03-28 MX MX2023011619A patent/MX2023011619A/es unknown
- 2022-03-29 AR ARP220100753A patent/AR125240A1/es unknown
- 2022-03-30 TW TW111112217A patent/TW202304975A/zh unknown
-
2023
- 2023-12-29 US US18/399,934 patent/US20240254222A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024512633A (ja) | 2024-03-19 |
IL307233A (en) | 2023-11-01 |
US20240254222A1 (en) | 2024-08-01 |
BR112023018061A2 (pt) | 2023-10-03 |
TW202304975A (zh) | 2023-02-01 |
CA3215274A1 (en) | 2022-10-06 |
WO2022207554A1 (en) | 2022-10-06 |
PE20240357A1 (es) | 2024-02-27 |
US20220389096A1 (en) | 2022-12-08 |
MX2023011619A (es) | 2023-10-11 |
AR125240A1 (es) | 2023-06-28 |
AU2022251786A1 (en) | 2023-10-05 |
KR20230162800A (ko) | 2023-11-28 |
EP4314047A1 (en) | 2024-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102365972B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
JP2023182590A (ja) | 治療的低密度リポタンパク質関連タンパク質6(lrp6)多価抗体の組成物および使用方法 | |
RU2571224C2 (ru) | Гуманизированные антитела против axl | |
KR101836501B1 (ko) | 근육 성장을 증가시키기 위한 조성물 및 방법 | |
JP2022137092A (ja) | 治療的低密度リポタンパク質関連タンパク質6(lrp6)抗体の組成物および使用方法 | |
AU2019201141B2 (en) | Novel antibody binding to TFPI and composition comprising the same | |
CN113248618B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
TW201605901A (zh) | Pd-1抗體、其抗原結合片段及其醫藥用途 | |
KR20170099918A (ko) | 항-axl 길항성 항체 | |
TW201018485A (en) | Bispecific anti-VEGF/anti-ANG-2 antibodies | |
TW201010723A (en) | Compositions and methods for antibodies targeting complement protein C5 | |
KR101817265B1 (ko) | 혈청 아밀로이드 p 성분에 특이적인 항원 결합 단백질 | |
JP2016513088A (ja) | 補体関連疾患の予防及び治療のためのc5抗体及び方法 | |
KR20220121808A (ko) | 항-pd-l1/항-b7-h3 다중특이적 항체 및 이의 용도 | |
KR20170089013A (ko) | Il-17c에 대한 항체 | |
KR20240052881A (ko) | Pmel17에 대한 항체 및 이의 접합체 | |
KR20150140752A (ko) | M-csf를 표적으로 하는 항체 | |
CN117396504A (zh) | 抗Sema3A抗体及其用途 | |
AU2013202069B2 (en) | PRLR-specific antibody and uses thereof | |
KR20240004694A (ko) | 항체 | |
AU2023238937A1 (en) | Anti-par2 antibodies | |
WO2023180767A1 (en) | Anti-par2 antibodies | |
KR20230012559A (ko) | 암 치료를 위한 결합 분자 | |
CN117756936A (zh) | 一种Axl拮抗抗体或抗原结合片段 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40099698 Country of ref document: HK |